WO2008144463A1 - Quinoline derivatives as pi3 kinase inhibitors - Google Patents

Quinoline derivatives as pi3 kinase inhibitors Download PDF

Info

Publication number
WO2008144463A1
WO2008144463A1 PCT/US2008/063819 US2008063819W WO2008144463A1 WO 2008144463 A1 WO2008144463 A1 WO 2008144463A1 US 2008063819 W US2008063819 W US 2008063819W WO 2008144463 A1 WO2008144463 A1 WO 2008144463A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
pyridinyl
amino
quinolinyl
group
Prior art date
Application number
PCT/US2008/063819
Other languages
French (fr)
Inventor
Nicholas D. Adams
Joelle Lorraine Burgess
Michael Gerard Darcy
Carla A. Donatelli
Steven David Knight
Kenneth Allen Newlander
Lance Ridgers
Martha Sarpong
Stanley J. Schmidt
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200830965T priority Critical patent/SI2162131T1/en
Priority to US12/600,745 priority patent/US8404837B2/en
Priority to EP08755632A priority patent/EP2162131B1/en
Priority to JP2010509462A priority patent/JP4814396B2/en
Priority to PL08755632T priority patent/PL2162131T3/en
Priority to CA2686016A priority patent/CA2686016C/en
Priority to KR1020097026354A priority patent/KR101458660B1/en
Priority to EA200971072A priority patent/EA019540B1/en
Priority to AU2008254915A priority patent/AU2008254915B2/en
Priority to MX2009012479A priority patent/MX2009012479A/en
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to ES08755632T priority patent/ES2404557T3/en
Priority to DK08755632.0T priority patent/DK2162131T3/en
Priority to BRPI0811761-6A2A priority patent/BRPI0811761A2/en
Priority to NZ580979A priority patent/NZ580979A/en
Priority to UAA200913251A priority patent/UA104408C2/en
Priority to MX2012009210A priority patent/MX342959B/en
Priority to CN2008800249784A priority patent/CN101754759B/en
Publication of WO2008144463A1 publication Critical patent/WO2008144463A1/en
Priority to IL202018A priority patent/IL202018A/en
Priority to HK10104231.9A priority patent/HK1137938A1/en
Priority to HRP20130252AT priority patent/HRP20130252T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • PI3 kinases phosphoinositide 3' OH kinase family
  • the present invention relates to the use of quinolines derivatives in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, particularly cancer.
  • PI3 kinases e.g. PBKalpha
  • PBKalpha membrane phospholipid pools
  • PI3 kinases e.g. PBKalpha
  • PBKalpha dual-specif ⁇ city kinase enzymes, meaning they display both: lipid kinase (phosphorylation of phosphoinositides) as well as protein kinase activity, shown to be capable of phosphorylation of protein as substrate, including auto-phosphorylation as intramolecular regulatory mechanism.
  • phospholipids signaling are activated in response to a variety of extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters such as described in Scheme I hereinafter and also by intracellular regulation by other signaling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PBKs by intra-cellular signaling events), such as small GTPases, kinases or phosphatases for example. Intracellular regulation can also occur as a result of aberrant expression or lack of expression of cellular oncogenes or tumor suppressors.
  • extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters such as described in Scheme I hereinafter and also by intracellular regulation by other signaling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PBKs by intra-cellular signaling events
  • inositol phospholipid (phosphoinositides) intracellular signaling pathways begin with activation of signaling molecules (extra cellular ligands, stimuli, receptor dimerization, transactivation by heterologous receptor (e.g. receptor tyrosine kinase) and the recruitment and activation of PBK including the involvement of G-protein linked transmembrane receptor integrated into the plasma membrane.
  • signaling molecules extra cellular ligands, stimuli, receptor dimerization, transactivation by heterologous receptor (e.g. receptor tyrosine kinase) and the recruitment and activation of PBK including the involvement of G-protein linked transmembrane receptor integrated into the plasma membrane.
  • heterologous receptor e.g. receptor tyrosine kinase
  • PBK converts the membrane phospholipid PI(4,5)P 2 into PI(3,4,5)P 3 that functions as a second messenger.
  • PI and PI(4)P are also substrates of PBK and can be phosphorylated and converted into PBP and PI(3,4)P 2 , respectively.
  • these phosphoinositides can be converted into other phosphoinositides by 5'- specific and 3 '-specific phophatases, thus PBK enzymatic activity results either directly or indirectly in the generation of two 3 ' -phosphoinositide subtypes that function as 2 n messengers in intra-cellular signal transduction pathways (Trends Biochem. Sci.
  • the closely related isoforms pi 10a and ⁇ are ubiquitously expressed, while ⁇ and ⁇ are more specifically expressed in the haematopoietic cell system, smooth muscle cells, myocytes and endothelial cells (Trends Biochem. Sci. 22(7) p.267-72 (1997) by Vanhaesebroeck et al.). Their expression might also be regulated in an inducible manner depending on the cellular, tissue type and stimuli as well as disease context. Inducibility of protein expression includes synthesis of protein as well as protein stabilization that is in part regulated by association with regulatory subunits.
  • class I PBKs can phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PI4P), and phosphatidylinositol-4,5-bisphosphate (PI(4,5)P 2 ) to produce phosphatidylinositol-3-phosphate (PBP), phosphatidylinositol-3,4-bisphosphate (PI(3,4)P 2 , and phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P 3 , respectively.
  • PI phosphatidylinositol
  • P4P phosphatidylinositol-4-phosphate
  • PI(4,5)P 2 phosphatidylinositol-4,5-bisphosphate
  • Class II PBKs phosphorylate PI and phosphatidylinositol-4-phosphate.
  • Class III PBKs can only phosphorylate PI (Vanhaesebrokeck et al., 1997, above; Vanhaesebroeck et al., 1999, above and Leslie et al, 2001, above)
  • phosphoinositide 3-kinases phosphorylate the hydroxyl of the third carbon of the inositol ring.
  • the phosphorylation of phosphoinositides that generate Ptdlns to 3,4,5-trisphosphate (PtdIns(3,4,5)P3), PtdIns(3,4)P2 and PtdIns(3)P produce second messengers for a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell motility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, vesicle trafficking and metabolic pathway (Katso et al, 2001, above and MoL Med.
  • G-protein coupled receptors mediate phosphoinositide 3'OH-kinase activation via small GTPases such as G ⁇ and Ras, and consequently PI3K signaling plays a central role in establishing and coordinating cell polarity and dynamic organization of the cytoskeleton - which together provides the driving force of cells to move.
  • Chemotaxis the directed movement of cells toward a concentration gradient of chemical attractants, also called chemokines is involved in many important diseases such as inflammation/auto-immunity, neurodegeneration, antiogenesis, invasion/metastasis and wound healing (Immunol. Today 21(6) p. 260-4 (2000) by Wyman et al.; Science 287(5455) p. 1049-53 (2000) by Hirsch et al.; FASEB J. 15(11) p. 2019-21 (2001) by Hirsch et al. and Nat. Immunol. 2(2) p. 108-15 (2001) by Gerard et al.).
  • PI3 -Kinase responsible for generating these phosphorylated signalling products, was originally identified as an activity associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at the 3'-hydroxyl of the inositol ring (Panayotou et al., Trends Cell Biol. 2 p. 358-60 (1992)).
  • PI phosphatidylinositol
  • class I PB kinases e.g. class IB isoform PI3K ⁇
  • class IB isoform PI3K ⁇ are dual-specific kinase enzymes, meaning they display both lipid kinase and protein kinase activity, shown to be capable of phosphorylation of other proteins as substrates, as well as auto-phosphorylation as an intra-molecular regulatory mechanism.
  • PB -kinase activation is therefore believed to be involved in a range of cellular responses including cell growth, differentiation, and apoptosis (Parker et al., Current Biology, 5 p. 577-99 (1995); Yao et al., Science, 267 p. 2003-05 (1995)).
  • PB -kinase appears to be involved in a number of aspects of leukocyte activation.
  • a p85-associated PI3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important costimulatory molecule for the activation of T-cells in response to antigen (Pages et al., Nature, 369 p.
  • Activation of T cells through CD28 lowers the threshold for activation by antigen and increases the magnitude and duration of the proliferative response. These effects are linked to increases in the transcription of a number of genes including interleukin-2 (IL2), an important T cell growth factor (Fraser et al., Science 251 p. 313-16 (1991)). Mutation of CD28 such that it can no longer interact with PI3 -kinase leads to a failure to initiate IL2 production, suggesting a critical role for PI3-kinase in T cell activation.
  • IL2 interleukin-2
  • Mutation of CD28 such that it can no longer interact with PI3 -kinase leads to a failure to initiate IL2 production, suggesting a critical role for PI3-kinase in T cell activation.
  • PDK ⁇ has been identified as a mediator of G beta-gamma-dependent regulation of JNK activity, and G beta-gamma are subunits of heterotrimeric G proteins (Lopez -Ilasaca et al., J. Biol. Chem. 273(5) p. 2505-8 (1998)).
  • Cellular processes in which PBKs play an essential role include suppression of apoptosis, reorganization of the actin skeleton, cardiac myocyte growth, glycogen synthase stimulation by insulin, TNF ⁇ - mediated neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells. Recently, (Laffargue et al., Immunity 16(3) p.
  • PBK ⁇ relays inflammatory signals through various G(i)-coupled receptors and its central to mast cell function, stimuli in context of leukocytes, immunology includes cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example (J. Cell. Sci. 114(Pt 16) p. 2903-10 (2001) by Lawlor et al.; Laffargue et al., 2002, above and Curr. Opinion Cell Biol. 14(2) p. 203-13 (2002) by Stephens et al.).
  • PB-kinase inhibitors Two compounds, LY294002 and wortmannin (cf. hereinafter), have been widely used as PB-kinase inhibitors. These compounds are non-specific PI3K inhibitors, as they do not distinguish among the four members of Class I PI3-kinases.
  • the IC50 values of wortmannin against each of the various Class I PI3 -kinases are in the range of 1-10 nM.
  • the IC50 values for LY294002 against each of these PI3-kinases is about 15-20 ⁇ M (Fruman et al, Ann. Rev. Biochem., 67, p.
  • wortmannin is a fungal metabolite which irreversibly inhibits PI3K activity by binding covalently to the catalytic domain of this enzyme. Inhibition of PBK activity by wortmannin eliminates subsequent cellular response to the extracellular factor.
  • neutrophils respond to the chemokine fJVIet-Leu- Phe (fMLP) by stimulating PDK and synthesizing Ptdlns (3, 4, 5)P3. This synthesis correlates with activation of the respirators burst involved in neutrophil destruction of invading microorganisms.
  • Class I PI3K is a heterodimer consisting of a pi 10 catalytic subunit and a regulatory subunit, and the family is further divided into class Ia and Class Ib enzymes on the basis of regulatory partners and mechanism of regulation.
  • Class Ia enzymes consist of three distinct catalytic subunits (pl lO ⁇ , pl lO ⁇ , and pl lO ⁇ ) that dimerise with five distinct regulatory subunits (p85 ⁇ , p55 ⁇ , p50 ⁇ , p85 ⁇ , and p55 ⁇ ), with all catalytic subunits being able to interact with all regulatory subunits to form a variety of heterodimers.
  • Class Ia PI3K are generally activated in response to growth factor-stimulation of receptor tyrosine kinases, via interaction of the regulatory subunit SH2 domains with specific phospho-tyrosine residues of the activated receptor or adaptor proteins such as IRS-I .
  • Small GTPases (ras as an example) are also involved in the activation of PI3K in conjunction with receptor tyrosine kinase activation.
  • Both pi 10a and pi lO ⁇ are constitutively expressed in all cell types, whereas pi lO ⁇ expression is more restricted to leukocyte populations and some epithelial cells.
  • the single Class Ib enzyme consists of a pl lO ⁇ catalytic subunit that interacts with a pi 01 regulatory subunit.
  • GPCR G-protein coupled receptor
  • PIK3CA gene activating mutations within pi 10a (PIK3CA gene) have been associated with various other tumors such as those of the colon and of the breast and lung (Samuels, et al., Science, 2004, 304, 554). Tumor- related mutations in p85 ⁇ have also been identified in cancers such as those of the ovary and colon (Philp et al., Cancer Research, 2001, 6J_, 7426-7429).
  • Class Ia PI3K contributes to tumourigenic events that occur upstream in signaling pathways, for example by way of ligand-dependent or ligand-independent activation of receptor tyrosine kinases, GPCR systems or integrins (Vara et al., Cancer Treatment Reviews, 2004, 30, 193- 204).
  • upstream signaling pathways examples include over-expression of the receptor tyrosine kinase Erb2 in a variety of tumors leading to activation of PI3K- mediated pathways (Harari et al., Oncogene, 2000, 19, 6102-6114) and over- expression of the oncogene Ras (Kauffmann-Zeh et al., Nature, 1997, 385, 544- 548).
  • Class Ia PI3Ks may contribute indirectly to tumourigenesis caused by various downstream signaling events.
  • loss of function of the PTEN tumor-suppressor phosphatase that catalyses conversion of PI(3,4,5)P3 back to PI(4,5)P2 is associated with a very broad range of tumors via deregulation of PI3K- mediated production of PI(3,4,5)P3 (Simpson and Parsons, Exp. Cell Res., 2001, 264, 29-41).
  • augmentation of the effects of other PI3K-mediated signaling events is believed to contribute to a variety of cancers, for example by activation of AKT (Nicholson and Andeson, Cellular Signaling. 2002, 14, 381-395).
  • class Ia PI3K enzymes also contributes to tumourigenesis via its function in tumor-associated stromal cells.
  • PI3K signaling is known to play an important role in mediating angiogenic events in endothelial cells in response to pro-angiogenic factors such as VEGF (abid et al., Arterioscler, Thromb. Vase. Biol., 2004, 24, 294-300).
  • VEGF vascular endothelial cells
  • Class I PI3K enzymes are also involved in motility and migration (Sawyer, Expert Opinion investing. Drugs, 2004, L3, 1-19), PI3K inhibitors are anticipated to provide therapeutic benefit via inhibition of tumor cell invasion and metastasis. Summary of the Invention
  • This invention relates to novel compounds of Formula (I):
  • R2 is an optionally substituted ring system selected from a group consisting of: formula (II), (III), (IV), (V), (VI), (VII),(VIII), (IX) and (X):
  • Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy;
  • R3 can be attached to any one of the four open carbon positions.
  • this invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • this invention relates to a method of treating cancer, which comprises administering to a subject in need thereof an effective amount of a compound of Formula (I).
  • this invention relates to a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and lung injuries, which comprises administering to a subject in need thereof an effective amount of a compound of Formula (I).
  • Included in the present invention are methods of co-administering the present PB kinase inhibiting compounds with further active ingredients.
  • compounds of Formula (I) inhibit one or more PI3 kinases.
  • the compounds of formula (I) inhibit PBK ⁇ .
  • compounds within the scope of this invention inhibit one or more PB kinases selected from:PI3K ⁇ , PBK ⁇ and PBK ⁇ .
  • this invention relates to novel compounds of Formula (I)(A): A)
  • R2 is an optionally substituted ring system selected from a group consisting of: formula (II), (III), and (IV) as defined above;
  • Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted
  • R2 is selected from a group consisting of: formula (V) ,(VI) and (IX) as defined above;
  • Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy;
  • R2 is selected from a group consisting of: formula (VII), (VIII) and (X) as defined above;
  • Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano,
  • X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (VII), (VIII) and (X) at least one X or Y is not carbon.
  • R2 is an optionally substituted ring system selected from a group consisting of: formula (II), (III), (IV), (V), (VI), and (VIII):
  • Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy;
  • X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (V), (VI) and (VIII) at least one X or Y is not carbon.
  • X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (V), (VI) and (VIII) at least one X or Y is not carbon.
  • R2 is an optionally substituted ring system selected from the group consisting of Formulas (V)(A), (VI)(A), (VI)(B) and (IX)(A):
  • X is C or N
  • Y is C, O, N or S
  • R2 is an optionally substituted ring system selected from the group consisting of Formulas (VII)(A), (VIII)(A) and (X)(A):
  • each Rl, R3, R4 and R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, acyloxy, and aryloxy; or R5 is R6, wherein R6 is -SO2NR80 or -NSO 2 R80, in which R80 is
  • this invention relates to novel compounds of Formula (I)(H):
  • Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl- ⁇ alkyl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, cyano, hydroxyl and alkoxy; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl
  • this invention relates to novel compounds of Formula (I)(J):
  • Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, cyano, hydroxyl and alkoxy; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl,
  • this invention relates to novel compounds of Formula (I)(K):
  • Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy; n is 0-2, m is 0-1;
  • R6 is -SO2NR80 or -NSO 2 R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, C1-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted C1 -C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: C1-C6alkyl, C1-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH 2 ) n COOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C1-C6cycloal
  • this invention relates to novel compounds of Formula (I)(L):
  • Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy; R6 is -SO2NR80 or -NSO 2 R8O, wherein R80 is selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, Cl-C6heterocycloalkyl, substituted Cl- C6alkyl, substituted Cl-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring
  • this invention relates to novel compounds of Formula (I)(M):
  • Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy;
  • R6 is -NSO 2 R8O, wherein R80 is selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, C1-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1 -C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: C1-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -
  • (CH 2 ) n COOH or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH 2 ) n COOH; n is 0-2, m is 0-1;
  • this invention relates to novel compounds of Formula (I)(N):
  • Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy;
  • R6 is -SO2NR80, wherein R80 is selected from a group consisting of: Cl- C6alkyl, Cl-C6cycloalkyl, Cl-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -
  • (CH 2 ) n COOH or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH 2 ) n COOH; n is 0-2, m is 0-1 or a pharmaceutically acceptable salt thereof.
  • this invention relates to compounds of Formulas (I)M) and (I)(N), wherein Rl is selected from the group consisting of: optionally substituted piperazine, optionally susbstituted pyridazine, optionally substituted morphline, optionally substituted pyrazole, substituted amino and optionally substituted piperidine.
  • this invention relates to compounds of Formulas (I)M) and (I)(N), wherein Rl is selected from the group consisting of: optionally substituted piperazine, optionally susbstituted pyridazine, optionally substituted morphline, optionally substituted pyrazole, substituted amino and optionally substituted piperidine;
  • R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, Cl- C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl and substituted aryl.
  • this invention relates to compounds of Formulas (I)M) and (I)(N), wherein Rl is selected from the group consisting of: optionally substituted piperazine, optionally susbstituted pyridazine, optionally substituted morphline, optionally substituted pyrazole, substituted amino and optionally substituted piperidine;
  • R80 is selected from a group consisting of: aryl optionally substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl- C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH 2 ) n COOH, or heteroaryl optionally substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl- C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CHz) n COOH; n is 0-2.
  • this invention relates to the compound defined in formula (I), (I)(A),
  • This invention also relates to a method of treating cancer, which comprises co-administering to a subject in need thereof an effective amount of a compound of
  • Formula (I), and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable salt thereof; and at least one anti- neoplastic agent such as one selected from the group consisting of: anti-microtubule agents, plantinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I hinibitors, hormones and hormonal anlogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors.
  • anti- neoplastic agent such as one selected from the group consisting of: anti-microtubule agents, plantinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I hinibitors, hormones and hormonal anlogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis
  • This invention also relates to a method of treating cancer, which comprises co-administering to a subject in need thereof an effective amount of a compound of
  • Formula (I), and/or a pharmaceutically acceptable salt thereof and at least one signal transduction pathway inhibitor such as one selected from the group consisting of: receptor tyrosine kinase inhibitor, non-receptor tyrosine kinase inhibitor,
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
  • Compounds of Formula (I) are included in the pharmaceutical compositions of the invention.
  • substituted amino is meant -NR30R40 wherein each R30 and R40 is independently selected from a group including hydrogen, C1- 6alkyl, acyl, C3-C7cycloalkyl, wherein at least one of R30 and R40 is not hydrogen.
  • acyl as used herein, unless otherwise defined, is meant -C(O)(alkyl), -C(O)(cycloalkyl), -C(O)(aryl) or -C(O)(heteroaryl), wherein heteroaryl and aryl are optionally substituted.
  • aryl aromatic, hydrocarbon, ring system.
  • the ring system may be monocyclic or fused polycyclic (e.g. bicyclic, tricyclic, etc.).
  • the monocyclic aryl ring is C5-C10, or C5-C7, or C5-C6, where these carbon numbers refer to the number of carbon atoms that form the ring system.
  • a C6 ring system i.e. a phenyl ring is a suitable aryl group.
  • the polycyclic ring is a bicyclic aryl group, where suitable bicyclic aryl groups are C8-C12, or C9-C10.
  • a naphthyl ring, which has 10 carbon atoms, is a suitable polycyclic aryl group.
  • heteroaryl an aromatic ring system containing carbon(s) and at least one heteroatom.
  • Heteroaryl may be monocyclic or polycyclic.
  • a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
  • a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junctions, for example, bicyclic heteroaryl is a polycyclic heteroaryl.
  • Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
  • Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (carbons and heteroatoms).
  • heteroaryl groups include but are not limited to: benzofuran, benzothiophene, furan, imidazole, indole, isothiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinoline, quinazoline, quinoxaline, thiazole, and thiophene.
  • monocyclic heteroaryl as used herein, unless otherwise defined, is meant a monocyclic heteroaryl ring containing 1-5 carbon atoms and 1-4 hetero atoms.
  • alkylcarboxy as used herein, unless otherwise defined, is meant -(CH 2 ) n COOR 8 o, wherein R80 is hydrogen or Cl-C6alkyl, n is 0-6.
  • alkoxy as used herein is meant -O(alkyl) including -OCH3, - OCH 2 CH 3 and -OC(CH3)3 where alkyl is as described herein.
  • alkylthio as used herein is meant -S(alkyl) including -SCH3, - SCH 2 CH3 where where alkyl is as described herein.
  • cycloalkyl as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C3-C12.
  • cycloalkyl and substituted cycloalkyl substituents as used herein include: cyclohexyl, aminocyclohexyl, cyclobutyl, aminocyclobutyl, 4- hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl4-methoxycyclohexyl, 4- methoxycyclohexyl, 4-carboxycyclohexyl, cyclopropyl, aminocyclopentyl, and cyclopentyl.
  • heterocycloalkyl as used herein is meant a non-aromatic, unsaturated or saturated, monocyclic or polycyclic, heterocyclic ring containing at least one carbon and at least one heteroatom.
  • exemplary monocyclic heterocyclic rings include: piperidine, piperazine, pyrrolidine, and morpholine.
  • exemplary polycyclic heterocyclic rings include quinuclidine.
  • substituted as used herein, unless otherwise defined, is meant that the subject chemical moiety has one to five substituents, suitably from one to three substituents selected from the group consisting of: hydrogen, halogen, Cl- C ⁇ alkyl, amino, urea, trifluoromethyl, -(CH 2 )XOOH, C3-C7cycloalkyl, substituted amino, aryl, heteroaryl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heterocycloalkyl, cyano, hydroxyl, alkoxy, alkylthio, aryloxy, acyloxy, acyl, acylamino, aminoacyl, arylamino, nitro, oxo, -CO 2 R 50 , -SO 2 R 70 , -NR 50 SO 2 R 70 , NR 50 C(O)R 75 and - CONRssR ⁇ o, wherein R50 and R55 are each independently
  • substituted when referred in the definition of R60, R70, R75, “arylamino", and “aryloxy”, is meant that the subject chemical moiety has one to five substituents, suitably from one to three, selected from the group consisting of: hydrogen, Cl-C6alkyl, halogen, trifluoromethyl, -(CH 2 ) n C00H, amino, substituted amino, cyano, hydroxyl, alkoxy, alkylthio, aryloxy, acyloxy, acyl, acylamino, and nitro, n is 0-6.
  • acyloxy as used herein is meant -OC(O)alkyl where alkyl is as described herein.
  • Examples of acyloxy substituents as used herein include: OC(O)CH3, -OC(O)CH(CH3)2 and -OC(O)(CH2)3CH3.
  • acylamino as used herein is meant -N(H)C(O)alkyl, - N(H)C(O)(cycloalkyl) where alkyl is as described herein.
  • N-acylamino substituents as used herein include: -N(H)C(O)CH 3 , -N(H)C(O)CH(CH 3 ) 2 and -N(H)C(OXCH 2 )3CH 3 .
  • aminoacyl as used herein is meant -C(O)N (alkyl) n , - C(O)N(cycloalkyl) n where alkyl is as described herein, n is 1-2.
  • aryloxy as used herein is meant -O(aryl), -O(substituted aryl), -O(heteroaryl) or -O(substituted heteroaryl).
  • arylamino as used herein is meant -NRgo(aryl), - NR 8 o(substituted aryl), -NR 8 o(heteroaryl) or -NR 8 o(substituted heteroaryl), wherein R80 is H, Cl-6alkyl or C3-C7cycloalkyl.
  • heteroatom oxygen, nitrogen or sulfur.
  • halogen as used herein is meant a substituent selected from bromide, iodide, chloride and fluoride.
  • alkyl and derivatives thereof and in all carbon chains as used herein, including alkyl chains defined by the term “-(CH2) n “, “-((CH2) m “ and the like, is meant a linear or branched, saturated or unsaturated hydrocarbon chain, and unless otherwise defined, the carbon chain will contain from 1 to 12 carbon atoms.
  • substituted alkyl an alkyl group substituted with one to six substituents selected from the group consisting of: halogen, trifluoromethyl, alkylcarboxy, amino, substituted amino, cyano, hydroxyl, alkoxy, alkylthio, aryloxy, acyloxy, acyl, acylamino, carbamate, urea, sulfonamate,
  • alkyl and substituted alkyl substituents as used herein include:
  • prophylatic therapy is meant the institution of measures to protect a person from a disease to which he or she has been, or may be, exposed. Also called preventive treatment.
  • co-administering and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a PI3 kinase inhibiting compound, as described herein, and a further active ingredient or ingredients.
  • further active ingredient or ingredients includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment.
  • the compounds are administered in a close time proximity to each other.
  • the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
  • compound as used herein includes all isomers of the compound. Examples of such isomers include: enantiomers, tautomers, rotamers.
  • Certain compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers, or two or more diastereoisomers. Accordingly, the compounds of this invention include mixtures of enantiomers/diastereoisomers as well as purified enantiomers/diastereoisomers or enantiomerically/diastereoisomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula I or II above as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted.
  • tautomer is an oxo substituent in place of a hydroxy substituent. Also, as stated above, it is understood that all tautomers and mixtures of tautomers are included within the scope of the compounds of Formula I or II.
  • esters can be employed, for example methyl, ethyl, pivaloyloxymethyl, and the like for -COOH, and acetate maleate and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics, for use as sustained release or prodrug formulations. It has now been found that compounds of the present invention are inhibitors of the Phosphatoinositides 3-kinases (PBKs), particularly PBK ⁇ .
  • PBKs Phosphatoinositides 3-kinases
  • PBK phosphatoinositides 3 -kinase
  • the compounds of the present invention are therefore useful in the treatment of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, particularly cancer.
  • Compounds according to Formula (I) are suitable for the modulation, notably the inhibition of the activity of phosphatoinositide 3-kinases (PBK), suitably phosphatoinositides 3-kinase (PBK ⁇ ). Therefore the compounds of the present invention are also useful for the treatment of disorders which are mediated by PBKs. Said treatment involves the modulation - notably the inhibition or the down regulation - of the phosphatoinositides 3-kinases.
  • the compounds of the present invention are used for the preparation of a medicament for the treatment of a disorder selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation, such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions, cardiovascular diseases such as athero-sclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction.
  • a disorder selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation, such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions, cardiovascular diseases such as at
  • the compounds of Formula (I) are useful for the treatment of autoimmune diseases or inflammatory diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis.
  • autoimmune diseases or inflammatory diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis.
  • the compounds of Formula (I) are useful for the treatment of neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions.
  • the compounds of Formula (I) are useful for the treatment of cardiovascular diseases such as atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction.
  • the compounds of Formula (I) are useful for the treatment of chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, in particular melanoma, Karposi's sarcoma, acute and chronic bacterial and virual infections, sepsis, transplantation rejection, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airway inflammation.
  • the pharmaceutically active compounds of the present invention are active as PB kinase inhibitors, particularly the compounds that inhibit PI3K ⁇ , either selectively or in conjunction with one or more of PDK ⁇ , PBK ⁇ , and/or PBK ⁇ , they exhibit therapeutic utility in treating cancer.
  • the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: brain (gliomas), glioblastomas, leukemias, Bannayan-Zonana syndrome, Cowden disease, Lhermitte- Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid.
  • brain gliomas
  • glioblastomas leukemias
  • Bannayan-Zonana syndrome Cowden disease
  • Lhermitte- Duclos disease breast
  • inflammatory breast cancer Wilm's tumor
  • Ewing's sarcoma Rhabdomyosarcoma
  • the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: Lymphoblastic T cell leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Hairy- cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, Chronic neutrophilic leukemia, Acute lymphoblastic T cell leukemia, Plasmacytoma, Immunoblastic large cell leukemia, Mantle cell leukemia, Multiple myeloma Megakaryoblastic leukemia, multiple myeloma, Acute megakaryocytic leukemia, promyelocytic leukemia and Erythroleukemia.
  • the cancer is selected from: Lymphoblastic T cell leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Hairy- cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, Chronic
  • the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma and follicular lymphoma.
  • the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: neuroblastoma, bladder cancer, urothelial cancer, lung cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor) and testicular cancer.
  • the cancer is selected from: neuroblastoma, bladder cancer, urothelial cancer, lung cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor) and testicular cancer.
  • a compound of Formula (I) When a compound of Formula (I) is administered for the treatment of cancer, the term “co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a PI3 kinase inhibiting compound, as described herein, and a further active ingredient or ingredients, known to be useful in the treatment of cancer, including chemotherapy and radiation treatment.
  • the term further active ingredient or ingredients, as used herein includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment for cancer.
  • the compounds are administered in a close time proximity to each other.
  • the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
  • any anti-neoplastic agent that has activity versus a susceptible tumor being treated may be co-administered in the treatment of cancer in the present invention.
  • examples of such agents can be found in Cancer Principles and Practice of Oncology by V. T. Devita and S. Hellman (editors), 6 th edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved.
  • Typical antineoplastic agents useful in the present invention include, but are not limited to, anti- microtubule agents such as diterpenoids and vinca alkaloids; platinum coordination complexes; alkylating agents such as nitrogen mustards, oxazaphosphorines, alky Sulfonates, nitrosoureas, and triazenes; antibiotic agents such as anthracyclins, actinomycins and bleomycins; topoisomerase II inhibitors such as epipodophyllotoxins; antimetabolites such as purine and pyrimidine analogues and anti-folate compounds; topoisomerase I inhibitors such as camptothecins; hormones and hormonal analogues; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; and cell cycle signaling inhibitors.
  • anti- microtubule agents such as diterpenoids and vinca alkaloids
  • Examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented AKT inhibiting compounds are chemotherapeutic agents.
  • Anti-microtubule or anti-mitotic agents are phase specific agents active against the microtubules of tumor cells during M or the mitosis phase of the cell cycle.
  • anti-microtubule agents include, but are not limited to, diterpenoids and vinca alkaloids.
  • Diterpenoids which are derived from natural sources, are phase specific anti -cancer agents that operate at the G 2 /M phases of the cell cycle. It is believed that the diterpenoids stabilize the ⁇ -tubulin subunit of the microtubules, by binding with this protein. Disassembly of the protein appears then to be inhibited with mitosis being arrested and cell death following. Examples of diterpenoids include, but are not limited to, paclitaxel and its analog docetaxel.
  • Paclitaxel 5 ⁇ ,20-epoxy-l,2 ⁇ ,4,7 ⁇ ,10 ⁇ ,13 ⁇ -hexa-hydroxytax-l l-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; is a natural diterpene product isolated from the Pacific yew tree Taxus brevifolia and is commercially available as an injectable solution TAXOL®. It is a member of the taxane family of terpenes. It was first isolated in 1971 by Wani et al. J. Am. Chem, Soc, 93:2325. 1971), who characterized its structure by chemical and X-ray crystallographic methods.
  • Paclitaxel has been approved for clinical use in the treatment of refractory ovarian cancer in the United States (Markman et al., Yale Journal of Biology and Medicine, 64:583, 1991; McGuire et al., Ann. Intern, Med., 111 :273,1989) and for the treatment of breast cancer (Holmes et al., J. Nat. Cancer Inst., 83:1797,1991.) It is a potential candidate for treatment of neoplasms in the skin (Einzig et. al., Proc. Am. Soc. Clin. Oncol., 20:46) and head and neck carcinomas (Forastire et. al., Sem.
  • the compound also shows potential for the treatment of polycystic kidney disease (Woo et. al., Nature, 368:750. 1994), lung cancer and malaria.
  • Treatment of patients with paclitaxel results in bone marrow suppression (multiple cell lineages, Ignoff, RJ. et. al, Cancer Chemotherapy Pocket Guide ⁇ 1998) related to the duration of dosing above a threshold concentration (5OnM) (Kearns, CM. et. al., Seminars in Oncology, 3(6) p.16-23, 1995).
  • 5OnM threshold concentration
  • Docetaxel (2R,3S)- N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5 ⁇ -20-epoxy-l,2 ⁇ ,4,7 ⁇ ,10 ⁇ ,13 ⁇ -hexahydroxytax-l l-en-9-one 4-acetate 2- benzoate, trihydrate; is commercially available as an injectable solution as TAXOTERE (D .
  • Docetaxel is indicated for the treatment of breast cancer.
  • Docetaxel is a semisynthetic derivative of paclitaxel q.v., prepared using a natural precursor, 10-deacetyl-baccatin III, extracted from the needle of the European Yew tree. The dose limiting toxicity of docetaxel is neutropenia.
  • Vinca alkaloids are phase specific anti-neoplastic agents derived from the periwinkle plant. Vinca alkaloids act at the M phase (mitosis) of the cell cycle by binding specifically to tubulin. Consequently, the bound tubulin molecule is unable to polymerize into microtubules. Mitosis is believed to be arrested in metaphase with cell death following. Examples of vinca alkaloids include, but are not limited to, vinblastine, vincristine, and vinorelbine. Vinblastine, vincaleukoblastine sulfate, is commercially available as
  • VELB AN® as an injectable solution. Although, it has possible indication as a second line therapy of various solid tumors, it is primarily indicated in the treatment of testicular cancer and various lymphomas including Hodgkin's Disease; and lymphocytic and histiocytic lymphomas. Myelosuppression is the dose limiting side effect of vinblastine.
  • Vincristine vincaleukoblastine, 22-oxo-, sulfate
  • ONCOVIN® an injectable solution.
  • Vincristine is indicated for the treatment of acute leukemias and has also found use in treatment regimens for Hodgkin's and non-Hodgkin's malignant lymphomas. Alopecia and neurologic effects are the most common side effect of vincristine and to a lesser extent myelosupression and gastrointestinal mucositis effects occur.
  • Platinum coordination complexes are non-phase specific anti-cancer agents, which are interactive with DNA.
  • the platinum complexes enter tumor cells, undergo, aquation and form intra- and interstrand crosslinks with DNA causing adverse biological effects to the tumor.
  • Examples of platinum coordination complexes include, but are not limited to, cisplatin and carboplatin.
  • Cisplatin cis-diamminedichloroplatinum
  • PLATINOL® an injectable solution.
  • Cisplatin is primarily indicated in the treatment of metastatic testicular and ovarian cancer and advanced bladder cancer.
  • the primary dose limiting side effects of cisplatin are nephrotoxicity, which may be controlled by hydration and diuresis, and ototoxicity.
  • Carboplatin platinum, diammine [l,l-cyclobutane-dicarboxylate(2-)-O,O'], is commercially available as PARAPLATIN® as an injectable solution.
  • Carboplatin is primarily indicated in the first and second line treatment of advanced ovarian carcinoma. Bone marrow suppression is the dose limiting toxicity of carboplatin.
  • Alkylating agents are non-phase anti-cancer specific agents and strong electrophiles. Typically, alkylating agents form covalent linkages, by alkylation, to DNA through nucleophilic moieties of the DNA molecule such as phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazole groups.
  • alkylation disrupts nucleic acid function leading to cell death.
  • alkylating agents include, but are not limited to, nitrogen mustards such as cyclophosphamide, melphalan, and chlorambucil; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; and triazenes such as dacarbazine.
  • Cyclophosphamide 2-[bis(2-chloroethyl)amino]tetrahydro-2H-l,3,2- oxazaphosphorine 2-oxide monohydrate, is commercially available as an injectable solution or tablets as CYTOXAN®. Cyclophosphamide is indicated as a single agent or in combination with other chemotherapeutic agents, in the treatment of malignant lymphomas, multiple myeloma, and leukemias. Alopecia, nausea, vomiting and leukopenia are the most common dose limiting side effects of cyclophosphamide.
  • Melphalan 4-[bis(2-chloroethyl)amino]-L-phenylalanine, is commercially available as an injectable solution or tablets as ALKERAN®. Melphalan is indicated for the palliative treatment of multiple myeloma and non-resectable epithelial carcinoma of the ovary. Bone marrow suppression is the most common dose limiting side effect of melphalan.
  • Chlorambucil 4-[bis(2-chloroethyl)amino]benzenebutanoic acid, is commercially available as LEUKERAN® tablets. Chlorambucil is indicated for the palliative treatment of chronic lymphatic leukemia, and malignant lymphomas such as lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. Bone marrow suppression is the most common dose limiting side effect of chlorambucil.
  • Busulfan 1 ,4-butanediol dimethanesulfonate, is commercially available as MYLERAN® TABLETS. Busulfan is indicated for the palliative treatment of chronic myelogenous leukemia. Bone marrow suppression is the most common dose limiting side effects of busulfan.
  • Carmustine 1, 3 -[bis(2-chloroethyl)-l -nitrosourea, is commercially available as single vials of lyophilized material as BiCNU®.
  • Carmustine is indicated for the palliative treatment as a single agent or in combination with other agents for brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Delayed myelosuppression is the most common dose limiting side effects of carmustine.
  • dacarbazine 5-(3,3-dimethyl- 1 -triazeno)-imidazole-4-carboxamide, is commercially available as single vials of material as DTIC-Dome®.
  • dacarbazine is indicated for the treatment of metastatic malignant melanoma and in combination with other agents for the second line treatment of Hodgkin's Disease. Nausea, vomiting, and anorexia are the most common dose limiting side effects of dacarbazine.
  • Antibiotic anti-neoplasties are non-phase specific agents, which bind or intercalate with DNA. Typically, such action results in stable DNA complexes or strand breakage, which disrupts ordinary function of the nucleic acids leading to cell death.
  • antibiotic anti-neoplastic agents include, but are not limited to, actinomycins such as dactinomycin, anthrocyclins such as daunorubicin and doxorubicin; and bleomycins.
  • Dactinomycin also know as Actinomycin D, is commercially available in injectable form as COSMEGEN®. Dactinomycin is indicated for the treatment of Wilm's tumor and rhabdomyosarcoma. Nausea, vomiting, and anorexia are the most common dose limiting side effects of dactinomycin.
  • Daunorubicin (8S-cis-)-8-acetyl-10-[(3-amino-2,3,6-trideoxy- ⁇ -L-lyxo- hexopyranosyl)oxy]-7,8,9, 10-tetrahydro-6,8, 11 -trihydroxy- 1 -methoxy-5 , 12 naphthacenedione hydrochloride, is commercially available as a liposomal injectable form as DAUNOXOME® or as an injectable as CERUBIDINE®. Daunorubicin is indicated for remission induction in the treatment of acute nonlymphocytic leukemia and advanced HIV associated Kaposi's sarcoma. Myelosuppression is the most common dose limiting side effect of daunorubicin.
  • Doxorubicin (8S, 10S)-10-[(3-amino-2,3,6-trideoxy- ⁇ -L-lyxo- hexopyranosyl)oxy]-8-glycoloyl, 7,8,9,10-tetrahydro-6,8, 11 -trihydroxy- 1 -methoxy- 5,12 naphthacenedione hydrochloride, is commercially available as an injectable form as RUBEX® or ADRIAMYCIN RDF®.
  • Doxorubicin is primarily indicated for the treatment of acute lymphoblastic leukemia and acute myeloblasts leukemia, but is also a useful component in the treatment of some solid tumors and lymphomas. Myelosuppression is the most common dose limiting side effect of doxorubicin.
  • Bleomycin a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus, is commercially available as BLENOXANE®. Bleomycin is indicated as a palliative treatment, as a single agent or in combination with other agents, of squamous cell carcinoma, lymphomas, and testicular carcinomas. Pulmonary and cutaneous toxicities are the most common dose limiting side effects of bleomycin.
  • Topoisomerase II inhibitors include, but are not limited to, epipodophyllotoxins.
  • Epipodophyllotoxins are phase specific anti-neoplastic agents derived from the mandrake plant. Epipodophyllotoxins typically affect cells in the S and G 2 phases of the cell cycle by forming a ternary complex with topoisomerase II and DNA causing DNA strand breaks. The strand breaks accumulate and cell death follows. Examples of epipodophyllotoxins include, but are not limited to, etoposide and teniposide.
  • Etoposide 4'-demethyl-epipodophyllotoxin 9[4,6-0-(R )-ethylidene- ⁇ -D- glucopyranoside]
  • VePESID® an injectable solution or capsules
  • VP-16 an injectable solution or capsules
  • Etoposide is indicated as a single agent or in combination with other chemotherapy agents in the treatment of testicular and non-small cell lung cancers. Myelosuppression is the most common side effect of etoposide. The incidence of leucopenia tends to be more severe than thrombocytopenia.
  • Teniposide 4'-demethyl-epipodophyllotoxin 9[4,6-0-(R )-thenylidene- ⁇ -D- glucopyranoside], is commercially available as an injectable solution as VUMON® and is commonly known as VM-26.
  • Teniposide is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia in children. Myelosuppression is the most common dose limiting side effect of teniposide. Teniposide can induce both leucopenia and thrombocytopenia.
  • Antimetabolite neoplastic agents are phase specific anti-neoplastic agents that act at S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting purine or pyrimidine base synthesis and thereby limiting DNA synthesis. Consequently, S phase does not proceed and cell death follows.
  • antimetabolite anti-neoplastic agents include, but are not limited to, fluorouracil, methotrexate, cytarabine, mecaptopurine, thioguanine, and gemcitabine. 5 -fluorouracil, 5-fluoro-2,4- (1H,3H) pyrimidinedione, is commercially available as fluorouracil.
  • 5 -fluorouracil leads to inhibition of thymidylate synthesis and is also incorporated into both RNA and DNA. The result typically is cell death.
  • 5 -fluorouracil is indicated as a single agent or in combination with other chemotherapy agents in the treatment of carcinomas of the breast, colon, rectum, stomach and pancreas. Myelosuppression and mucositis are dose limiting side effects of 5-fluorouracil.
  • Other fiuoropyrimidine analogs include 5-fluoro deoxyuridine (floxuridine) and 5-fluorodeoxyuridine monophosphate.
  • Cytarabine 4-amino-l- ⁇ -D-arabinofuranosyl-2 (lH)-pyrimidinone, is commercially available as CYTOS AR-U® and is commonly known as Ara-C. It is believed that cytarabine exhibits cell phase specificity at S-phase by inhibiting DNA chain elongation by terminal incorporation of cytarabine into the growing DNA chain. Cytarabine is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia. Other cytidine analogs include 5-azacytidine and 2',2'-difluorodeoxycytidine (gemcitabine). Cytarabine induces leucopenia, thrombocytopenia, and mucositis.
  • Mercaptopurine 1 ,7-dihydro-6H-purine-6-thione monohydrate, is commercially available as PURINETHOL®.
  • Mercaptopurine exhibits cell phase specificity at S-phase by inhibiting DNA synthesis by an as of yet unspecified mechanism.
  • Mercaptopurine is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia. Myelosuppression and gastrointestinal mucositis are expected side effects of mercaptopurine at high doses.
  • a useful mercaptopurine analog is azathioprine.
  • Thioguanine 2-amino- 1 ,7-dihydro-6H-purine-6-thione, is commercially available as TABLOID®.
  • Thioguanine exhibits cell phase specificity at S-phase by inhibiting DNA synthesis by an as of yet unspecified mechanism.
  • Thioguanine is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia.
  • Myelosuppression including leucopenia, thrombocytopenia, and anemia, is the most common dose limiting side effect of thioguanine administration. However, gastrointestinal side effects occur and can be dose limiting.
  • Other purine analogs include pentostatin, erythrohydroxynonyladenine, fludarabine phosphate, and cladribine.
  • Gemcitabine 2'-deoxy-2', 2'-difluorocytidine monohydrochloride ( ⁇ - isomer), is commercially available as GEMZAR®.
  • Gemcitabine exhibits cell phase specificity at S-phase and by blocking progression of cells through the Gl/S boundary.
  • Gemcitabine is indicated in combination with cisplatin in the treatment of locally advanced non-small cell lung cancer and alone in the treatment of locally advanced pancreatic cancer.
  • Myelosuppression including leucopenia, thrombocytopenia, and anemia, is the most common dose limiting side effect of gemcitabine administration.
  • Methotrexate N-[4[[(2,4-diamino-6-pteridinyl) methyl]methylamino] benzoyl] -L-glutamic acid, is commercially available as methotrexate sodium. Methotrexate exhibits cell phase effects specifically at S-phase by inhibiting DNA synthesis, repair and/or replication through the inhibition of dyhydrofolic acid reductase which is required for synthesis of purine nucleotides and thymidylate.
  • Methotrexate is indicated as a single agent or in combination with other chemotherapy agents in the treatment of choriocarcinoma, meningeal leukemia, non- Hodgkin's lymphoma, and carcinomas of the breast, head, neck, ovary and bladder.
  • Myelosuppression (leucopenia, thrombocytopenia, and anemia) and mucositis are expected side effect of methotrexate administration.
  • Camptothecins including, camptothecin and camptothecin derivatives are available or under development as Topoisomerase I inhibitors. Camptothecins cytotoxic activity is believed to be related to its Topoisomerase I inhibitory activity. Examples of camptothecins include, but are not limited to irinotecan, topotecan, and the various optical forms of 7-(4-methylpiperazino-methylene)-10,l l- ethylenedioxy-20-camptothecin described below.
  • Irinotecan is a derivative of camptothecin which binds, along with its active metabolite SN-38, to the topoisomerase I - DNA complex.
  • cytotoxicity occurs as a result of irreparable double strand breaks caused by interaction of the topoisomerase I : DNA : irintecan or SN-38 ternary complex with replication enzymes.
  • Irinotecan is indicated for treatment of metastatic cancer of the colon or rectum.
  • the dose limiting side effects of irinotecan HCl are myelosuppression, including neutropenia, and GI effects, including diarrhea.
  • Topotecan HCl (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-lH- pyrano[3',4',6,7]indolizino[l,2-b]quinoline-3,14-(4H,12H)-dione monohydrochloride, is commercially available as the injectable solution HYCAMTIN®.
  • Topotecan is a derivative of camptothecin which binds to the topoisomerase I - DNA complex and prevents religation of singles strand breaks caused by Topoisomerase I in response to torsional strain of the DNA molecule.
  • Topotecan is indicated for second line treatment of metastatic carcinoma of the ovary and small cell lung cancer.
  • the dose limiting side effect of topotecan HCl is myelosuppression, primarily neutropenia.
  • camptothecin derivative of formula A following, currently under development, including the racemic mixture (R,S) form as well as the R and S enantiomers:
  • Hormones and hormonal analogues are useful compounds for treating cancers in which there is a relationship between the hormone(s) and growth and/or lack of growth of the cancer.
  • hormones and hormonal analogues useful in cancer treatment include, but are not limited to, adrenocorticosteroids such as prednisone and prednisolone which are useful in the treatment of malignant lymphoma and acute leukemia in children; aminoglutethimide and other aromatase inhibitors such as anastrozole, letrazole, vorazole, and exemestane useful in the treatment of adrenocortical carcinoma and hormone dependent breast carcinoma containing estrogen receptors; progestrins such as megestrol acetate useful in the treatment of hormone dependent breast cancer and endometrial carcinoma; estrogens, androgens, and anti-androgens such as flutamide, nilutamide, bicalutamide, cyproterone acetate and 5 ⁇ -reductases
  • GnRH gonadotropin-releasing hormone
  • LH leutinizing hormone
  • FSH follicle stimulating hormone
  • Signal transduction pathway inhibitors are those inhibitors, which block or inhibit a chemical process which evokes an intracellular change. As used herein this change is cell proliferation or differentiation.
  • Signal tranduction inhibitors useful in the present invention include inhibitors of receptor tyrosine kinases, non-receptor tyrosine kinases, SH2/SH3domain blockers, serine/threonine kinases, phosphotidyl inositol-3 kinases, myo-inositol signaling, and Ras oncogenes.
  • Several protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth. Such protein tyrosine kinases can be broadly classified as receptor or non-receptor kinases.
  • Receptor tyrosine kinases are transmembrane proteins having an extracellular ligand binding domain, a transmembrane domain, and a tyrosine kinase domain. Receptor tyrosine kinases are involved in the regulation of cell growth and are generally termed growth factor receptors. Inappropriate or uncontrolled activation of many of these kinases, i.e. aberrant kinase growth factor receptor activity, for example by over-expression or mutation, has been shown to result in uncontrolled cell growth. Accordingly, the aberrant activity of such kinases has been linked to malignant tissue growth. Consequently, inhibitors of such kinases could provide cancer treatment methods.
  • Growth factor receptors include, for example, epidermal growth factor receptor (EGFr), platelet derived growth factor receptor (PDGFr), erbB2, erbB4, vascular endothelial growth factor receptor (VEGFr), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), insulin growth factor -I (IGFI) receptor, macrophage colony stimulating factor (cfms), BTK, ckit, cmet, fibroblast growth factor (FGF) receptors, Trk receptors (TrkA, TrkB, and TrkC), ephrin (eph) receptors, and the RET protooncogene.
  • EGFr epidermal growth factor receptor
  • PDGFr platelet derived growth factor receptor
  • erbB2 erbB4
  • VEGFr vascular endothelial growth factor receptor
  • TIE-2 vascular endothelial growth factor receptor
  • TIE-2 t
  • inhibitors of growth receptors include ligand antagonists, antibodies, tyrosine kinase inhibitors and anti-sense oligonucleotides.
  • Growth factor receptors and agents that inhibit growth factor receptor function are described, for instance, in Kath, John C, Exp. Opin. Ther. Patents (2000) 10(6):803-818; Shawver et al DDT VoI 2, No. 2 February 1997; and Lofts, F. J. et al, "Growth factor receptors as targets", New Molecular Targets for Cancer Chemotherapy, ed. Workman, Paul and Kerr, David, CRC press 1994, London.
  • Non-receptor tyrosine kinases which are not growth factor receptor kinases are termed non-receptor tyrosine kinases.
  • Non-receptor tyrosine kinases for use in the present invention include cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (Focal adhesion kinase), Brutons tyrosine kinase, and Bcr-Abl.
  • Such non-receptor kinases and agents which inhibit non-receptor tyrosine kinase function are described in Sinh, S.
  • SH2/SH3 domain blockers are agents that disrupt SH2 or SH3 domain binding in a variety of enzymes or adaptor proteins including, PI3-K p85 subunit,
  • Src family kinases Src family kinases, adaptor molecules (She, Crk, Nek, Grb2) and Ras-GAP.
  • SH2/SH3 domains as targets for anti-cancer drugs are discussed in Smithgall, T.E.
  • Inhibitors of Serine/Threonine Kinases including MAP kinase cascade blockers which include blockers of Raf kinases (rafk), Mitogen or Extracellular Regulated Kinase (MEKs), and Extracellular Regulated Kinases (ERKs); and Protein kinase C family member blockers including blockers of PKCs (alpha, beta, gamma, epsilon, mu, lambda, iota, zeta).
  • IkB kinase family IKKa, IKKb
  • PKB family kinases akt kinase family members
  • TGF beta receptor kinases TGF beta receptor kinases.
  • Serine/Threonine kinases and inhibitors thereof are described in Yamamoto, T., Taya, S., Kaibuchi, K., (1999), Journal of Biochemistry. 126 (5) 799-803; Brodt, P, Samani, A., and Navab, R. (2000), Biochemical Pharmacology, 60. 1101-1107; Massague, J., Weis-Garcia, F. (1996) Cancer Surveys. 27:41-64; Philip, P.A., and Harris, A.L. (1995), Cancer Treatment and Research. 78: 3-27, Lackey, K. et al Bioorganic and Medicinal Chemistry Letters, (10), 2000, 223-226; U.S. Patent No.
  • Myo-inositol signaling inhibitors such as phospholipase C blockers and Myoinositol analogues.
  • signal inhibitors are described in Powis, G., and Kozikowski A., (1994) New Molecular Targets for Cancer Chemotherapy ed., Paul Workman and David Kerr, CRC press 1994, London.
  • Ras Oncogene Another group of signal transduction pathway inhibitors are inhibitors of Ras Oncogene.
  • Such inhibitors include inhibitors of farnesyltransferase, geranyl-geranyl transferase, and CAAX proteases as well as anti-sense oligonucleotides, ribozymes and immunotherapy.
  • Such inhibitors have been shown to block ras activation in cells containing wild type mutant ras, thereby acting as antiproliferation agents.
  • Ras oncogene inhibition is discussed in Scharovsky, O. G., Rozados, V. R., Gervasoni, S.I. Matar, P. (2000), Journal of Biomedical Science. 7(4) 292-8; Ashby, M.N. (1998), Current Opinion in Lipidology. 9 (2) 99 - 102; and BioChim. Biophys. Acta, (19899) 1423(3):19-30.
  • antibody antagonists to receptor kinase ligand binding may also serve as signal transduction inhibitors.
  • This group of signal transduction pathway inhibitors includes the use of humanized antibodies to the extracellular ligand binding domain of receptor tyrosine kinases.
  • Imclone C225 EGFR specific antibody see Green, M. C. et al, Monoclonal Antibody Therapy for Solid Tumors, Cancer Treat.
  • Herceptin ® erbB2 antibody see Tyrosine Kinase Signalling in Breast cance ⁇ erbB Family Receptor Tyrosine Kniases, Breast cancer Res., 2000, 2(3), 176-183
  • 2CB VEGFR2 specific antibody see Brekken, R. A. et al, Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice, Cancer Res. (2000) 60, 5117-5124).
  • Non-receptor kinase angiogenesis inhibitors may also be useful in the present invention.
  • Inhibitors of angiogenesis related VEGFR and TIE2 are discussed above in regard to signal transduction inhibitors (both receptors are receptor tyrosine kinases).
  • Angiogenesis in general is linked to erbB2/EGFR signaling since inhibitors of erbB2 and EGFR have been shown to inhibit angiogenesis, primarily VEGF expression. Accordingly, non-receptor tyrosine kinase inhibitors may be used in combination with the compounds of the present invention.
  • anti-VEGF antibodies which do not recognize VEGFR (the receptor tyrosine kinase), but bind to the ligand; small molecule inhibitors of integrin (alpha v betas) that will inhibit angiogenesis; endostatin and angiostatin (non-RTK) may also prove useful in combination with the disclosed compounds.
  • VEGFR the receptor tyrosine kinase
  • small molecule inhibitors of integrin alpha v betas
  • endostatin and angiostatin non-RTK
  • Agents used in immunotherapeutic regimens may also be useful in combination with the compounds of formula (I).
  • immunologic strategies to generate an immune response. These strategies are generally in the realm of tumor vaccinations.
  • the efficacy of immunologic approaches may be greatly enhanced through combined inhibition of signaling pathways using a small molecule inhibitor. Discussion of the immunologic/tumor vaccine approach against erbB2/EGFR are found in Reilly RT et al. (2000), Cancer Res. 60: 3569-3576; and Chen Y, Hu D, Eling DJ, Robbins J, and Kipps TJ. (1998), Cancer Res. 58: 1965-1971.
  • Agents used in proapoptotic regimens may also be used in the combination of the present invention.
  • Members of the Bcl-2 family of proteins block apoptosis. Upregulation of bcl-2 has therefore been linked to chemoresistance.
  • EGF epidermal growth factor
  • Cell cycle signalling inhibitors inhibit molecules involved in the control of the cell cycle.
  • a family of protein kinases called cyclin dependent kinases (CDKs) and their interaction with a family of proteins termed cyclins controls progression through the eukaryotic cell cycle. The coordinate activation and inactivation of different cyclin/CDK complexes is necessary for normal progression through the cell cycle.
  • CDKs cyclin dependent kinases
  • Several inhibitors of cell cycle signalling are under development. For instance, examples of cyclin dependent kinases, including CDK2, CDK4, and CDK6 and inhibitors for the same are described in, for instance, Rosania et al, Exp. Opin. Ther. Patents (2000) 10(2):215-230.
  • the cancer treatment method of the claimed invention includes the co-administration a compound of formula I and/or a pharmaceutically acceptable salt thereof and at least one anti-neoplastic agent, such as one selected from the group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors.
  • anti-neoplastic agent such as one selected from the group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors,
  • the pharmaceutically active compounds of the present invention are active as PB kinase inhibitors, particularly the compounds that modulate/inhibit PBK ⁇ , it is useful in treating cancer. Because the pharmaceutically active compounds of the present invention are also active against one or more of PI3K ⁇ , PBK ⁇ , and/or PBK ⁇ , they exhibit therapeutic utility in treating a disease state selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and lung injuries.
  • a disease state selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and lung injuries.
  • a disease state selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, cancer, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection or lung injuries
  • coadministering and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a PB kinase inhibiting compound, as described herein, and a further active ingredient or ingredients, known to be useful in the treatment of such autoimmune disorder, cancer, inflammatory diseases, cardiovascular disease, neurodegenerative disease, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and/or lung injuries.
  • Biological assays PI3K alpha Leadseeker SPA Assay
  • PI3 kinases particularly PI3K ⁇ .
  • the exemplified compounds were tested and found active against PBK ⁇ .
  • the ICso's ranged from about 1 nM to 10 ⁇ M. The majority of the compounds were under 500 nM; the most active compounds were under 10 nM.
  • Example 249 The compound of Example 249 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 1.6 nM against PBK ⁇ .
  • Example 252 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 0.8 nM against PBK ⁇ .
  • the compound of Example 263 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 7.9 nM against PBK ⁇ .
  • Example 289 The compound of Example 289 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 2.5 nM against PBK ⁇ .
  • Example 154 The compound of Example 154 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 316 nM against PBK ⁇ .
  • Example 156 The compound of Example 156 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 79 nM against PBK ⁇ .
  • Example 224 The compound of Example 224 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 1000 nM against PBK ⁇ . Assay principle
  • SPA imaging beads are microspheres containing scintillant which emit light in the red region of the visible spectrum. As a result, these beads are ideally suited to use with a CCD imager such as the Viewlux.
  • the Leadseeker beads used in this system are polystyrene beads that have been coupled with polyethyleneimine. When added to the assay mixture, the beads absorb both the substrate (PIP2) and product (PIP3).
  • Adsorbed P -PIP3 will cause an increase in signal, measured as ADUs (analog to digital units).
  • ADUs analog to digital units
  • Solid compounds are typically plated with 0.1 ⁇ l of 100% DMSO in all wells (except column 6 and 18) of a 384-well, flat bottom, low volume plate (Greiner 784075).
  • the compounds are serially diluted (3-fold in 100% DMSO) across the plate from column 1 to column 12 and column 13 to column 24 and leave column 6 and 18 containing only DMSO to yield 1 lconcentraions for each test compound.
  • the assay buffer contains MOPS (pH 6.5), CHAPS, and DTT.
  • PI3K alpha and PIP2 L-alpha-D-myo-Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2]3-O-phospho linked, D(+)-sn- 1 ,2-di-O-octanoylglyceryl, CellSignals # 901) are mixed and incubated in the plate with compound for 30min prior to starting the reaction with the addition of P 33 -ATP and MgCl 2 (reagents added using Zoom). Enzyme-free wells (column 18) are typically done to determine the low control.
  • PEI-PS Leadseeker beads in PBS/EDTA/CHAPS are added (by Multidrop) to quench the reaction, and the plates are allowed to incubate for at least one hour (typically overnight) before centrifugation.
  • the signal is determined using a Viewlux detector and is then imported into curve fitting software (Activity Base) for construction of concentration response curves.
  • the percent inhibition of activity is calculated relative to high controls (Cl, 0.1 ⁇ l DMSO in column 6, rows A-P)) and low controls
  • IC50 values are converted to pIC50 values, i.e., -log IC50 in Molar concentration.
  • Compound plate o Prepare in polypropylene round-bottomed 96-well plates; 8 compounds per plate, 11-pt titrations of each (3x serial dilution), DMSO in last column (0.15% f.c. on cells) o 15ul in first well, lOul DMSO in the rest; take 5ul from first well and mix in next, continue across plate (excluding last column); seal with foil lid and place at 4degC DAY 2 • Take out Lysis buffer inhibitors (4degC/-20degC) and compound plates
  • Block MSD plates o Make 20ml 3% blocking solution/plate (600 mg blocker A in 20ml
  • BT474, HCC 1954 and T-47D (human breast) were cultured in RPMI- 1640 containing 10% fetal bovine serum at 37°C in 5% CO 2 incubator.
  • Cells were split into T75 flask (Falcon #353136) two to three days prior to assay set up at density which yields approximately 70-80% confluence at time of harvest for assay.
  • Cells were harvested using 0.25% trypsin-EDTA (Sigma #4049). Cell counts were performed on cell suspension using Trypan Blue exclusion staining. Cells were then plated in 384 well black flat bottom polystyrene (Greiner #781086) in 48 ⁇ l of culture media per well at 1,000 cells/well.
  • test compounds were added the following day.
  • the test compounds were prepared in clear bottom polypropylene 384 well plates (Greiner#781280) with consecutive two fold dilutions. 4 ⁇ l of these dilutions were added to 105 ⁇ l culture media, after mixing the solution, 2 ⁇ l of these dilutions were added into each well of the cell plates. The final concentration of DMSO in all wells was 0.15%. Cells were incubated at 37°C, 5% CO 2 for 72 hours.
  • the pharmaceutically active compounds within the scope of this invention are useful as PI3 Kinase inhibitors in mammals, particularly humans, in need thereof.
  • the present invention therefore provides a method of treating diseases associated with PI3 kinase inhibition, particularly: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries and other conditions requiring PI3 kinase modulation/inhibition, which comprises administering an effective compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of Formula (I) also provide for a method of treating the above indicated disease states because of their ability to act as PD inhibitors.
  • the drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.
  • Solid or liquid pharmaceutical carriers are employed.
  • Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • Liquid carriers include syrup, peanut oil, olive oil, saline, and water.
  • the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit.
  • the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
  • the pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.
  • Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably 0.001 - 50 mg/kg.
  • the selected dose is administered preferably from 1-6 times daily, orally or parenterally.
  • Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion.
  • Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular PB kinase inhibitor in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
  • the method of this invention of inducing PB kinase inhibitory activity in mammals, including humans, comprises administering to a subject in need of such activity an effective PB kinase modulating/inhibiting amount of a pharmaceutically active compound of the present invention.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use as a PB kinase inhibitor.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in therapy.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
  • the invention also provides for a pharmaceutical composition for use as a PB inhibitor which comprises a compound of Formula (I) or a pharmaceutically acceptable carrier.
  • the invention also provides for a pharmaceutical composition for use in the treatment of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, which comprises a compound of Formula (I) or a pharmaceutically acceptable carrier.
  • the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, including compounds known to have utility when used in combination with a PB kinase inhibitor.
  • the resultant mixture was filtered to give the title compound (9.13 g) as a tan solid.
  • the residual supernatant was concentrated to dryness and purified by silica gel chromatography (100% ethyl acetate to 2% methanol in ethyl acetate) to provide an additional 0.036 g of the title compound as a tan solid (combined 9.166 g, 92% yield).
  • 6-bromo-4-(l ⁇ -pyrazol-4-yl)quinoline (330 mg,1.2 mmol), 4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi-l,3,2-dioxaborolane (304 mg, 1.2 mmol), dichloro- [l,rbis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (48 mg, 0.06 mmol), potassium acetate (352 mg, 3.6 mmol), in dioxane (5 mL) was heated at 100 °C for 1.5 h and cooled to room temperature. LCMS indicated the reaction was complete (formation of 4-(lH-pyrazol-4-yl)-6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)quinoline).
  • This compound was prepared in one pot (three steps) with no workups between steps.
  • the crude product was partially purified by HPLC chromatography acetonitrile/water/0.1 % TFA. At this point the product was 85% pure. It was free based with sodium carbonate and further purified by silica gel chromatography eluting with methylene chloride/0-2% (methanol/concentrated ammonium hydroxide solution 9/1) to obtain the title compound (29 mg, 0 6%).
  • WO2005110410 was used to prepare intermediates A-C.
  • An oral dosage form for administering the present invention is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.
  • An injectable form for administering the present invention is produced by stirring 1.5% by weight of compound of example 1 in 10% by volume propylene glycol in water.
  • sucrose, calcium sulfate dihydrate and an PI3K inhibitor as shown in
  • Table II below are mixed and granulated in the proportions shown with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with the starch, talc and stearic acid;, screened and compressed into a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)

Abstract

Invented is a method of inhibiting the activity/function of PB kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Description

OUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
Field of the invention
This invention relates to the use of quinoline derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or
PI3Kγ, particularly PI3Kα. Suitably, the present invention relates to the use of quinolines derivatives in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, particularly cancer.
Background of the invention
Cellular membranes represent a large store of second messengers that can be enlisted in a variety of signal transduction pathways. In regards function and regulation of effector enzymes in phospholipids signaling pathways, these enzymes generate second messengers from the membrane phospholipid pools (class I PI3 kinases (e.g. PBKalpha) are dual-specifϊcity kinase enzymes, meaning they display both: lipid kinase (phosphorylation of phosphoinositides) as well as protein kinase activity, shown to be capable of phosphorylation of protein as substrate, including auto-phosphorylation as intramolecular regulatory mechanism. These enzymes of phospholipids signaling are activated in response to a variety of extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters such as described in Scheme I hereinafter and also by intracellular regulation by other signaling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PBKs by intra-cellular signaling events), such as small GTPases, kinases or phosphatases for example. Intracellular regulation can also occur as a result of aberrant expression or lack of expression of cellular oncogenes or tumor suppressors. The inositol phospholipid (phosphoinositides) intracellular signaling pathways begin with activation of signaling molecules (extra cellular ligands, stimuli, receptor dimerization, transactivation by heterologous receptor (e.g. receptor tyrosine kinase) and the recruitment and activation of PBK including the involvement of G-protein linked transmembrane receptor integrated into the plasma membrane.
PBK converts the membrane phospholipid PI(4,5)P2 into PI(3,4,5)P3 that functions as a second messenger. PI and PI(4)P are also substrates of PBK and can be phosphorylated and converted into PBP and PI(3,4)P2, respectively. In addition, these phosphoinositides can be converted into other phosphoinositides by 5'- specific and 3 '-specific phophatases, thus PBK enzymatic activity results either directly or indirectly in the generation of two 3 ' -phosphoinositide subtypes that function as 2n messengers in intra-cellular signal transduction pathways (Trends Biochem. Sci. 22(7) p.267-72 (1997) by Vanhaesebroeck et al: Chem. Rev. 101(8) p.2365-80 (2001) by Leslie et al (2001); Annu. Rev. Cell.Dev. Biol. 17p, 615-75 (2001) by Katso et al. and Cell. MoI. Life Sci. 59(5) p.761-79 (2002) by Toker et al.). Multiple PBK isoforms categorized by their catalytic subunits, their regulation by corresponding regulatory subunits, expression patterns and signaling-specific functions (pi 10a, β, δ and γ) perform this enzymatic reaction (Exp. Cell. Res. 25 (1) p. 239-54 (1999) by Vanhaesebroeck and Katso et al., 2001, above).
The closely related isoforms pi 10a and β are ubiquitously expressed, while δ and γ are more specifically expressed in the haematopoietic cell system, smooth muscle cells, myocytes and endothelial cells (Trends Biochem. Sci. 22(7) p.267-72 (1997) by Vanhaesebroeck et al.). Their expression might also be regulated in an inducible manner depending on the cellular, tissue type and stimuli as well as disease context. Inducibility of protein expression includes synthesis of protein as well as protein stabilization that is in part regulated by association with regulatory subunits. To date, eight mammalian PBKs have been identified, divided into three main classes (I, II, and III) on the basis of sequence homology, structure, binding partners, mode of activation, and substrate preference. In vitro, class I PBKs can phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PI4P), and phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) to produce phosphatidylinositol-3-phosphate (PBP), phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2, and phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3, respectively. Class II PBKs phosphorylate PI and phosphatidylinositol-4-phosphate. Class III PBKs can only phosphorylate PI (Vanhaesebrokeck et al., 1997, above; Vanhaesebroeck et al., 1999, above and Leslie et al, 2001, above)
Scheme I: Conversion of PI(4,5)P2 to PIP3
Figure imgf000004_0001
As illustrated in Scheme A above, phosphoinositide 3-kinases (PBKs) phosphorylate the hydroxyl of the third carbon of the inositol ring. The phosphorylation of phosphoinositides that generate Ptdlns to 3,4,5-trisphosphate (PtdIns(3,4,5)P3), PtdIns(3,4)P2 and PtdIns(3)P produce second messengers for a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell motility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, vesicle trafficking and metabolic pathway (Katso et al, 2001, above and MoL Med. Today 6(9) p. 347-57 (2000) by Stein). G-protein coupled receptors mediate phosphoinositide 3'OH-kinase activation via small GTPases such as Gβγ and Ras, and consequently PI3K signaling plays a central role in establishing and coordinating cell polarity and dynamic organization of the cytoskeleton - which together provides the driving force of cells to move.
Chemotaxis - the directed movement of cells toward a concentration gradient of chemical attractants, also called chemokines is involved in many important diseases such as inflammation/auto-immunity, neurodegeneration, antiogenesis, invasion/metastasis and wound healing (Immunol. Today 21(6) p. 260-4 (2000) by Wyman et al.; Science 287(5455) p. 1049-53 (2000) by Hirsch et al.; FASEB J. 15(11) p. 2019-21 (2001) by Hirsch et al. and Nat. Immunol. 2(2) p. 108-15 (2001) by Gerard et al.).
Advances using genetic approaches and pharmacological tools have provided insights into signalling and molecular pathways that mediate chemotaxis in response to chemoattractant activated G-protein coupled receptors. PI3 -Kinase, responsible for generating these phosphorylated signalling products, was originally identified as an activity associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at the 3'-hydroxyl of the inositol ring (Panayotou et al., Trends Cell Biol. 2 p. 358-60 (1992)). However, more recent biochemical studies revealed that class I PB kinases (e.g. class IB isoform PI3Kγ) are dual-specific kinase enzymes, meaning they display both lipid kinase and protein kinase activity, shown to be capable of phosphorylation of other proteins as substrates, as well as auto-phosphorylation as an intra-molecular regulatory mechanism.
PB -kinase activation, is therefore believed to be involved in a range of cellular responses including cell growth, differentiation, and apoptosis (Parker et al., Current Biology, 5 p. 577-99 (1995); Yao et al., Science, 267 p. 2003-05 (1995)). PB -kinase appears to be involved in a number of aspects of leukocyte activation. A p85-associated PI3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important costimulatory molecule for the activation of T-cells in response to antigen (Pages et al., Nature, 369 p. 327-29 (1994); Rudd, Immunity 4 p. 527-34 (1996)). Activation of T cells through CD28 lowers the threshold for activation by antigen and increases the magnitude and duration of the proliferative response. These effects are linked to increases in the transcription of a number of genes including interleukin-2 (IL2), an important T cell growth factor (Fraser et al., Science 251 p. 313-16 (1991)). Mutation of CD28 such that it can no longer interact with PI3 -kinase leads to a failure to initiate IL2 production, suggesting a critical role for PI3-kinase in T cell activation. PDKγ has been identified as a mediator of G beta-gamma-dependent regulation of JNK activity, and G beta-gamma are subunits of heterotrimeric G proteins (Lopez -Ilasaca et al., J. Biol. Chem. 273(5) p. 2505-8 (1998)). Cellular processes in which PBKs play an essential role include suppression of apoptosis, reorganization of the actin skeleton, cardiac myocyte growth, glycogen synthase stimulation by insulin, TNFα- mediated neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells. Recently, (Laffargue et al., Immunity 16(3) p. 441-51 (2002)) it has been described that PBKγ relays inflammatory signals through various G(i)-coupled receptors and its central to mast cell function, stimuli in context of leukocytes, immunology includes cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example (J. Cell. Sci. 114(Pt 16) p. 2903-10 (2001) by Lawlor et al.; Laffargue et al., 2002, above and Curr. Opinion Cell Biol. 14(2) p. 203-13 (2002) by Stephens et al.).
Specific inhibitors against individual members of a family of enzymes provide invaluable tools for deciphering functions of each enzyme. Two compounds, LY294002 and wortmannin (cf. hereinafter), have been widely used as PB-kinase inhibitors. These compounds are non-specific PI3K inhibitors, as they do not distinguish among the four members of Class I PI3-kinases. For example, the IC50 values of wortmannin against each of the various Class I PI3 -kinases are in the range of 1-10 nM. Similarly, the IC50 values for LY294002 against each of these PI3-kinases is about 15-20 μM (Fruman et al, Ann. Rev. Biochem., 67, p. 481-507 (1998)), also 5-10 microM on CK2 protein kinase and some inhibitory activity on phospholipases. Wortmannin is a fungal metabolite which irreversibly inhibits PI3K activity by binding covalently to the catalytic domain of this enzyme. Inhibition of PBK activity by wortmannin eliminates subsequent cellular response to the extracellular factor. For example, neutrophils respond to the chemokine fJVIet-Leu- Phe (fMLP) by stimulating PDK and synthesizing Ptdlns (3, 4, 5)P3. This synthesis correlates with activation of the respirators burst involved in neutrophil destruction of invading microorganisms. Treatment of neutrophils with wortmannin prevents the fMLP-induced respiratory burst response (Thelen et al., Proc. Natl. Acad. Sci. USA, 91, p. 4960-64 (1994)). Indeed, these experiments with wortmannin, as well as other experimental evidence, shows that PI3K activity in cells of hematopoietic lineage, particularly neutrophils, monocytes, and other types of leukocytes, is involved in many of the non-memory immune response associated with acute and chronic inflammation.
Figure imgf000007_0001
LY294 Wortmannin
Based on studies using wortmannin, there is evidence that PI3-kinase function is also required for some aspects of leukocyte signaling through G-protein coupled receptors (Thelen et al., 1994, above). Moreover, it has been shown that wortmannin and LY294002 block neutrophil migration and superoxide release. Cyclooxygenase inhibiting benzofuran derivatives are disclosed by John M. Janusz et al., in J. Med. Chem. 1998; Vol. 41, No. 18. It is now well understood that deregulation of onocogenes and tumour- suppressor genes contributes to the formation of malignant tumours, for example by way of increase cell growth and proliferation or increased cell survival. It is also now known that signaling pathways mediated by the PBK family have a central role in a number of cell processes including proliferation and survival, and deregulation of these pathways is a causative factor a wide spectrum of human cancers and other diseases (Katso et al., Annual Rev. Cell Dev. Biol, 2001, YV. 615-617 and Foster et al, J. Cell Science, 2003, H6: 3037-3040).
Class I PI3K is a heterodimer consisting of a pi 10 catalytic subunit and a regulatory subunit, and the family is further divided into class Ia and Class Ib enzymes on the basis of regulatory partners and mechanism of regulation. Class Ia enzymes consist of three distinct catalytic subunits (pl lOα, pl lOβ, and pl lOδ) that dimerise with five distinct regulatory subunits (p85α, p55α, p50α, p85β, and p55γ), with all catalytic subunits being able to interact with all regulatory subunits to form a variety of heterodimers. Class Ia PI3K are generally activated in response to growth factor-stimulation of receptor tyrosine kinases, via interaction of the regulatory subunit SH2 domains with specific phospho-tyrosine residues of the activated receptor or adaptor proteins such as IRS-I . Small GTPases (ras as an example) are also involved in the activation of PI3K in conjunction with receptor tyrosine kinase activation. Both pi 10a and pi lOβ are constitutively expressed in all cell types, whereas pi lOδ expression is more restricted to leukocyte populations and some epithelial cells. In contrast, the single Class Ib enzyme consists of a pl lOγ catalytic subunit that interacts with a pi 01 regulatory subunit. Furthermore, the Class Ib enzyme is activated in response to G-protein coupled receptor (GPCR) systems and its expression appears to be limited to leukocytes.
There is now considerable evidence indicating that Class Ia PI3K enzymes contribute to tumourigenesis in a wide variety of human cancers, either directly or indirectly (Vivanco and Sawyers, Nature Reviews Cancer, 2002, 2, 489-501). For example, the pi 10a subunit is amplified in some tumours such as those of the ovary (Shayesteh, et al, Nature Genetics. 1999, 21 : 99-102) and cervix (Ma et al, Oncogene, 2000, \9_: 2739-2744). More recently, activating mutations within pi 10a (PIK3CA gene) have been associated with various other tumors such as those of the colon and of the breast and lung (Samuels, et al., Science, 2004, 304, 554). Tumor- related mutations in p85α have also been identified in cancers such as those of the ovary and colon (Philp et al., Cancer Research, 2001, 6J_, 7426-7429). In addition to direct effects, it is believed that activation of Class Ia PI3K contributes to tumourigenic events that occur upstream in signaling pathways, for example by way of ligand-dependent or ligand-independent activation of receptor tyrosine kinases, GPCR systems or integrins (Vara et al., Cancer Treatment Reviews, 2004, 30, 193- 204). Examples of such upstream signaling pathways include over-expression of the receptor tyrosine kinase Erb2 in a variety of tumors leading to activation of PI3K- mediated pathways (Harari et al., Oncogene, 2000, 19, 6102-6114) and over- expression of the oncogene Ras (Kauffmann-Zeh et al., Nature, 1997, 385, 544- 548). In addition, Class Ia PI3Ks may contribute indirectly to tumourigenesis caused by various downstream signaling events. For example, loss of function of the PTEN tumor-suppressor phosphatase that catalyses conversion of PI(3,4,5)P3 back to PI(4,5)P2 is associated with a very broad range of tumors via deregulation of PI3K- mediated production of PI(3,4,5)P3 (Simpson and Parsons, Exp. Cell Res., 2001, 264, 29-41). Furthermore, augmentation of the effects of other PI3K-mediated signaling events is believed to contribute to a variety of cancers, for example by activation of AKT (Nicholson and Andeson, Cellular Signaling. 2002, 14, 381-395). In addition to a role in mediating proliferative and survival signaling in tumor cells, there is also good evidence that class Ia PI3K enzymes also contributes to tumourigenesis via its function in tumor-associated stromal cells. For examples, PI3K signaling is known to play an important role in mediating angiogenic events in endothelial cells in response to pro-angiogenic factors such as VEGF (abid et al., Arterioscler, Thromb. Vase. Biol., 2004, 24, 294-300). As Class I PI3K enzymes are also involved in motility and migration (Sawyer, Expert Opinion investing. Drugs, 2004, L3, 1-19), PI3K inhibitors are anticipated to provide therapeutic benefit via inhibition of tumor cell invasion and metastasis. Summary of the Invention
This invention relates to novel compounds of Formula (I):
Figure imgf000010_0001
(I)
in which
R2 is an optionally substituted ring system selected from a group consisting of: formula (II), (III), (IV), (V), (VI), (VII),(VIII), (IX) and (X):
Figure imgf000010_0002
Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2; X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (V) to (X) at least one X or Y is not carbon; further provided that R2 is not quinoline or substituted quinoline.
R3 can be attached to any one of the four open carbon positions. Suitably, this invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Suitably, this invention relates to a method of treating cancer, which comprises administering to a subject in need thereof an effective amount of a compound of Formula (I). Suitably, this invention relates to a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and lung injuries, which comprises administering to a subject in need thereof an effective amount of a compound of Formula (I).
Included in the present invention are methods of co-administering the present PB kinase inhibiting compounds with further active ingredients.
Detailed Description of the Invention Present compounds of Formula (I) inhibit one or more PI3 kinases. Suitably, the compounds of formula (I) inhibit PBKα. Also, compounds within the scope of this invention inhibit one or more PB kinases selected from:PI3Kδ, PBKβ and PBKγ. Suitably, this invention relates to novel compounds of Formula (I)(A):
Figure imgf000012_0001
A)
in which
R2 is an optionally substituted ring system selected from a group consisting of: formula (II), (III), and (IV) as defined above;
Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted
C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2;
X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof;
Suitably, included among the presently invented compounds of formula (I) are those of formula (I)(B),
Figure imgf000012_0002
wherein R2 is selected from a group consisting of: formula (V) ,(VI) and (IX) as defined above;
Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2; X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (V), (VI) and (IX) at least one X or Y is not carbon.
Suitably, included among the presently invented compounds of formula (I) are those of formula (I)(C),
Figure imgf000013_0001
wherein R2 is selected from a group consisting of: formula (VII), (VIII) and (X) as defined above; Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2;
X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (VII), (VIII) and (X) at least one X or Y is not carbon.
Suitably, included among the presently invented compounds of formula (I) are those of formula (I)(D):
Figure imgf000014_0001
in which
R2 is an optionally substituted ring system selected from a group consisting of: formula (II), (III), (IV), (V), (VI), and (VIII):
(V (VIM)
Figure imgf000014_0002
Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2;
X is C or N; Y is C, O, N or S; and/or a pharmaceutically acceptable salt thereof; provided that in each of formula (V), (VI) and (VIII) at least one X or Y is not carbon. Suitably, among the present invention are compounds of Formula
(I)(D),wherein Rl is heteroaryl or substituted heteroaryl; R2 is selected from agroup consisting of: formula (III) and formula (VI).
Suitably, among the present invention are compounds of Formulas (I), (I)(A), (I)(B), (I)(C) and (I)(D), wherein R2 is pyridinyl or substituted pyridinyl. Suitably, among the present invention are compounds of Formulas (I), (I)(A),
(I)(B), (I)(C) and (I)(D), wherein R2 is not pyridinyl or substituted pyridinyl.
Suitably, among the present invention are compounds of Formula (I) wherein R2 is an optionally substituted ring system selected from the group consisting of Formulas (V)(A), (VI)(A), (VI)(B) and (IX)(A):
Figure imgf000015_0001
wherein X is C or N; Y is C, O, N or S;
Suitably, among the present invention are compounds of Formula (I) wherein R2 is an optionally substituted ring system selected from the group consisting of Formulas (VII)(A), (VIII)(A) and (X)(A):
(VII) (X)(A)
Figure imgf000016_0001
wherein X is C or N; Y is C, O, N or S; provided that at least one Y is not carbon. Suitably, this invention relates to novel compounds of Formula (I)(G):
in which each Rl, R3, R4 and R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, acyloxy, and aryloxy; or R5 is R6, wherein R6 is -SO2NR80 or -NSO2R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, Cl- C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(Cf^)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or - (CH2)nCOOH, wherein n is 0-2, n is 0-2, m is 0-3; or a pharmaceutically acceptable salt thereof;
Suitably, this invention relates to novel compounds of Formula (I)(H):
Figure imgf000017_0001
in which
Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-βalkyl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, cyano, hydroxyl and alkoxy; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, cyano, hydroxyl and alkoxy; or R5 is R6, wherein R6 is -SO2NR80 or -NSO2R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, Cl- C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C 1 -C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or - (CH2)XOOH, wherein n is 0-2, n is 0-2, m is 0-2; or a pharmaceutically acceptable salt thereof;
Suitably, this invention relates to novel compounds of Formula (I)(J):
Figure imgf000018_0001
in which
Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, cyano, hydroxyl and alkoxy; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, cyano, hydroxyl, alkoxy, nitro; R6 is -SO2NR80 or -NSO2R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, C1-Cβheterocycloalkyl, substituted Cl-C6alkyl, substituted C 1 -C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-Cβcycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH, wherein n is 0-2; n is 0-2, m is 0-2; or a pharmaceutically acceptable salt thereof.
Suitably, this invention relates to novel compounds of Formula (I)(K):
Figure imgf000019_0001
in which Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy; n is 0-2, m is 0-1;
R6 is -SO2NR80 or -NSO2R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, C1-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted C1 -C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: C1-C6alkyl, C1-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH, wherein n is 0-2; or a pharmaceutically acceptable salt thereof.
Suitably, this invention relates to novel compounds of Formula (I)(L):
Figure imgf000020_0001
in which
Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy; R6 is -SO2NR80 or -NSO2R8O, wherein R80 is selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, Cl-C6heterocycloalkyl, substituted Cl- C6alkyl, substituted Cl-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-Cβcycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH; n is 0-2, m is 0-1; or a pharmaceutically acceptable salt thereof.
Suitably, this invention relates to novel compounds of Formula (I)(M):
Figure imgf000021_0001
in which Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy;
R6 is -NSO2R8O, wherein R80 is selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, C1-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1 -C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: C1-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -
(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH; n is 0-2, m is 0-1;
or a pharmaceutically acceptable salt thereof.
Suitably, this invention relates to novel compounds of Formula (I)(N):
Figure imgf000022_0001
in which Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy;
R6 is -SO2NR80, wherein R80 is selected from a group consisting of: Cl- C6alkyl, Cl-C6cycloalkyl, Cl-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -
(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH; n is 0-2, m is 0-1 or a pharmaceutically acceptable salt thereof.
Suitably, this invention relates to compounds of Formulas (I)M) and (I)(N), wherein Rl is selected from the group consisting of: optionally substituted piperazine, optionally susbstituted pyridazine, optionally substituted morphline, optionally substituted pyrazole, substituted amino and optionally substituted piperidine.
Suitably, this invention relates to compounds of Formulas (I)M) and (I)(N), wherein Rl is selected from the group consisting of: optionally substituted piperazine, optionally susbstituted pyridazine, optionally substituted morphline, optionally substituted pyrazole, substituted amino and optionally substituted piperidine;
R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, Cl- C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl and substituted aryl. Suitably, this invention relates to compounds of Formulas (I)M) and (I)(N), wherein Rl is selected from the group consisting of: optionally substituted piperazine, optionally susbstituted pyridazine, optionally substituted morphline, optionally substituted pyrazole, substituted amino and optionally substituted piperidine;
R80 is selected from a group consisting of: aryl optionally substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl- C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl- C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CHz)nCOOH; n is 0-2.
Suitably, this invention relates to the compound defined in formula (I), (I)(A),
(I)(B), (I)(C), (I)D), (I)(E), (I)(F), (I)(G), (I)(H), (I)(J), (I)(K), (I)(M) or (I)(N).
Suitably, among the present invention are compounds selected from a group consisting of: 5-[4-(4-pyridinyl)-6-quinolinyl]- 1H-indazol-3-amine;
4,4'-di-4-pyridinyl-6,6'-biquinoline;
3 - (4-morpholinylsulf onyl) - 5 - [4- (4-pyridinyl) -6-quinolinyl] -2-pyridinamine ;
2-amino-N-methyl- 5 - [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinesulf onamide ;
2-amino-N,N-dimethyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; 2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
5-[4-(4-pyridinyl)-6-quinolinyl]-3-(1H-tetrazol-5-yl)-2-pyridinamine;
6-(3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-4-(4-pyridinyl)quinoline;
6-(l-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(4-pyridinyl)quinoline;
3-(l-piperidinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine; 2-amino-N-ethyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
2-amino-N-[2-(dimethylamino)ethyl]-N-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide; 2-amino-N-(3-pyridinylmethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-N-3-pyridinyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
2-amino-N-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; 2-amino-N-(3-hydroxypropyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
3 - ( 1 -piperazinylsulf onyl) -5 - [4- (4-pyridinyl)- 6-quinolinyl] -2-pyridinamine ;
3-{ [4-(methylsulfonyl)-l-piperazinyl]sulfonyl}-5-[4-(4-pyridinyl)-6-quinolinyl]-2- pyridinamine; 2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-N-[3-(l-pyrrolidinyl)propyl]-3- pyridinesulfonamide;
3-[(3-amino-1H-pyrazol-l-yl)sulfonyl]-5-[4-(4-pyridinyl)-6-quinolinyl]-2- pyridinamine;
3-[(4-methyl-l-piperazinyl)sulfonyl]-5-[4-(4-pyridinyl)-6-quinolinyl]-2- pyridinamine;
2-[4-({2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}sulfonyl)-l- piperazinyl] ethanol ;
2-amino-N-(2,4-difluorophenyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide; 2-amino-N-[3-(2-oxo-l-pyrrolidinyl)propyl]-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-N-2-pyridinyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
2-amino-N-4-pyridinyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
3- { [4-(2-chlorophenyl)- l-piperazinyl]sulfonyl } -5- [4-(4-pyridinyl)-6-quinolinyl] -2- pyridinamine;
2-amino-N-[2-(methyloxy)ethyl]-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
N,N-dimethyl-3-(4-morpholinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2- pyridinamine; N-methyl-3-(4-morpholinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2- pyridinamine;
N-ethyl-3-(4-morpholinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine; N,N-diethyl-3-(4-morpholinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2- pyridinamine;
6-[6-(ethyloxy)-5-(4-morpholinylsulfonyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
6-[6-(methyloxy)-5-(4-morpholinylsulfonyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline; 3-methyl-7-[4-(4-pyridinyl)-6-quinolinyl]-2H-l,2,4-benzothiadiazine 1,1-dioxide;
6-[4-(4-pyridinyl)-6-quinolinyl]-3,4-dihydro-l(2H)-isoquinolinone;
4-(4-pyridinyl)-6-(1H-pyrrolo[2,3-b ]pyridin-5-yl)quinoline;
6-(1H-indazol-5-yl)-4-(4-pyridinyl)quinoline;
6-[4-(4-pyridinyl)-6-quinolinyl]-1H-indazol-3-amine; 4-(4-pyridinyl)-6-(1H-pyrrolo[2,3-b ]pyridin-4-yl)quinoline;
6-(1H-indazol-6-yl)-4-(4-pyridinyl)quinoline;
{3-oxo-6-[4-(4-pyridinyl)-6-quinolinyl]-2,3-dihydro-1H-isoindol-l-yl}acetic acid;
4-(4-pyridinyl)-6-(7H-pyrrolo[2,3-(i]pyrimidin-4-yl)quinoline;
6-[4-(4-pyridinyl)-6-quinolinyl]-l,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; 6-[4-(4-pyridinyl)-6-quinolinyl][l,3]oxazolo[4,5-b]pyridin-2(3H)-one;
6-(1H-pyrazolo[3,4-b ]pyridin-5-yl)-4-(4-pyridinyl)quinoline;
4-(4-pyridinyl)-6-(1H-[l,2,3]triazolo[4,5--b]pyridin-6-yl)quinoline;
6-(1H-imidazo[4,5-b]pyridin-6-yl)-4-(4-pyridinyl)quinoline;
6-(l-oxido-3-pyridinyl)-4-(4-pyridinyl)quinoline; 4-(4-pyridinyl)-6-(1H-pyrrolo[3,2-b ]pyridin-6-yl)quinoline;
5-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrazolo[3,4-b ]pyridin-3-amine;
6-(3-methyl-1H-pyrazolo[3,4-b ]pyrazin-5-yl)-4-(4-pyridinyl)quinoline;
2-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrazolo[3,4-b]pyridin-3- yl}propanamide; N-{5-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrazolo[3,4-b ]pyridin-3-yl}acetamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrazolo[3,4-b ]pyridin-3- yl}methanesulfonamide;
2-(methyloxy)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrazolo[3,4-b ]pyridin-3-yl}acetamide; 6-pyrazolo[l,5-α]pyrimidin-6-yl-4-(4-pyridinyl)quinoline;
5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazolo[3,4-b ]pyridin-3-one;
6-(l-methyl-1H-pyrrolo[3,2-b ]pyridin-6-yl)-4-(4-pyridinyl)quinoline; 6-(3-methyl-1H-pyrazolo[3,4-b ]pyridin-5-yl)-4-(4-pyridinyl)quinoline;
3-[6-(1H-pyrazolo[3,4-b ]pyridin-5-yl)-4-quinolinyl]benzenesulfonamide;
7-[4-(4-pyridinyl)-6-quinolinyl]-2H-pyrido[3,2-b][l,4]oxazin-3(4H)-one;
4-[4-(4-pyridinyl)-6-quinolinyl]-l,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one; 2-amino-N,N-dimethyl-5-[2-methyl-4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-5-[8-fluoro-4-(4-pyridinyl)-6-quinolinyl]-N,N-dimethyl-3- pyridinesulfonamide;
2-amino-N,N-dimethyl-5-[8-methyl-4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-5-[7-fluoro-4-(4-pyridinyl)-6-quinolinyl]-N,N-dimethyl-3- pyridinesulfonamide;
5-[5-fluoro-4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
5-[7-methyl-4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; 5-[5-methyl-4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
4- (4-pyridinyl)- 6- [5- (trifluoromethyl) -3 -pyridinyl] quinoline ;
(4,6-di-4-pyridinylquinoline;
6-(3-pyridinyl)-4-(4-pyridinyl)quinoline;
6-(2-pyridinyl)-4-(4-pyridinyl)quinoline; 6-(2,l,3-benzoxadiazol-5-yl)-4-(4-pyridinyl)quinoline;
6-(2,l,3-benzothiadiazol-5-yl)-4-(4-pyridinyl)quinoline;
5 - [4- (4-pyridinyl)- 6-quinolinyl] -1,2- dihy dro- 3H-pyrazol- 3 - one ;
2-ethyl-6-[4-(4-pyridinyl)-6-quinolinyl]-4(1H)-pyrimidinone;
7 - [4- (4-pyridinyl)- 6-quinolinyl] -2-quinoxalinol ; 2-(4-morpholinyl)-7-[4-(4-pyridinyl)-6-quinolinyl]quinoxaline;
4-(4-morpholinyl)-6-[4-(4-pyridinyl)-6-quinolinyl]quinazoline; l-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one; l-(3-methylphenyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one; l-(3-chlorophenyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one; l-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one;
N-(2,4-difluorophenyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
6-(1H-indol-5-yl)-4-(4-pyridinyl)quinoline; 6-(1H-indol-6-yl)-4-(4-pyridinyl)quinoline;
5-[4-(4-pyridinyl)-6-quinolinyl]-l,3-dihydro-2H-indol-2-one;
6-[4-(4-pyridinyl)-6-quinolinyl]-l,3-dihydro-2H-indol-2-one;
7-[4-(4-pyridinyl)-6-quinolinyl]-4(1H)-quinazolinone; 6-[4-(4-pyridinyl)-6-quinolinyl]-4(1H)-quinazolinone;
6-[4-(4-pyridinyl)-6-quinolinyl]-l,2-benzisothiazol-3(2H)-one 1,1-dioxide;
6-[4-(4-pyridinyl)-6-quinolinyl]-l,8-naphthyridin-2(1H)-one;
6-(l,3-benzoxazol-5-yl)-4-(4-pyridinyl)quinoline;
7-[4-(4-pyridinyl)-6-quinolinyl]-l,4-dihydropyrido[2,3-b]pyrazine-2,3-dione; 3-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinecarboxamide;
5 - [4- (4-pyridinyl)- 6-quinolinyl] - 3-pyridinamine ;
4-[4-(4-pyridinyl)-6-quinolinyl]thieno[2,3-c]pyridine-2-carboxamide; methyl 4-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxylate;
4-[4-(4-pyridinyl)-6-quinolinyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; 6-(lΗ-benzimidazol-2-yl)-4-(4-pyridinyl)quinoline;
6-(lH-imidazo[4,5-c]pyridin-2-yl)-4-(4-pyridinyl)quinoline;
6-(lH-imidazo[4,5-b]pyridin-2-yl)-4-(4-pyridinyl)quinoline;
6-(lH-purin-8-yl)-4-(4-pyridinyl)quinoline;
6-imidazo[l,2-a]pyridin-6-yl-4-(4-pyridinyl)quinoline; 6-imidazo[l,2-a]pyrimidin-6-yl-4-(4-pyridinyl)quinoline;
1 - { 6- [4- (4-pyridinyl)-6-quinolinyl] imidazo [ 1 ,2-a]pyridin-3-yl } - 1 -propanone;
6-(4-pyridazinyl)-4-(4-pyridinyl)quinoline;
1 - { 6- [4- (4-pyridinyl)-6-quinolinyl] imidazo [ 1 ,2-a]pyridin-3-yl } - 1 -propanol;
4-(l-piperidinyl)-6-(lH-pyrazolo[3,4-b]pyridin-5-yl)quinoline; 4-(4-morpholinyl)-6-(lH-pyrazolo[3,4-b]pyridin-5-yl)quinoline;
4-(4-methyl-l-piperazinyl)-6-(lH-pyrazolo[3,4-b]pyridin-5-yl)quinoline;
4- (4-pyridazinyl) -6- ( 1 H-pyrrolo [2 ,3 -b]pyridin- 5 -yl)quinoline ;
6-(lH-imidazo[4,5-b]pyridin-6-yl)-4-(l-piperidinyl)quinoline;
6-(lH-imidazo[4,5-b]pyridin-6-yl)-4-(4-morpholinyl)quinoline; 2-amino-5-{4-[3-(aminosulfonyl)phenyl]-6-quinolinyl}-N,N-dimethyl-3- pyridinesulfonamide;
2-amino-N,N-dimethyl-5-[4-(2-methyl-4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-5-(4-{3-[(dimethylamino)sulfonyl]phenyl}-6-quinolinyl)-N,N-dimethyl-3- pyridinesulfonamide;
2-amino-N,N-dimethyl-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinesulfonamide; 2-amino-N,N-dimethyl-5-[4-(lH-pyrazol-4-yl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-N,N-dimethyl-5-(4-phenyl-6-quinolinyl)-3-pyridinesulfonamide;
2-amino-N,N-dimethyl-5-[4-(lH-pyrazol-3-yl)-6-quinolinyl]-3- pyridinesulfonamide; 2-amino-5-[4-(2,6-dimethyl-4-pyridinyl)-6-quinolinyl]-N,N-dimethyl-3- pyridinesulfonamide;
2-amino-5-(4-{3-[(aminosulfonyl)methyl]phenyl}-6-quinolinyl)-N,N-dimethyl-3- pyridinesulfonamide;
2-amino-5-[4-(3-cyanophenyl)-6-quinolinyl]-N,N-dimethyl-3-pyridinesulfonamide; 2-amino-5-{4-[5-(aminosulfonyl)-3-pyridinyl]-6-quinolinyl}-N,N-dimethyl-3- pyridinesulfonamide;
5,5'-(4,6-quinolinediyl)di(3-pyridinesulfonamide);
2-amino-N,N-dimethyl-5-[4-(3-{[(l-methylethyl)amino]sulfonyl}phenyl)-6- quinolinyl] -3 -pyridinesulfonamide ; 2-amino-N,N-dimethyl-5-(4-{3-[(methylamino)sulfonyl]phenyl}-6-quinolinyl)-3- pyridinesulfonamide;
2-amino-N,N-dimethyl-5-{4-[6-(4-methyl-l-piperazinyl)-3-pyridinyl]-6- quinolinyl } -3-pyridinesulfonamide;
5-[4-(3-cyanophenyl)-6-quinolinyl]-3-pyridinesulfonamide; 5-[4-(2-methyl-4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
5 - [4- (4-pyridazinyl) -6-quinolinyl] -3 -pyridinesulfonamide;
5-{4-[6-(4-methyl-l-piperazinyl)-3-pyridinyl]-6-quinolinyl}-3-pyridinesulfonamide;
5-[4-(2,6-dimethyl-4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
5-[4-(lH-pyrazol-4-yl)-6-quinolinyl]-3-pyridinesulfonamide; 5 - (4- { 3 - [(dimethylamino)sulf onyl] phenyl } - 6-quinolinyl)- 3-pyridinesulfonamide ;
5-[4-(l-methyl-lH-pyrazol-4-yl)-6-quinolinyl]-3-pyridinesulfonamide;
5-{4-[2-(4-morpholinylmethyl)phenyl]-6-quinolinyl}-3-pyridinesulfonamide; 5- { 4- [2- (4-morpholinylcarbonyl)phenyl] -6-quinolinyl } -3-pyridinesulf onamide; 5-{4-[2-(4-morpholinyl)phenyl]-6-quinolinyl}-3-pyridinesulfonamide; 4'-(4-pyridinyl)-3,4-dihydro-6,6'-biquinolin-2(1H)-one; 6-[4-(4-pyridinyl)-6-quinolinyl]-3,4-dihydro-l,8-naphthyridin-2(1H)-one; 2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinecarbaldehyde;
{2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}methyl acetate;
5-[4-(4-pyridinyl)-6-quinolinyl]-2,3-pyridinediamine;
2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinecarboxamide;
6-[4-(4-pyridinyl)-6-quinolinyl]pyrido[2,3-b ]pyrimidin-4(1H)-one; 5-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-l,2-dihydro-3H-pyrazol-3-one;
7-[4-(4-pyridinyl)-6-quinolinyl]pyrido[3,2-b ]pyrimidin-4(1H)-one;
6-[5-(1H-pyrazol-5-yl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
N-(2,4-difluorophenyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinecarboxamide;
6-[2-(methyloxy)-4-pyridinyl]-4-(4-pyridinyl)quinoline; 6- [6- (methyloxy ) - 3 -pyridinyl] -4- (4-pyridinyl)quinoline ;
4-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinol;
6-[2-(methyloxy)-5-pyrimidinyl]-4-(4-pyridinyl)quinoline;
{ 6- [4- (4-pyridinyl)-6-quinolinyl] -2-pyridinyl } methanol;
6-(2-chloro-4-pyridinyl)-4-(4-pyridinyl)quinoline; 4-(4-pyridinyl)-6-(5-pyrimidinyl)quinoline;
5 - [4- (4-pyridinyl)- 6-quinolinyl] -2( 1 Η) -pyrimidinone;
6- [2 , 6-bis (methyloxy ) -3 -pyridinyl] -4- (4-pyridinyl)quinoline ; 6-[6-(4-methyl-l-piperazinyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline; 6-[6-(4-morpholinyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline; 6-(6-chloro-3-pyridinyl)-4-(4-pyridinyl)quinoline;
6-[6-(ethyloxy)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
Ν,Ν-dimethyl-3-({5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinyl}oxy)-l- propanamine;
5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinecarboxamide; methyl 5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinecarboxylate;
N- { 5- [4- (4-pyridinyl) - 6-quinolinyl] -2-pyridinyl } acetamide ;
N-[2-(4-morpholinyl)ethyl]-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine; 6-[6-(l-piperazinyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
6- [5- (methyloxy ) - 3 -pyridinyl] -4- (4-pyridinyl)quinoline ;
6-(6-fluoro-3-pyridinyl)-4-(4-pyridinyl)quinoline;
5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyrimidinecarbonitrile; 6- [2- (methyloxy ) - 3 -pyridinyl] -4- (4-pyridinyl)quinoline ;
5 - [4- (4-pyridinyl)- 6-quinolinyl] - 3-pyridinec arbonitrile ;
6-[6-(methyloxy)-2-pyridinyl]-4-(4-pyridinyl)quinoline;
6-[5-(4-morpholinylcarbonyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
6- [4- (methyloxy) - 3 -pyridinyl] -4- (4-pyridinyl)quinoline ; 6- [5- (4-morpholinylsulf onyl) - 3 -pyridinyl] -4- (4-pyridinyl)quinoline ;
7-[4-(4-pyridinyl)-6-quinolinyl]-2,3-dihydro[l,4]dioxino[2,3-b]pyridine;
5 - [4- (4-pyridinyl)- 6-quinolinyl] - 3-pyridinesulf onamide ;
2-(methyloxy)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinecarbaldehyde;
6-(4-chloro-3-pyridinyl)-4-(4-pyridinyl)quinoline; 4-(4-pyridinyl)-6-[5-(lH-tetrazol-5-yl)-3-pyridinyl]quinoline;
N-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N,N-dimethyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
6- [4-methyl- 6-(methyloxy ) -3 -pyridinyl] -4- (4-pyridinyl)quinoline ;
N-{4-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinyl}acetamide; 6-(4-methyl-3-pyridinyl)-4-(4-pyridinyl)quinoline;
6-[5-(l,3,4-oxadiazol-2-yl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
2-amino-N-(4-pyridinylmethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-N,N-diethyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; 5-[4-(4-pyridinyl)-6-quinolinyl]-3-(l-pyrrolidinylsulfonyl)-2-pyridinamine;
2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-N-[2-(l-pyrrolidinyl)ethyl]-3- pyridinesulfonamide;
6-[6-(methylsulfonyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
2-amino-N-(phenylmethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; 2-amino-N-(2-hydroxyethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide; l-({2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}sulfonyl)-4-piperidinol; 2-amino-N-(2-aminoethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
6-[5-(methylthio)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
6-[5-(methylsulfonyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
2-amino-N-(2-hydroxyethyl)-N-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
2-amino-N-cyclopropyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
2-amino-N-l,3-benzodioxol-5-yl-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide;
N,N-diethyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; l-({5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}sulfonyl)-4-piperidinol;
4-(4-pyridinyl)-6-[5-(l-pyrrolidinylsulfonyl)-3-pyridinyl]quinoline;
N-(2-hydroxyethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N-(phenylmethyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
5-[4-(4-pyridinyl)-6-quinolinyl]-N-[2-(l-pyrrolidinyl)ethyl]-3-pyridinesulfonamide; 6-{5-[(4-methyl-l-piperazinyl)sulfonyl]-3-pyridinyl}-4-(4-pyridinyl)quinoline;
N-cyclopropyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N- [2- (methyloxy )ethyl] -5 - [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinesulfonamide ;
N-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N-l,3-benzodioxol-5-yl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide; N- (3 -pyridinylmethyl) - 5 - [4- (4-pyridinyl) -6-quinolinyl] - 3 -pyridinesulfonamide ;
N-2-pyridinyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N-(2-chlorophenyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N-cyclohexyl- 5 - [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinesulfonamide ;
N- [2- (methyloxy )phenyl] - 5 - [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinesulfonamide; 2,4-difluoro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; l-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-1H-imidazole-4- sulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-2-thiophenesulfonamide;
3,5-dimethyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-4- isoxazolesulfonamide;
3,4-bis(methyloxy)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide; 2-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-l-propanesulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}cyclopropanesulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; and 1 -phenyl-N- { 5 - [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinyl } methanesulf onamide ;
5-{4-[3-chloro-4-(methyloxy)phenyl]-6-quinolinyl}-3-pyridinesulfonamide;
5-{4-[3-(aminosulfonyl)phenyl]-6-quinolinyl}-3-pyridinesulfonamide;
5- { 4-[ 1 -(2-hydroxy ethyl)- lH-pyrazol-4-yl] -6-quinolinyl } - 3 -pyridinesulf onamide;
Ν-(cyclopropylsulfonyl)-Ν-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}cyclopropanesulfonamide;
N-(2,4-difluorophenyl)-5-[4-(l-ethyl-lH-pyrazol-4-yl)-6-quinolinyl]-3- pyridinesulfonamide;
N-methyl-N-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N-(2,4-difluorophenyl)-5-(4-{ l-[2-(dimethylamino)ethyl]-lH-pyrazol-4-yl}-6- quinolinyl)-3-pyridinesulfonamide;
N-(2,4-difluorophenyl)-5-[4-(4-isoquinolinyl)-6-quinolinyl]-3-pyridinesulfonamide;
N-phenyl-N'-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}urea;
2-{4-[6-(5-{ [(2,4-difluorophenyl)amino]sulfonyl}-3-pyridinyl)-4-quinolinyl]-lH- pyrazol- 1 -yl } acetamide ; N-{5-[4-(l-methyl-lH-pyrazol-4-yl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
4'-(4-pyridinyl)-3,6'-biquinoline;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzamide;
5-[4-(l-benzofuran-2-yl)-6-quinolinyl]-N-(2,4-difluorophenyl)-3- pyridinesulfonamide;
6-[5-(lH-pyrazol-4-yl)-3-pyridinyl]-4-(4-pyridinyl)quinoline;
N,N-diethyl-2-oxo-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3- pyridinesulfonamide;
4-cyano-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; N-methyl-N-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinecarboxamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}ethanesulfonamide;
4-(methyloxy)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
4-(l-methylethyl)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
2-chloro- 5 - [4- (4-pyridinyl) -6-quinolinyl] -3 -pyridinamine ; 4-fluoro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{5-[4-(l-ethyl-lH-pyrazol-4-yl)-6-quinolinyl]-3-pyridinyl}-2,4- difluorobenzenesulfonamide;
1 -methyl-N- { 5- [4- (4-pyridinyl)- 6-quinolinyl] - 3 -pyridinyl } - 1 H-pyrazole- 3 - sulfonamide; 2-fiuoro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{2-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{2-cyano-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
2-methyl-5-nitro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
N- { 5- [4- (4-pyridinyl) - 6-quinolinyl] -3 -pyridinyl } - 1 H-pyrazole-4- sulfonamide ;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-2-methyl-5- nitrobenzenesulf onamide ;
N-{2-chloro-5-[4-(l-ethyl-lH-pyrazol-4-yl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
N- { 2-chloro- 5 - [4- (4-pyridazinyl) - 6-quinolinyl] - 3 -pyridinyl } benzenesulf onamide ;
3-nitro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinyl}benzenesulfonamide;
2-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
2,4-difluoro-N-{5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
5-fluoro-2-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-3- nitrobenzenesulf onamide ; N-{2-chloro-5-[4-(2-methyl-4-pyridinyl)-6-quinolinyl]-3- pyridinyl jbenzenesulfonamide;
N- { 2-chloro-5- [4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl } -2- methylbenzenesulf onamide ;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-3- fluorobenzenesulf onamide ;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-2-thiophenesulfonamide; N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}cyclopropanesulfonamide;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-5-fluoro-2- methylbenzenesulf onamide ;
N-(2-chloro-5-{4-[3-(methylsulfonyl)phenyl]-6-quinolinyl}-3- pyridinyl)benzenesulf onamide ; N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-3,5-dimethyl-4- isoxazolesulfonamide;
2,4-difluoro-N-(5-{4-[3-(methylsulfonyl)phenyl]-6-quinolinyl}-3- pyridinyl)benzenesulf onamide ;
2,4-difluoro-N-{5-[4-(2-methyl-4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
3-(methyloxy)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl }benzenesulfonamide;
N-[4-(cyanomethyl)phenyl]-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide;
3-fluoro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; N-{2-(methyloxy)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
N- { 2-chloro-5- [4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl } -2,4- difluorobenzenesulfonamide;
3-nitro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; N-{5-[4-(l-benzofuran-2-yl)-6-quinolinyl]-3-pyridinyl}-2,4- difluorobenzenesulfonamide;
3-cyano-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-4-
(trifluoromethyl)benzenesulfonamide; N-{2-hydroxy-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-3-
(trifluoromethyl)benzenesulfonamide; N-{5-[4-(l-benzofuran-2-yl)-6-quinolinyl]-2-chloro-3- pyridinyl} jbenzenesulfonamide;
N-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzamide;
2,4-difluoro-N-{5-[4-(4-fluorophenyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
N-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
2,4-difluoro-N-[5-(4-pyrazolo[l,5-a]pyridin-3-yl-6-quinolinyl)-3- pyridinyl]benzenesulfonamide;
2,4-difluoro-N-{5-[4-(2-fluorophenyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
2,4-difluoro-N-(5-{4-[4-(trifluoromethyl)phenyl]-6-quinolinyl}-3- pyridinyl)benzenesulf onamide ;
2,4-difluoro-N-(5-{4-[4-(methylsulfonyl)phenyl]-6-quinolinyl}-3- pyridinyl)benzenesulf onamide ; methyl l-methyl-5-[({5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}amino)sulfonyl]- lH-pyrrole-2-carboxylate;
5-bromo-2-(methyloxy)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
5-(5-isoxazolyl)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-2- thiophenesulf onamide;
2,4-difluoro-N-{5-[4-(3-fluorophenyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
2,4-difluoro-N-(5-{4-[3-(trifluoromethyl)phenyl]-6-quinolinyl}-3- pyridinyl)benzenesulf onamide ; 2-chloro-4-cyano-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
N-[5-(4-{3-[(dimethylamino)sulfonyl]phenyl}-6-quinolinyl)-3-pyridinyl]-2,4- difluorobenzenesulfonamide;
N-[5-(4-{4-[(dimethylamino)sulfonyl]phenyl}-6-quinolinyl)-3-pyridinyl]-2,4- difluorobenzenesulfonamide; l,2-dimethyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-lH-imidazole-4- sulf onamide; 3-[6-(5-{[(2,4-difluorophenyl)sulfonyl]amino}-3-pyridinyl)-4- quinolinyl]benzamide;
4-[6-(5-{[(2,4-difluorophenyl)sulfonyl]amino}-3-pyridinyl)-4- quinolinyl]benzamide; N- {4-[6-(5-{ [(2,4-difluorophenyl)sulfonyl] amino }-3-pyridinyl)-4- quinolinyl]phenyl } acetamide ;
N- {3-[6-(5-{ [(2,4-difluorophenyl)sulfonyl] amino }-3-pyridinyl)-4- quinolinyl]phenyl } acetamide ;
6-(4-morpholinyl)-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-3- pyridinesulfonamide;
2-fluoro-4-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-2-furansulfonamide;
1 ,3 -dimethyl-N- { 5 - [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinyl } - 1 H-pyrazole-4- sulfonamide;
N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-2-
(trifluoromethyl)benzenesulfonamide;
N-{2-(methyloxy)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}cyclohexanesulfonamide; N-[5-(4-cyclopentyl-6-quinolinyl)-2-(methyloxy)-3-pyridinyl]benzenesulfonamide;
2,5-dichloro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
3-cyano-4-fluoro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide;
N- { 5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}- 1-pyrrolidinesulfonamide; (5Z)-5-({5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}methylidene)-l,3- thiazolidine-2,4-dione;
N-{2-(methyloxy)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}cyclopropanesulfonamide;
N- { 5- [4- (4-pyridinyl) - 6-quinolinyl] - 3 -pyridinyl } -2-pyridinesulf onamide ; l,2-dimethyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-lH-imidazole-5- sulf onamide; l-methyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-3-(trifiuoromethyl)-lH- pyrazole-4-sulfonamide; l,3,5-trimethyl-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}-lH-pyrazole-4- sulfonamide;
N-{2-(ethyloxy)-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; N,N-dimethyl-N'-{5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}sulfamide;
N- { 2-chloro- 5 - [4- (4-pyridazinyl) - 6-quinolinyl] - 3 -pyridinyl } -2 ,4- difluorobenzenesulfonamide;
N- {2-chloro- l-oxido-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide; N-{6-methyl-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;
N-{2-(methyloxy)-5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl } methanesulf onamide ;
N-{2-chloro-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinyl}methanesulfonamide;
2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide; and/or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating cancer, which comprises co-administering to a subject in need thereof an effective amount of a compound of
Formula (I), and/or a pharmaceutically acceptable salt thereof; and at least one anti- neoplastic agent such as one selected from the group consisting of: anti-microtubule agents, plantinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I hinibitors, hormones and hormonal anlogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors.
This invention also relates to a method of treating cancer, which comprises co-administering to a subject in need thereof an effective amount of a compound of
Formula (I), and/or a pharmaceutically acceptable salt thereof; and at least one signal transduction pathway inhibitor such as one selected from the group consisting of: receptor tyrosine kinase inhibitor, non-receptor tyrosine kinase inhibitor,
SH2/SH3 domain blocker, serine/threonine kinase inhibitor, phosphotidyl inositol-3 kinase inhibitor, myo-inositol singaling inhibitor, and Ras oncogene inhibitor. As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function. Compounds of Formula (I) are included in the pharmaceutical compositions of the invention.
Definitions
By the term "substituted amino" as used herein, is meant -NR30R40 wherein each R30 and R40 is independently selected from a group including hydrogen, C1- 6alkyl, acyl, C3-C7cycloalkyl, wherein at least one of R30 and R40 is not hydrogen.
By the term "acyl" as used herein, unless otherwise defined, is meant -C(O)(alkyl), -C(O)(cycloalkyl), -C(O)(aryl) or -C(O)(heteroaryl), wherein heteroaryl and aryl are optionally substituted.
By the term "aryl" as used herein, unless otherwise defined, is meant aromatic, hydrocarbon, ring system. The ring system may be monocyclic or fused polycyclic (e.g. bicyclic, tricyclic, etc.). In various embodiments, the monocyclic aryl ring is C5-C10, or C5-C7, or C5-C6, where these carbon numbers refer to the number of carbon atoms that form the ring system. A C6 ring system, i.e. a phenyl ring is a suitable aryl group. In various embodiments, the polycyclic ring is a bicyclic aryl group, where suitable bicyclic aryl groups are C8-C12, or C9-C10. A naphthyl ring, which has 10 carbon atoms, is a suitable polycyclic aryl group.
By the term "heteroaryl" as used herein, unless otherwise defined, is meant an aromatic ring system containing carbon(s) and at least one heteroatom. Heteroaryl may be monocyclic or polycyclic. A monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms. A polycyclic heteroaryl ring may contain fused, spiro or bridged ring junctions, for example, bicyclic heteroaryl is a polycyclic heteroaryl. Bicyclic heteroaryl rings may contain from 8 to 12 member atoms. Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (carbons and heteroatoms). Exemplary heteroaryl groups include but are not limited to: benzofuran, benzothiophene, furan, imidazole, indole, isothiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinoline, quinazoline, quinoxaline, thiazole, and thiophene.
By the term "monocyclic heteroaryl" as used herein, unless otherwise defined, is meant a monocyclic heteroaryl ring containing 1-5 carbon atoms and 1-4 hetero atoms.
By the term "alkylcarboxy" as used herein, unless otherwise defined, is meant -(CH2)nCOOR8o, wherein R80 is hydrogen or Cl-C6alkyl, n is 0-6.
By the term "alkoxy" as used herein is meant -O(alkyl) including -OCH3, - OCH2CH3 and -OC(CH3)3 where alkyl is as described herein.
By the term "alkylthio" as used herein is meant -S(alkyl) including -SCH3, - SCH2CH3 where where alkyl is as described herein. The term "cycloalkyl" as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C3-C12.
Examples of cycloalkyl and substituted cycloalkyl substituents as used herein include: cyclohexyl, aminocyclohexyl, cyclobutyl, aminocyclobutyl, 4- hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl4-methoxycyclohexyl, 4- methoxycyclohexyl, 4-carboxycyclohexyl, cyclopropyl, aminocyclopentyl, and cyclopentyl.
By the term "heterocycloalkyl" as used herein is meant a non-aromatic, unsaturated or saturated, monocyclic or polycyclic, heterocyclic ring containing at least one carbon and at least one heteroatom. Exemplary monocyclic heterocyclic rings include: piperidine, piperazine, pyrrolidine, and morpholine. Exemplary polycyclic heterocyclic rings include quinuclidine.
By the term "substituted" as used herein, unless otherwise defined, is meant that the subject chemical moiety has one to five substituents, suitably from one to three substituents selected from the group consisting of: hydrogen, halogen, Cl- Cβalkyl, amino, urea, trifluoromethyl, -(CH2)XOOH, C3-C7cycloalkyl, substituted amino, aryl, heteroaryl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heterocycloalkyl, cyano, hydroxyl, alkoxy, alkylthio, aryloxy, acyloxy, acyl, acylamino, aminoacyl, arylamino, nitro, oxo, -CO2R50, -SO2R70, -NR50SO2R70, NR50C(O)R75 and - CONRssRβo, wherein R50 and R55 are each independently selected from: hydrogen, alkyl, and C3-C7cycloalkyl; R55 and R60 can optionally form a heterocycloalkyl ring; n is O to 6; R75 is selected from the group consisting of: Cl-C6alkyl, C3- 7cylcoalkyl, substituted C3-7cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, amino, substituted amino, arylamino, Cl-C6heterocycloalkyl, alkoxy, aryloxy and substituted Cl-C6heterocycloalkyl; each R60 and R70 is independently selected from the group consisting of: Cl-C6alkyl, C3-C7cycloalkyl, substituted Cl- C6heterocycloalkyl, C1-C6heterocycloalkyl, halogen, amino, substituted amino, arylamino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, -(CH2)nC00H, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from the group consisting of: Cl-C6alkyl, C3-C7cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or - (CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from the group consisting of: Cl- C6alkyl, C3-C7cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH.
By the term "substituted", when referred in the definition of R60, R70, R75, "arylamino", and "aryloxy", is meant that the subject chemical moiety has one to five substituents, suitably from one to three, selected from the group consisting of: hydrogen, Cl-C6alkyl, halogen, trifluoromethyl, -(CH2)nC00H, amino, substituted amino, cyano, hydroxyl, alkoxy, alkylthio, aryloxy, acyloxy, acyl, acylamino, and nitro, n is 0-6.
By the term "acyloxy" as used herein is meant -OC(O)alkyl where alkyl is as described herein. Examples of acyloxy substituents as used herein include: OC(O)CH3, -OC(O)CH(CH3)2 and -OC(O)(CH2)3CH3.
By the term "acylamino" as used herein is meant -N(H)C(O)alkyl, - N(H)C(O)(cycloalkyl) where alkyl is as described herein. Examples of N-acylamino substituents as used herein include: -N(H)C(O)CH3, -N(H)C(O)CH(CH3)2 and -N(H)C(OXCH2)3CH3.
By the term "aminoacyl" as used herein is meant -C(O)N (alkyl)n, - C(O)N(cycloalkyl)n where alkyl is as described herein, n is 1-2. By the term "aryloxy" as used herein is meant -O(aryl), -O(substituted aryl), -O(heteroaryl) or -O(substituted heteroaryl).
By the term "arylamino" as used herein is meant -NRgo(aryl), - NR8o(substituted aryl), -NR8o(heteroaryl) or -NR8o(substituted heteroaryl), wherein R80 is H, Cl-6alkyl or C3-C7cycloalkyl.
By the term "heteroatom" as used herein is meant oxygen, nitrogen or sulfur.
By the term "halogen" as used herein is meant a substituent selected from bromide, iodide, chloride and fluoride.
By the term "alkyl" and derivatives thereof and in all carbon chains as used herein, including alkyl chains defined by the term "-(CH2)n", "-((CH2)m" and the like, is meant a linear or branched, saturated or unsaturated hydrocarbon chain, and unless otherwise defined, the carbon chain will contain from 1 to 12 carbon atoms.
By the term "substituted alkyl" as used herein is meant an alkyl group substituted with one to six substituents selected from the group consisting of: halogen, trifluoromethyl, alkylcarboxy, amino, substituted amino, cyano, hydroxyl, alkoxy, alkylthio, aryloxy, acyloxy, acyl, acylamino, carbamate, urea, sulfonamate,
C3-7cycloheteralkyl, C3-7cycloalkyl and nitro.
Examples of alkyl and substituted alkyl substituents as used herein include:
-CH3, -CH2-CH3, -CH2-CH2-CH3, -CH(CH3)2, -CH2-CH2-C(CH3)3, -CH2-CF3, -C≡C-C(CH3)3, -C≡C-CH2-OH, cyclopropylmethyl, -CH2-C(CH3)2-CH2-NH2, -C≡C-C6H5, -C≡C-C(CH3)2-OH, -CH2-CH(OH)-CH(OH)-CH(OH)-CH(OH)- CH2-OH, piperidinylmethyl, methoxyphenylethyl, -C(CH3)3, -(CH2)3-CH3, -CH2- CH(CH3)2, -CH(CH3)-CH2-CH3, -CH=CH2, and -C≡C-CH3_
By the term "treating" and derivatives thereof as used herein, is meant prophylatic and therapeutic therapy. Prophylatic therapy is meant the institution of measures to protect a person from a disease to which he or she has been, or may be, exposed. Also called preventive treatment.
By the term "co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a PI3 kinase inhibiting compound, as described herein, and a further active ingredient or ingredients. The term further active ingredient or ingredients, as used herein, includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment. Suitably, if the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
The term "compound" as used herein includes all isomers of the compound. Examples of such isomers include: enantiomers, tautomers, rotamers.
In formula (V) to (X), when a "dot" bond is drawn between two atoms, it is meant that such bond can be either single or double bond. A ring system containing such bonds can be aromatic or non-aromatic.
Certain compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers, or two or more diastereoisomers. Accordingly, the compounds of this invention include mixtures of enantiomers/diastereoisomers as well as purified enantiomers/diastereoisomers or enantiomerically/diastereoisomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula I or II above as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted. Further, an example of a possible tautomer is an oxo substituent in place of a hydroxy substituent. Also, as stated above, it is understood that all tautomers and mixtures of tautomers are included within the scope of the compounds of Formula I or II.
Compounds of Formula (I) are included in the pharmaceutical compositions of the invention. Where a -COOH or -OH group is present, pharmaceutically acceptable esters can be employed, for example methyl, ethyl, pivaloyloxymethyl, and the like for -COOH, and acetate maleate and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics, for use as sustained release or prodrug formulations. It has now been found that compounds of the present invention are inhibitors of the Phosphatoinositides 3-kinases (PBKs), particularly PBKα. When the phosphatoinositides 3 -kinase (PBK) enzyme is inhibited by a compound of the present invention, PBK is unable to exert its enzymatic, biological and/or pharmacological effects. The compounds of the present invention are therefore useful in the treatment of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, particularly cancer. Compounds according to Formula (I) are suitable for the modulation, notably the inhibition of the activity of phosphatoinositide 3-kinases (PBK), suitably phosphatoinositides 3-kinase (PBKα). Therefore the compounds of the present invention are also useful for the treatment of disorders which are mediated by PBKs. Said treatment involves the modulation - notably the inhibition or the down regulation - of the phosphatoinositides 3-kinases.
Suitably, the compounds of the present invention are used for the preparation of a medicament for the treatment of a disorder selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation, such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions, cardiovascular diseases such as athero-sclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction.
Suitably, the compounds of Formula (I) are useful for the treatment of autoimmune diseases or inflammatory diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis.
Suitably, the compounds of Formula (I) are useful for the treatment of neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions. Suitably, the compounds of Formula (I) are useful for the treatment of cardiovascular diseases such as atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction.
Suitably, the compounds of Formula (I) are useful for the treatment of chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, in particular melanoma, Karposi's sarcoma, acute and chronic bacterial and virual infections, sepsis, transplantation rejection, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airway inflammation.
Because the pharmaceutically active compounds of the present invention are active as PB kinase inhibitors, particularly the compounds that inhibit PI3Kα, either selectively or in conjunction with one or more of PDKδ, PBKβ, and/or PBKγ, they exhibit therapeutic utility in treating cancer.
Suitably, the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: brain (gliomas), glioblastomas, leukemias, Bannayan-Zonana syndrome, Cowden disease, Lhermitte- Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid.
Suitably, the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: Lymphoblastic T cell leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Hairy- cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, Chronic neutrophilic leukemia, Acute lymphoblastic T cell leukemia, Plasmacytoma, Immunoblastic large cell leukemia, Mantle cell leukemia, Multiple myeloma Megakaryoblastic leukemia, multiple myeloma, Acute megakaryocytic leukemia, promyelocytic leukemia and Erythroleukemia. Suitably, the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma and follicular lymphoma. Suitably, the invention relates to a method of treating cancer in a mammal, including a human, wherein the cancer is selected from: neuroblastoma, bladder cancer, urothelial cancer, lung cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor) and testicular cancer.
When a compound of Formula (I) is administered for the treatment of cancer, the term "co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a PI3 kinase inhibiting compound, as described herein, and a further active ingredient or ingredients, known to be useful in the treatment of cancer, including chemotherapy and radiation treatment. The term further active ingredient or ingredients, as used herein, includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment for cancer. Preferably, if the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
Typically, any anti-neoplastic agent that has activity versus a susceptible tumor being treated may be co-administered in the treatment of cancer in the present invention. Examples of such agents can be found in Cancer Principles and Practice of Oncology by V. T. Devita and S. Hellman (editors), 6th edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Typical antineoplastic agents useful in the present invention include, but are not limited to, anti- microtubule agents such as diterpenoids and vinca alkaloids; platinum coordination complexes; alkylating agents such as nitrogen mustards, oxazaphosphorines, alky Sulfonates, nitrosoureas, and triazenes; antibiotic agents such as anthracyclins, actinomycins and bleomycins; topoisomerase II inhibitors such as epipodophyllotoxins; antimetabolites such as purine and pyrimidine analogues and anti-folate compounds; topoisomerase I inhibitors such as camptothecins; hormones and hormonal analogues; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; and cell cycle signaling inhibitors.
Examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented AKT inhibiting compounds are chemotherapeutic agents.
Anti-microtubule or anti-mitotic agents are phase specific agents active against the microtubules of tumor cells during M or the mitosis phase of the cell cycle. Examples of anti-microtubule agents include, but are not limited to, diterpenoids and vinca alkaloids.
Diterpenoids, which are derived from natural sources, are phase specific anti -cancer agents that operate at the G2/M phases of the cell cycle. It is believed that the diterpenoids stabilize the β-tubulin subunit of the microtubules, by binding with this protein. Disassembly of the protein appears then to be inhibited with mitosis being arrested and cell death following. Examples of diterpenoids include, but are not limited to, paclitaxel and its analog docetaxel.
Paclitaxel, 5β,20-epoxy-l,2α,4,7β,10β,13α-hexa-hydroxytax-l l-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; is a natural diterpene product isolated from the Pacific yew tree Taxus brevifolia and is commercially available as an injectable solution TAXOL®. It is a member of the taxane family of terpenes. It was first isolated in 1971 by Wani et al. J. Am. Chem, Soc, 93:2325. 1971), who characterized its structure by chemical and X-ray crystallographic methods. One mechanism for its activity relates to paclitaxel's capacity to bind tubulin, thereby inhibiting cancer cell growth. Schiff et al., Proc. Natl, Acad, Sci. USA, 77: 1561-1565 (1980); Schiff et al., Nature, 277:665-667 (1979); Kumar, J. Biol, Chem, 256: 10435-10441 (1981). For a review of synthesis and anticancer activity of some paclitaxel derivatives see: D. G. I. Kingston et al., Studies in Organic Chemistry vol. 26, entitled "New trends in Natural Products Chemistry 1986", Attaur-Rahman, P.W. Le Quesne, Eds. (Elsevier, Amsterdam, 1986) pp 219-235. Paclitaxel has been approved for clinical use in the treatment of refractory ovarian cancer in the United States (Markman et al., Yale Journal of Biology and Medicine, 64:583, 1991; McGuire et al., Ann. Intern, Med., 111 :273,1989) and for the treatment of breast cancer (Holmes et al., J. Nat. Cancer Inst., 83:1797,1991.) It is a potential candidate for treatment of neoplasms in the skin (Einzig et. al., Proc. Am. Soc. Clin. Oncol., 20:46) and head and neck carcinomas (Forastire et. al., Sem. Oncol., 20:56, 1990). The compound also shows potential for the treatment of polycystic kidney disease (Woo et. al., Nature, 368:750. 1994), lung cancer and malaria. Treatment of patients with paclitaxel results in bone marrow suppression (multiple cell lineages, Ignoff, RJ. et. al, Cancer Chemotherapy Pocket Guide^ 1998) related to the duration of dosing above a threshold concentration (5OnM) (Kearns, CM. et. al., Seminars in Oncology, 3(6) p.16-23, 1995).
Docetaxel, (2R,3S)- N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5β-20-epoxy-l,2α,4,7β,10β,13α-hexahydroxytax-l l-en-9-one 4-acetate 2- benzoate, trihydrate; is commercially available as an injectable solution as TAXOTERE (D . Docetaxel is indicated for the treatment of breast cancer. Docetaxel is a semisynthetic derivative of paclitaxel q.v., prepared using a natural precursor, 10-deacetyl-baccatin III, extracted from the needle of the European Yew tree. The dose limiting toxicity of docetaxel is neutropenia.
Vinca alkaloids are phase specific anti-neoplastic agents derived from the periwinkle plant. Vinca alkaloids act at the M phase (mitosis) of the cell cycle by binding specifically to tubulin. Consequently, the bound tubulin molecule is unable to polymerize into microtubules. Mitosis is believed to be arrested in metaphase with cell death following. Examples of vinca alkaloids include, but are not limited to, vinblastine, vincristine, and vinorelbine. Vinblastine, vincaleukoblastine sulfate, is commercially available as
VELB AN® as an injectable solution. Although, it has possible indication as a second line therapy of various solid tumors, it is primarily indicated in the treatment of testicular cancer and various lymphomas including Hodgkin's Disease; and lymphocytic and histiocytic lymphomas. Myelosuppression is the dose limiting side effect of vinblastine.
Vincristine, vincaleukoblastine, 22-oxo-, sulfate, is commercially available as ONCOVIN® as an injectable solution. Vincristine is indicated for the treatment of acute leukemias and has also found use in treatment regimens for Hodgkin's and non-Hodgkin's malignant lymphomas. Alopecia and neurologic effects are the most common side effect of vincristine and to a lesser extent myelosupression and gastrointestinal mucositis effects occur. Vinorelbine, 3',4'-didehydro -4'-deoxy-C'-norvincaleukoblastine [R-
(R*,R*)-2,3-dihydroxybutanedioate (l :2)(salt)], commercially available as an injectable solution of vinorelbine tartrate (NA VELB INE®), is a semisynthetic vinca alkaloid. Vinorelbine is indicated as a single agent or in combination with other chemotherapeutic agents, such as cisplatin, in the treatment of various solid tumors, particularly non- small cell lung, advanced breast, and hormone refractory prostate cancers. Myelosuppression is the most common dose limiting side effect of vinorelbine.
Platinum coordination complexes are non-phase specific anti-cancer agents, which are interactive with DNA. The platinum complexes enter tumor cells, undergo, aquation and form intra- and interstrand crosslinks with DNA causing adverse biological effects to the tumor. Examples of platinum coordination complexes include, but are not limited to, cisplatin and carboplatin.
Cisplatin, cis-diamminedichloroplatinum, is commercially available as PLATINOL® as an injectable solution. Cisplatin is primarily indicated in the treatment of metastatic testicular and ovarian cancer and advanced bladder cancer. The primary dose limiting side effects of cisplatin are nephrotoxicity, which may be controlled by hydration and diuresis, and ototoxicity.
Carboplatin, platinum, diammine [l,l-cyclobutane-dicarboxylate(2-)-O,O'], is commercially available as PARAPLATIN® as an injectable solution. Carboplatin is primarily indicated in the first and second line treatment of advanced ovarian carcinoma. Bone marrow suppression is the dose limiting toxicity of carboplatin. Alkylating agents are non-phase anti-cancer specific agents and strong electrophiles. Typically, alkylating agents form covalent linkages, by alkylation, to DNA through nucleophilic moieties of the DNA molecule such as phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazole groups. Such alkylation disrupts nucleic acid function leading to cell death. Examples of alkylating agents include, but are not limited to, nitrogen mustards such as cyclophosphamide, melphalan, and chlorambucil; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; and triazenes such as dacarbazine.
Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-l,3,2- oxazaphosphorine 2-oxide monohydrate, is commercially available as an injectable solution or tablets as CYTOXAN®. Cyclophosphamide is indicated as a single agent or in combination with other chemotherapeutic agents, in the treatment of malignant lymphomas, multiple myeloma, and leukemias. Alopecia, nausea, vomiting and leukopenia are the most common dose limiting side effects of cyclophosphamide.
Melphalan, 4-[bis(2-chloroethyl)amino]-L-phenylalanine, is commercially available as an injectable solution or tablets as ALKERAN®. Melphalan is indicated for the palliative treatment of multiple myeloma and non-resectable epithelial carcinoma of the ovary. Bone marrow suppression is the most common dose limiting side effect of melphalan.
Chlorambucil, 4-[bis(2-chloroethyl)amino]benzenebutanoic acid, is commercially available as LEUKERAN® tablets. Chlorambucil is indicated for the palliative treatment of chronic lymphatic leukemia, and malignant lymphomas such as lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. Bone marrow suppression is the most common dose limiting side effect of chlorambucil.
Busulfan, 1 ,4-butanediol dimethanesulfonate, is commercially available as MYLERAN® TABLETS. Busulfan is indicated for the palliative treatment of chronic myelogenous leukemia. Bone marrow suppression is the most common dose limiting side effects of busulfan. Carmustine, 1, 3 -[bis(2-chloroethyl)-l -nitrosourea, is commercially available as single vials of lyophilized material as BiCNU®. Carmustine is indicated for the palliative treatment as a single agent or in combination with other agents for brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Delayed myelosuppression is the most common dose limiting side effects of carmustine.
Dacarbazine, 5-(3,3-dimethyl- 1 -triazeno)-imidazole-4-carboxamide, is commercially available as single vials of material as DTIC-Dome®. Dacarbazine is indicated for the treatment of metastatic malignant melanoma and in combination with other agents for the second line treatment of Hodgkin's Disease. Nausea, vomiting, and anorexia are the most common dose limiting side effects of dacarbazine. Antibiotic anti-neoplasties are non-phase specific agents, which bind or intercalate with DNA. Typically, such action results in stable DNA complexes or strand breakage, which disrupts ordinary function of the nucleic acids leading to cell death. Examples of antibiotic anti-neoplastic agents include, but are not limited to, actinomycins such as dactinomycin, anthrocyclins such as daunorubicin and doxorubicin; and bleomycins.
Dactinomycin, also know as Actinomycin D, is commercially available in injectable form as COSMEGEN®. Dactinomycin is indicated for the treatment of Wilm's tumor and rhabdomyosarcoma. Nausea, vomiting, and anorexia are the most common dose limiting side effects of dactinomycin. Daunorubicin, (8S-cis-)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo- hexopyranosyl)oxy]-7,8,9, 10-tetrahydro-6,8, 11 -trihydroxy- 1 -methoxy-5 , 12 naphthacenedione hydrochloride, is commercially available as a liposomal injectable form as DAUNOXOME® or as an injectable as CERUBIDINE®. Daunorubicin is indicated for remission induction in the treatment of acute nonlymphocytic leukemia and advanced HIV associated Kaposi's sarcoma. Myelosuppression is the most common dose limiting side effect of daunorubicin.
Doxorubicin, (8S, 10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo- hexopyranosyl)oxy]-8-glycoloyl, 7,8,9,10-tetrahydro-6,8, 11 -trihydroxy- 1 -methoxy- 5,12 naphthacenedione hydrochloride, is commercially available as an injectable form as RUBEX® or ADRIAMYCIN RDF®. Doxorubicin is primarily indicated for the treatment of acute lymphoblastic leukemia and acute myeloblasts leukemia, but is also a useful component in the treatment of some solid tumors and lymphomas. Myelosuppression is the most common dose limiting side effect of doxorubicin.
Bleomycin, a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus, is commercially available as BLENOXANE®. Bleomycin is indicated as a palliative treatment, as a single agent or in combination with other agents, of squamous cell carcinoma, lymphomas, and testicular carcinomas. Pulmonary and cutaneous toxicities are the most common dose limiting side effects of bleomycin.
Topoisomerase II inhibitors include, but are not limited to, epipodophyllotoxins.
Epipodophyllotoxins are phase specific anti-neoplastic agents derived from the mandrake plant. Epipodophyllotoxins typically affect cells in the S and G2 phases of the cell cycle by forming a ternary complex with topoisomerase II and DNA causing DNA strand breaks. The strand breaks accumulate and cell death follows. Examples of epipodophyllotoxins include, but are not limited to, etoposide and teniposide.
Etoposide, 4'-demethyl-epipodophyllotoxin 9[4,6-0-(R )-ethylidene-β-D- glucopyranoside], is commercially available as an injectable solution or capsules as VePESID® and is commonly known as VP-16. Etoposide is indicated as a single agent or in combination with other chemotherapy agents in the treatment of testicular and non-small cell lung cancers. Myelosuppression is the most common side effect of etoposide. The incidence of leucopenia tends to be more severe than thrombocytopenia.
Teniposide, 4'-demethyl-epipodophyllotoxin 9[4,6-0-(R )-thenylidene-β-D- glucopyranoside], is commercially available as an injectable solution as VUMON® and is commonly known as VM-26. Teniposide is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia in children. Myelosuppression is the most common dose limiting side effect of teniposide. Teniposide can induce both leucopenia and thrombocytopenia. Antimetabolite neoplastic agents are phase specific anti-neoplastic agents that act at S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting purine or pyrimidine base synthesis and thereby limiting DNA synthesis. Consequently, S phase does not proceed and cell death follows. Examples of antimetabolite anti-neoplastic agents include, but are not limited to, fluorouracil, methotrexate, cytarabine, mecaptopurine, thioguanine, and gemcitabine. 5 -fluorouracil, 5-fluoro-2,4- (1H,3H) pyrimidinedione, is commercially available as fluorouracil. Administration of 5 -fluorouracil leads to inhibition of thymidylate synthesis and is also incorporated into both RNA and DNA. The result typically is cell death. 5 -fluorouracil is indicated as a single agent or in combination with other chemotherapy agents in the treatment of carcinomas of the breast, colon, rectum, stomach and pancreas. Myelosuppression and mucositis are dose limiting side effects of 5-fluorouracil. Other fiuoropyrimidine analogs include 5-fluoro deoxyuridine (floxuridine) and 5-fluorodeoxyuridine monophosphate.
Cytarabine, 4-amino-l-β-D-arabinofuranosyl-2 (lH)-pyrimidinone, is commercially available as CYTOS AR-U® and is commonly known as Ara-C. It is believed that cytarabine exhibits cell phase specificity at S-phase by inhibiting DNA chain elongation by terminal incorporation of cytarabine into the growing DNA chain. Cytarabine is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia. Other cytidine analogs include 5-azacytidine and 2',2'-difluorodeoxycytidine (gemcitabine). Cytarabine induces leucopenia, thrombocytopenia, and mucositis.
Mercaptopurine, 1 ,7-dihydro-6H-purine-6-thione monohydrate, is commercially available as PURINETHOL®. Mercaptopurine exhibits cell phase specificity at S-phase by inhibiting DNA synthesis by an as of yet unspecified mechanism. Mercaptopurine is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia. Myelosuppression and gastrointestinal mucositis are expected side effects of mercaptopurine at high doses. A useful mercaptopurine analog is azathioprine.
Thioguanine, 2-amino- 1 ,7-dihydro-6H-purine-6-thione, is commercially available as TABLOID®. Thioguanine exhibits cell phase specificity at S-phase by inhibiting DNA synthesis by an as of yet unspecified mechanism. Thioguanine is indicated as a single agent or in combination with other chemotherapy agents in the treatment of acute leukemia. Myelosuppression, including leucopenia, thrombocytopenia, and anemia, is the most common dose limiting side effect of thioguanine administration. However, gastrointestinal side effects occur and can be dose limiting. Other purine analogs include pentostatin, erythrohydroxynonyladenine, fludarabine phosphate, and cladribine. Gemcitabine, 2'-deoxy-2', 2'-difluorocytidine monohydrochloride (β- isomer), is commercially available as GEMZAR®. Gemcitabine exhibits cell phase specificity at S-phase and by blocking progression of cells through the Gl/S boundary. Gemcitabine is indicated in combination with cisplatin in the treatment of locally advanced non-small cell lung cancer and alone in the treatment of locally advanced pancreatic cancer. Myelosuppression, including leucopenia, thrombocytopenia, and anemia, is the most common dose limiting side effect of gemcitabine administration.
Methotrexate, N-[4[[(2,4-diamino-6-pteridinyl) methyl]methylamino] benzoyl] -L-glutamic acid, is commercially available as methotrexate sodium. Methotrexate exhibits cell phase effects specifically at S-phase by inhibiting DNA synthesis, repair and/or replication through the inhibition of dyhydrofolic acid reductase which is required for synthesis of purine nucleotides and thymidylate. Methotrexate is indicated as a single agent or in combination with other chemotherapy agents in the treatment of choriocarcinoma, meningeal leukemia, non- Hodgkin's lymphoma, and carcinomas of the breast, head, neck, ovary and bladder. Myelosuppression (leucopenia, thrombocytopenia, and anemia) and mucositis are expected side effect of methotrexate administration.
Camptothecins, including, camptothecin and camptothecin derivatives are available or under development as Topoisomerase I inhibitors. Camptothecins cytotoxic activity is believed to be related to its Topoisomerase I inhibitory activity. Examples of camptothecins include, but are not limited to irinotecan, topotecan, and the various optical forms of 7-(4-methylpiperazino-methylene)-10,l l- ethylenedioxy-20-camptothecin described below.
Irinotecan HCl, (4S)-4,1 l-diethyl-4-hydroxy-9-[(4-piperidinopiperidino) carbonyloxy]- 1 H-pyrano[3 ' ,4' ,6,7]indolizino[ 1 ,2-b]quinoline-3 , 14(4H, 12H)-dione hydrochloride, is commercially available as the injectable solution CAMPTOSAR®. Irinotecan is a derivative of camptothecin which binds, along with its active metabolite SN-38, to the topoisomerase I - DNA complex. It is believed that cytotoxicity occurs as a result of irreparable double strand breaks caused by interaction of the topoisomerase I : DNA : irintecan or SN-38 ternary complex with replication enzymes. Irinotecan is indicated for treatment of metastatic cancer of the colon or rectum. The dose limiting side effects of irinotecan HCl are myelosuppression, including neutropenia, and GI effects, including diarrhea.
Topotecan HCl, (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-lH- pyrano[3',4',6,7]indolizino[l,2-b]quinoline-3,14-(4H,12H)-dione monohydrochloride, is commercially available as the injectable solution HYCAMTIN®. Topotecan is a derivative of camptothecin which binds to the topoisomerase I - DNA complex and prevents religation of singles strand breaks caused by Topoisomerase I in response to torsional strain of the DNA molecule. Topotecan is indicated for second line treatment of metastatic carcinoma of the ovary and small cell lung cancer. The dose limiting side effect of topotecan HCl is myelosuppression, primarily neutropenia.
Also of interest, is the camptothecin derivative of formula A following, currently under development, including the racemic mixture (R,S) form as well as the R and S enantiomers:
Figure imgf000055_0001
known by the chemical name "7-(4-methylpiperazino-methylene)- 10,11- ethylenedioxy-20(R,S)-camptothecin (racemic mixture) or "7-(4-methylpiperazino- methylene)-10,l l-ethylenedioxy-20(R)-camptothecin (R enantiomer) or "7-(4- methylpiperazino-methylene)- 10, 1 l-ethylenedioxy-20(S)-camptothecin (S enantiomer). Such compound as well as related compounds are described, including methods of making, in U.S. Patent Nos. 6,063,923; 5,342,947; 5,559,235; 5,491,237 and pending U.S. patent Application No. 08/977,217 filed November 24, 1997.
Hormones and hormonal analogues are useful compounds for treating cancers in which there is a relationship between the hormone(s) and growth and/or lack of growth of the cancer. Examples of hormones and hormonal analogues useful in cancer treatment include, but are not limited to, adrenocorticosteroids such as prednisone and prednisolone which are useful in the treatment of malignant lymphoma and acute leukemia in children; aminoglutethimide and other aromatase inhibitors such as anastrozole, letrazole, vorazole, and exemestane useful in the treatment of adrenocortical carcinoma and hormone dependent breast carcinoma containing estrogen receptors; progestrins such as megestrol acetate useful in the treatment of hormone dependent breast cancer and endometrial carcinoma; estrogens, androgens, and anti-androgens such as flutamide, nilutamide, bicalutamide, cyproterone acetate and 5α-reductases such as finasteride and dutasteride, useful in the treatment of prostatic carcinoma and benign prostatic hypertrophy; anti-estrogens such as tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, as well as selective estrogen receptor modulators (SERMS) such those described in U.S. Patent Nos. 5,681,835, 5,877,219, and 6,207,716, useful in the treatment of hormone dependent breast carcinoma and other susceptible cancers; and gonadotropin-releasing hormone (GnRH) and analogues thereof which stimulate the release of leutinizing hormone (LH) and/or follicle stimulating hormone (FSH) for the treatment prostatic carcinoma, for instance, LHRH agonists and antagagonists such as goserelin acetate and luprolide.
Signal transduction pathway inhibitors are those inhibitors, which block or inhibit a chemical process which evokes an intracellular change. As used herein this change is cell proliferation or differentiation. Signal tranduction inhibitors useful in the present invention include inhibitors of receptor tyrosine kinases, non-receptor tyrosine kinases, SH2/SH3domain blockers, serine/threonine kinases, phosphotidyl inositol-3 kinases, myo-inositol signaling, and Ras oncogenes. Several protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth. Such protein tyrosine kinases can be broadly classified as receptor or non-receptor kinases.
Receptor tyrosine kinases are transmembrane proteins having an extracellular ligand binding domain, a transmembrane domain, and a tyrosine kinase domain. Receptor tyrosine kinases are involved in the regulation of cell growth and are generally termed growth factor receptors. Inappropriate or uncontrolled activation of many of these kinases, i.e. aberrant kinase growth factor receptor activity, for example by over-expression or mutation, has been shown to result in uncontrolled cell growth. Accordingly, the aberrant activity of such kinases has been linked to malignant tissue growth. Consequently, inhibitors of such kinases could provide cancer treatment methods. Growth factor receptors include, for example, epidermal growth factor receptor (EGFr), platelet derived growth factor receptor (PDGFr), erbB2, erbB4, vascular endothelial growth factor receptor (VEGFr), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), insulin growth factor -I (IGFI) receptor, macrophage colony stimulating factor (cfms), BTK, ckit, cmet, fibroblast growth factor (FGF) receptors, Trk receptors (TrkA, TrkB, and TrkC), ephrin (eph) receptors, and the RET protooncogene. Several inhibitors of growth receptors are under development and include ligand antagonists, antibodies, tyrosine kinase inhibitors and anti-sense oligonucleotides. Growth factor receptors and agents that inhibit growth factor receptor function are described, for instance, in Kath, John C, Exp. Opin. Ther. Patents (2000) 10(6):803-818; Shawver et al DDT VoI 2, No. 2 February 1997; and Lofts, F. J. et al, "Growth factor receptors as targets", New Molecular Targets for Cancer Chemotherapy, ed. Workman, Paul and Kerr, David, CRC press 1994, London.
Tyrosine kinases, which are not growth factor receptor kinases are termed non-receptor tyrosine kinases. Non-receptor tyrosine kinases for use in the present invention, which are targets or potential targets of anti-cancer drugs, include cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (Focal adhesion kinase), Brutons tyrosine kinase, and Bcr-Abl. Such non-receptor kinases and agents which inhibit non-receptor tyrosine kinase function are described in Sinh, S. and Corey, S.J., (1999) Journal of Hematotherapy and Stem Cell Research 8 (5): 465 - 80; and Bolen, J.B., Brugge, J.S., (1997) Annual review of Immunology. 15: 371-404.
SH2/SH3 domain blockers are agents that disrupt SH2 or SH3 domain binding in a variety of enzymes or adaptor proteins including, PI3-K p85 subunit,
Src family kinases, adaptor molecules (She, Crk, Nek, Grb2) and Ras-GAP. SH2/SH3 domains as targets for anti-cancer drugs are discussed in Smithgall, T.E.
(1995), Journal of Pharmacological and Toxicological Methods. 34(3) 125-32.
Inhibitors of Serine/Threonine Kinases including MAP kinase cascade blockers which include blockers of Raf kinases (rafk), Mitogen or Extracellular Regulated Kinase (MEKs), and Extracellular Regulated Kinases (ERKs); and Protein kinase C family member blockers including blockers of PKCs (alpha, beta, gamma, epsilon, mu, lambda, iota, zeta). IkB kinase family (IKKa, IKKb), PKB family kinases, akt kinase family members, and TGF beta receptor kinases. Such Serine/Threonine kinases and inhibitors thereof are described in Yamamoto, T., Taya, S., Kaibuchi, K., (1999), Journal of Biochemistry. 126 (5) 799-803; Brodt, P, Samani, A., and Navab, R. (2000), Biochemical Pharmacology, 60. 1101-1107; Massague, J., Weis-Garcia, F. (1996) Cancer Surveys. 27:41-64; Philip, P.A., and Harris, A.L. (1995), Cancer Treatment and Research. 78: 3-27, Lackey, K. et al Bioorganic and Medicinal Chemistry Letters, (10), 2000, 223-226; U.S. Patent No. 6,268,391; and Martinez-Iacaci, L., et al, Int. J. Cancer (2000), 88(1), 44-52. Inhibitors of Phosphotidyl inositol-3 Kinase family members including blockers of PI3-kinase, ATM, DNA-PK, and Ku may also be useful in the present invention. Such kinases are discussed in Abraham, R.T. (1996), Current Opinion in Immunology. 8 (3) 412-8; Canman, CE. , Lim, D.S. (1998), Oncogene 17 (25) 3301- 3308; Jackson, S.P. (1997), International Journal of Biochemistry and Cell Biology. 29 (7):935-8; and Zhong, H. et al, Cancer res, (2000) 60(6), 1541-1545.
Also of interest in the present invention are Myo-inositol signaling inhibitors such as phospholipase C blockers and Myoinositol analogues. Such signal inhibitors are described in Powis, G., and Kozikowski A., (1994) New Molecular Targets for Cancer Chemotherapy ed., Paul Workman and David Kerr, CRC press 1994, London.
Another group of signal transduction pathway inhibitors are inhibitors of Ras Oncogene. Such inhibitors include inhibitors of farnesyltransferase, geranyl-geranyl transferase, and CAAX proteases as well as anti-sense oligonucleotides, ribozymes and immunotherapy. Such inhibitors have been shown to block ras activation in cells containing wild type mutant ras, thereby acting as antiproliferation agents. Ras oncogene inhibition is discussed in Scharovsky, O. G., Rozados, V. R., Gervasoni, S.I. Matar, P. (2000), Journal of Biomedical Science. 7(4) 292-8; Ashby, M.N. (1998), Current Opinion in Lipidology. 9 (2) 99 - 102; and BioChim. Biophys. Acta, (19899) 1423(3):19-30.
As mentioned above, antibody antagonists to receptor kinase ligand binding may also serve as signal transduction inhibitors. This group of signal transduction pathway inhibitors includes the use of humanized antibodies to the extracellular ligand binding domain of receptor tyrosine kinases. For example Imclone C225 EGFR specific antibody (see Green, M. C. et al, Monoclonal Antibody Therapy for Solid Tumors, Cancer Treat. Rev., (2000), 26(4), 269-286); Herceptin ® erbB2 antibody (see Tyrosine Kinase Signalling in Breast canceπerbB Family Receptor Tyrosine Kniases, Breast cancer Res., 2000, 2(3), 176-183); and 2CB VEGFR2 specific antibody (see Brekken, R. A. et al, Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice, Cancer Res. (2000) 60, 5117-5124).
Non-receptor kinase angiogenesis inhibitors may also be useful in the present invention. Inhibitors of angiogenesis related VEGFR and TIE2 are discussed above in regard to signal transduction inhibitors (both receptors are receptor tyrosine kinases). Angiogenesis in general is linked to erbB2/EGFR signaling since inhibitors of erbB2 and EGFR have been shown to inhibit angiogenesis, primarily VEGF expression. Accordingly, non-receptor tyrosine kinase inhibitors may be used in combination with the compounds of the present invention. For example, anti-VEGF antibodies, which do not recognize VEGFR (the receptor tyrosine kinase), but bind to the ligand; small molecule inhibitors of integrin (alphav betas) that will inhibit angiogenesis; endostatin and angiostatin (non-RTK) may also prove useful in combination with the disclosed compounds. (See Bruns CJ et al (2000), Cancer Res., 60: 2926-2935; Schreiber AB, Winkler ME, and Derynck R. (1986), Science, 232: 1250-1253; Yen L et al. (2000), Oncogene 19: 3460-3469). Agents used in immunotherapeutic regimens may also be useful in combination with the compounds of formula (I). There are a number of immunologic strategies to generate an immune response. These strategies are generally in the realm of tumor vaccinations. The efficacy of immunologic approaches may be greatly enhanced through combined inhibition of signaling pathways using a small molecule inhibitor. Discussion of the immunologic/tumor vaccine approach against erbB2/EGFR are found in Reilly RT et al. (2000), Cancer Res. 60: 3569-3576; and Chen Y, Hu D, Eling DJ, Robbins J, and Kipps TJ. (1998), Cancer Res. 58: 1965-1971. Agents used in proapoptotic regimens (e.g., bcl-2 antisense oligonucleotides) may also be used in the combination of the present invention. Members of the Bcl-2 family of proteins block apoptosis. Upregulation of bcl-2 has therefore been linked to chemoresistance. Studies have shown that the epidermal growth factor (EGF) stimulates anti-apoptotic members of the bcl-2 family (i.e., mcl-1). Therefore, strategies designed to downregulate the expression of bcl-2 in tumors have demonstrated clinical benefit and are now in Phase II/III trials, namely Genta's G3139 bcl-2 antisense oligonucleotide. Such proapoptotic strategies using the antisense oligonucleotide strategy for bcl-2 are discussed in Water JS et al. (2000), J. Clin. Oncol. 18: 1812-1823; and Kitada S et al. (1994), Antisense Res. Dev. 4: 71- 79.
Cell cycle signalling inhibitors inhibit molecules involved in the control of the cell cycle. A family of protein kinases called cyclin dependent kinases (CDKs) and their interaction with a family of proteins termed cyclins controls progression through the eukaryotic cell cycle. The coordinate activation and inactivation of different cyclin/CDK complexes is necessary for normal progression through the cell cycle. Several inhibitors of cell cycle signalling are under development. For instance, examples of cyclin dependent kinases, including CDK2, CDK4, and CDK6 and inhibitors for the same are described in, for instance, Rosania et al, Exp. Opin. Ther. Patents (2000) 10(2):215-230. In one embodiment, the cancer treatment method of the claimed invention includes the co-administration a compound of formula I and/or a pharmaceutically acceptable salt thereof and at least one anti-neoplastic agent, such as one selected from the group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors. Because the pharmaceutically active compounds of the present invention are active as PB kinase inhibitors, particularly the compounds that modulate/inhibit PBKα, it is useful in treating cancer. Because the pharmaceutically active compounds of the present invention are also active against one or more of PI3Kδ, PBKβ, and/or PBKγ, they exhibit therapeutic utility in treating a disease state selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and lung injuries.
When a compound of Formula (I) is administered for the treatment of a disease state selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, cancer, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection or lung injuries, the term "coadministering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a PB kinase inhibiting compound, as described herein, and a further active ingredient or ingredients, known to be useful in the treatment of such autoimmune disorder, cancer, inflammatory diseases, cardiovascular disease, neurodegenerative disease, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection and/or lung injuries. Biological assays PI3K alpha Leadseeker SPA Assay
Compounds of the present invention were tested according to the following assays and found as inhibitors of PI3 kinases, particularly PI3Kα. The exemplified compounds were tested and found active against PBKα. The ICso's ranged from about 1 nM to 10 μM. The majority of the compounds were under 500 nM; the most active compounds were under 10 nM.
The compound of Example 249 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 1.6 nM against PBKα.
The compound of Example 252 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 0.8 nM against PBKα. The compound of Example 263 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 7.9 nM against PBKα.
The compound of Example 289 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 2.5 nM against PBKα.
The compound of Example 154 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 316 nM against PBKα.
The compound of Example 156 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 79 nM against PBKα.
The compound of Example 224 was tested generally according to the assays described herein and in at least one experimental run exhibited a IC50 value: equal to 1000 nM against PBKα. Assay principle
SPA imaging beads are microspheres containing scintillant which emit light in the red region of the visible spectrum. As a result, these beads are ideally suited to use with a CCD imager such as the Viewlux. The Leadseeker beads used in this system are polystyrene beads that have been coupled with polyethyleneimine. When added to the assay mixture, the beads absorb both the substrate (PIP2) and product (PIP3).
Adsorbed P -PIP3 will cause an increase in signal, measured as ADUs (analog to digital units). This protocol details the use of the PEI-PS Leadseeker beads for assays using His-pl 10/p85 PI3K alpha.
Assay protocol
Solid compounds are typically plated with 0.1 μl of 100% DMSO in all wells (except column 6 and 18) of a 384-well, flat bottom, low volume plate (Greiner 784075). The compounds are serially diluted (3-fold in 100% DMSO) across the plate from column 1 to column 12 and column 13 to column 24 and leave column 6 and 18 containing only DMSO to yield 1 lconcentraions for each test compound.
The assay buffer contains MOPS (pH 6.5), CHAPS, and DTT. PI3K alpha and PIP2 (L-alpha-D-myo-Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2]3-O-phospho linked, D(+)-sn- 1 ,2-di-O-octanoylglyceryl, CellSignals # 901) are mixed and incubated in the plate with compound for 30min prior to starting the reaction with the addition of P33-ATP and MgCl2 (reagents added using Zoom). Enzyme-free wells (column 18) are typically done to determine the low control. PEI-PS Leadseeker beads in PBS/EDTA/CHAPS are added (by Multidrop) to quench the reaction, and the plates are allowed to incubate for at least one hour (typically overnight) before centrifugation. The signal is determined using a Viewlux detector and is then imported into curve fitting software (Activity Base) for construction of concentration response curves. The percent inhibition of activity is calculated relative to high controls (Cl, 0.1 μl DMSO in column 6, rows A-P)) and low controls
(Cl, 5 μl of 40 uM PIP2 in buffer in column 18, rows A-P) using, 100*(l-(Ul-
C2)/(C1-C2)). The concentration of test compound yielding 50% inhibition is determined using the equation, y = ((Vmax*x) / (K+x)) + Y2, where "K" is equal to the IC50. The IC50 values are converted to pIC50 values, i.e., -log IC50 in Molar concentration.
Celluar assays: DAY l
• Plate cells before noon o 1OK cells/well in clear flat-bottomed 96-well plates (f.v. 105ul) o Last four wells in last column receive media only o Place in 37degC incubator overnight
• Compound plate o Prepare in polypropylene round-bottomed 96-well plates; 8 compounds per plate, 11-pt titrations of each (3x serial dilution), DMSO in last column (0.15% f.c. on cells) o 15ul in first well, lOul DMSO in the rest; take 5ul from first well and mix in next, continue across plate (excluding last column); seal with foil lid and place at 4degC DAY 2 • Take out Lysis buffer inhibitors (4degC/-20degC) and compound plates
(4degC), thaw on bench top; make Ix Tris wash buffer (WB) to fill reservoir on plate washer and top off bench supply (use MiIiQ), turn on centrifuge to allow it to cool
• Block MSD plates o Make 20ml 3% blocking solution/plate (600 mg blocker A in 20ml
WB), add 150ul/well and incubate at RT for at least 1 hr
• Add compound (while blocking) o Add 300ul growth media (RPMI w/ Q, 10% FBS) per well (682x dil of compound) to each compound plate o Add 5ul compound dilution into each well (f.v. 11 OuI) on duplicate plates o Place in 37degC incubator for 30min • Make lysates o Prepare MSD Lysis buffer; for 10ml add 200ul protease inhibitor solution, and lOOul each of Phosphatase inhibitors I & II {Keep on ice until ready for use) o Remove plates post-incubation, aspirate media with plate washer, wash Ix with cold PBS, and add 80ul MSD Lysis buffer per well; incubate on shaker at 4degC for >30min o Spin cold at 2500rpm for lOmin; leave plates in 4degC centrifuge until ready for use • AKT duplex assay o Wash plates (4x with 200ul/well WB in plate washer); tap plates on paper towel to blot o Add 60ul of lysates/well, incubate on shaker at RT for 1 hr o During incubation prepare detection Ab (3 ml/plate; 2 ml WB and 1 ml blocking solution w/ Ab at 1OnM); repeat wash step as above o Add 25ul of Ab/well, incubate on shaker at RT for 1 hr; repeat wash step as above o Add 150ul/well Ix Read Buffer (dilute 4x stock in ddH2O,
20ml/plate), read immediately • Analysis o Observe all the data points at each compound concentration. o The data point from highest inhibitor concentration must be equal or greater than 70% of DMSO control. o IC50 for duplicate runs must be within 2-fold of each other (not flagged in summary template). o Y min must be greater than zero; if both mins are red flagged (>35) then compound is listed as inactive (IC50= > highest dose). If only one min is red flagged, but still <50 then call IC50 as listed. o Any data points equal or greater than 30% off the curve will not be considered. Cell Growth/Death Assay:
BT474, HCC 1954 and T-47D (human breast) were cultured in RPMI- 1640 containing 10% fetal bovine serum at 37°C in 5% CO2 incubator. Cells were split into T75 flask (Falcon #353136) two to three days prior to assay set up at density which yields approximately 70-80% confluence at time of harvest for assay. Cells were harvested using 0.25% trypsin-EDTA (Sigma #4049). Cell counts were performed on cell suspension using Trypan Blue exclusion staining. Cells were then plated in 384 well black flat bottom polystyrene (Greiner #781086) in 48 μl of culture media per well at 1,000 cells/well. All plates were placed at 5% CO2, 37°C overnight and test compounds were added the following day. One plate was treated with CellTiter-Glo (Promega #G7573) for a day 0 (t=0) measurement and read as described below. The test compounds were prepared in clear bottom polypropylene 384 well plates (Greiner#781280) with consecutive two fold dilutions. 4 μl of these dilutions were added to 105 μl culture media, after mixing the solution, 2 μl of these dilutions were added into each well of the cell plates. The final concentration of DMSO in all wells was 0.15%. Cells were incubated at 37°C, 5% CO2 for 72 hours. Following 72 hours of incubation with compounds each plate was developed and read. CellTiter-Glo reagent was added to assay plates using a volume equivalent to the cell culture volume in the wells. Plates were shaken for approximately two minutes and incubated at room temperature for approximately 30 minutes and chemiluminescent signal was read on the Analyst GT (Molecular Devices) reader. Results were expressed as a percent of the t=0 and plotted against the compound concentration. Cell growth inhibition was determined for each compound by fitting the dose response with a 4 or 6 parameter curve fit using XLfit software and determining the concentration that inhibited 50% of the cell growth (gIC50) with the Y min as the t=0 and Y max as the DMSO control. Value from wells with no cells was subtracted from all samples for background correction. Additional references: The compounds of the present invention can also be tested to determine their inhibitory activity at PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ according to the assays in the following references: For all PBK isoforms:
1. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms: Meier, T.I.; Cook, J.A.; Thomas, J.E.; Radding, J.A.; Horn, C; Lingaraj, T.; Smith, M. C. Protein Expr. Purif, 2004, 35(2), 218.
2. Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity: Drees, B. E.; Weipert, A.; Hudson, H.; Ferguson, C. G.; Chakravarty, L.; Prestwich, G.D. Comb. Chem. High Throughput. Screen., 2003, 6(4), 321. For PI3Kγ: WO 2005/011686 Al
The pharmaceutically active compounds within the scope of this invention are useful as PI3 Kinase inhibitors in mammals, particularly humans, in need thereof.
The present invention therefore provides a method of treating diseases associated with PI3 kinase inhibition, particularly: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries and other conditions requiring PI3 kinase modulation/inhibition, which comprises administering an effective compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) also provide for a method of treating the above indicated disease states because of their ability to act as PD inhibitors. The drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.
The pharmaceutically active compounds of the present invention are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products. Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably 0.001 - 50 mg/kg. When treating a human patient in need of a PBK inhibitor, the selected dose is administered preferably from 1-6 times daily, orally or parenterally. Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular PB kinase inhibitor in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
The method of this invention of inducing PB kinase inhibitory activity in mammals, including humans, comprises administering to a subject in need of such activity an effective PB kinase modulating/inhibiting amount of a pharmaceutically active compound of the present invention.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use as a PB kinase inhibitor. The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in therapy.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
The invention also provides for a pharmaceutical composition for use as a PB inhibitor which comprises a compound of Formula (I) or a pharmaceutically acceptable carrier.
The invention also provides for a pharmaceutical composition for use in the treatment of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, which comprises a compound of Formula (I) or a pharmaceutically acceptable carrier.
In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, including compounds known to have utility when used in combination with a PB kinase inhibitor. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
Experimental Details
The compounds of the following examples are readily made according to Schemes 1 or by analogous methods. Scheme 1:
Figure imgf000070_0001
Conditions: a) 2 M HCl in diethylether, THF, rt; then sodium iodide, propionitrile, reflux; b) aryl (Rl) bromide, palladium catalyst, 2 M K2CO3, dioxane, heat; c) bis(pinacolato)diboron, potassium acetate, palladium catalyst, dioxane, heat; d) heteroaryl (R2) bromide, palladium catalyst, saturated aqueous NaHCθ3, dioxane, heat.
Example 1
5 - [4- (4-pyridinyl)- 6-quinolinyl] - 3-pyridinesulf onamide
Figure imgf000070_0002
a) 6-bromo-4-iodoquinoline
Following the general procedure of Wolf, Christian et al. (SynLett 2003 12, 1801-1804), to a solution of 6-bromo-4-chloroquinoline (30 g, 0.124 mol) in anhydrous THF (500 mL) was added 2 M HCl in diethylether (74 mL, 0.148 mol). A white precipitate formed immediately. After stirring for 30 min, the suspension was concentrated in vacuo and dried under vacuum to provide 6-bromo-4- chloroquinoline hydrochloride as an off-white solid (34.6 g, quantitative yield).
A 3-neck roundbottom flask equipped with a reflux condenser and mechanical stirrer was charged with 6-bromo-4-chloroquinoline hydrochloride (34.6 g, 0.124 mol), anhydrous sodium iodide (92.93 g, 0.62 mol) and propionitrile (1 L). The resulting slurry was stirred vigorously at reflux for 96 hrs. The solution was cooled to room temperature and 500 mL of 10% K2CO3 solution was added, followed by a 200 mL of a 5% sodium sulfite solution. The reaction mixture was extracted with CH2Cl2 (600 mL x 4). The combined organic extracts were dried (Na2SO4), filtered and cone, in vacuo to provide the title compound as an off-white solid (41.8 g, Quantitative yield), which was used without further purification. LCMS [M]+ = 333.8, 334.8, 336.0 and 337.0; H1 NMR (400 MHz, rf-DMSO) δ (ppm) = 7.98-7.96 (2 H, m), 8.14-8.16 (1 H, m), 8.23 (1 H, d), 8.53 (1 H, d).
b) 6-bromo-4- (4-pyridinyl)quinoline
A l L sealed tube charged with 6-bromo-4-iodoquinoline (11.58 g, 0.0347 mol), 4-pyridineboronic acid (5.97 g, 0.0486 mol), tetrakis(triphenyphosphine)palladium[0] (2.0 g, 0.00173 mol), 2 M aqueous potassium carbonate (152 mL) and 1,4-dioxane (152 mL) was stirred at 100 °C for 28 hrs. After cooling to rt, the organic layer was separated and the aqueous portion extracted with EtOAc (200 mL x 3). The combined organic extracts were dried (Na2SO4), filtered and partially concentrated in vacuo. The resultant mixture was filtered to give the title compound (9.13 g) as a tan solid. The residual supernatant was concentrated to dryness and purified by silica gel chromatography (100% ethyl acetate to 2% methanol in ethyl acetate) to provide an additional 0.036 g of the title compound as a tan solid (combined 9.166 g, 92% yield).
LCMS [M]+ =285.9; 287.8. H1 NMR (400 MHz, J-DMSO) δ (ppm) = 7.53- 7.71 (3 H, m), 7.85 (1 H, s), 8.05 (1 H, d), 8.17 (1 H, d), 8.81 (2 H, d), 9.05 (1 H, d)
c) 4-(4-pyridinyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinoline
A mixture of (6-bromo-4-(4-pyridinyl)quinoline (5.0 g, 17.5 mmol), bis(pinacolato)diboron (4.9 g, 19.3 mmole), potassium acetate (5.2 g, 52.6 mmol), and dichloro-[l,rbis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (430 mg, 0.53 mmol) in dioxane (30 mL) was heated at 130 °C for 4 h and cooled to room temperature. The reaction was cooled and filtered through Na2SO4 and Celite onto silica. The mixture was purified by silica gel chromatography eluting with EtOAc/ ethanol (0-20% methanol gradient) to give the title compound as a semi-pure solid. (2.14 g, 64 % ) mix of boronic acid and ester used without further purification.
d) 5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonamide
A mixture of 4-(4-pyridmyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)quinoline (250 mg, 0.75 mmol), 5-bromopyridine-3-sulfonamide (213 mg, 0.9 mmol), tetrakistriphenylphosphine palladium (0) (95 mg, 0.08 mmol), and saturated aqueous NaHCO3 (2.5 mL), and dioxane (5 mL) ) was heated at 120 °C for 1 h and cooled to room temperature. The reaction mixture was filtered through Celite and the solvent was removed under reduced pressure. The crude product was purified by Gilson reverse phase HPLC (8-25% 6 min gradient 0.1% TFA in H2O / CH3CN) followed by neutralization with saturated aqueous NaHCO3 and extracted into EtOAc. Evaporation provided the title compound as an off white solid. (85 mg, 31%). ESMS [M+H]+= 363.1
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 1:
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0003
Scheme 2:
Figure imgf000093_0001
Conditions: a) heteroaryl (R2) boronic acid or heteroaryl (R2) boronate, palladium catalyst, 2 M potassium carbonate, heat, or heteroaryl (R2) stannane, palladium catalyst, dioxane, heat.
Example 107
6-[5-(methylsulfonyl)-3-pyridinyl]-4-(4-pyridinyl)quinoline
Figure imgf000093_0002
A mixture of (6-bromo-4-(4-pyridinyl)quinoline (250 mg, 0.88 mmol), 5- methylsulfonyl pyridine-3-boronic acid (201 mg, 1.0 mmol), tetrakistriphenylphosphme palladium (0) (104 mg, 0.09 mmol), and sat. aqueous NaHCO3 (1.75 mL), in dioxane (5 mL) was heated at 110 °C for 1 h then cooled to room temperature. The rxn was filtered through Celite and Na2SO4 onto silica and the crude product was purified by column chromatography (5% EtOAc/Hex - 10% Ethanol/EtOAc ; 30 min gradient). Evaporation and precipitation from MeOH/water (2/98) provided the title compound as a yellow solid. (160 mg, 50%). ESMS [M+H]+= 362.1
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 107:
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0003
Scheme 3:
Figure imgf000098_0001
Conditions: a) aryl (Rl) boronic acid or aryl (Rl) boronate, palladium catalyst, 2 M potassium carbonate, dioxane, heat; then heteroaryl (R2) boronic acid or heteroaryl (R2) boronate, palladium catalyst, 2 M potassium carbonate, heat.
Example 139
2-amino-5-{4-[3-(aminosulfonyl)phenyl]-6-quinolinyl}-3-pyridinesulfonamide
Figure imgf000098_0002
A mixture of 4-iodo-6-bromoquinoline (1.18 g, 3.53 mmol), 3-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzenesulfonamide (1 g, 3.53 mmol), dichloro- [l,rbis(diphenylphosphino) ferrocene] palladium (II) dichloromethane adduct (177 mg, 0.176 mmol), 2 M potassium carbonate (5 mL), in dioxane (15 mL) was heated at 100 °C for 1.5 h and cooled to room temperature. LCMS indicated the reaction was finished. To the finished reaction was added 2-amino-5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3-pyridinesulfonamide (1.2 g, 4 mmol), Dichloro- [l,l'bis(diphenylphosphino) ferrocene] Palladium (II) dichloromethane adduct (177 mg, 0.176 mmol), and 2 M potassium carbonate (5 mL). The reaction was heated at 100°C for 3 h and cooled to room temperature. The dioxane and water were separated and the dioxane evaporated to get the crude product which was purified on silica gel eluting with ethyl acetate/methanol, 0-3% methanol. The product which crystallized from ethyl acetate contained ethyl acetate. The ethyl acetate was removed by dissolving the product in a excess of acetone and evaporation. Residual acetone was then removed by triturating with distilled water at 60 deg followed by filtration and drying under vacuum. A yield of the title compound (540 mg, 31 %) was obtained. MS(ES)+ m/e 484 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 139
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0003
Scheme 4:
Figure imgf000101_0001
Conditions: a) aryl (Rl) boronic acid or aryl (Rl) boronate, palladium catalyst, 2 M potassium carbonate, dioxane, heat; b) bis(pinacolato)diboron, potassium acetate, palladium catalyst, dioxane, heat; then heteroaryl (R2) bromide, palladium catalyst, 2 M potassium carbonate, heat.
Example 153
2-amino-5-[4-(1H-pyrazol-4-yl)-6-quinolinyl]-3-pyridinesulfonamide
Figure imgf000101_0002
a) 6-bromo-4-(1H-pyrazol-4-yl)quinoline A mixture of 6-bromo-4-iodoquinoline (1.37 g, 4 mmol) and 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lΗ-pyrazole (852 mg, 4 mmol), dichloro- [l,l'bis(diphenylphosphino) ferrocene] palladium (II) dichloromethane adduct (162 mg, 0.2 mmol), 2 M potassium carbonate (6 mL), in dioxane (25 mL) was heated at 100 °C for 1.5 h and cooled to room temperature.The dioxane and water were separated and the dioxane evaporated to get the crude product which was purified on silica gel eluting with ethyl acetate/methanol, 0-3% methanol. A yield of the title compound (340 mg, 34 %) was obtained. MS(ES)+ m/e 275 [M+H]+.
b) 2-amino-5-[4-(1H-pyrazol-4-yl)-6-quinolinyl]-3-pyridinesulfonamide
6-bromo-4-(lΗ-pyrazol-4-yl)quinoline(330 mg,1.2 mmol), 4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi-l,3,2-dioxaborolane (304 mg, 1.2 mmol), dichloro- [l,rbis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (48 mg, 0.06 mmol), potassium acetate (352 mg, 3.6 mmol), in dioxane (5 mL) was heated at 100 °C for 1.5 h and cooled to room temperature. LCMS indicated the reaction was complete (formation of 4-(lH-pyrazol-4-yl)-6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)quinoline).
To this same reaction mixture was added dichloro- [l,rbis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (48 mg, 0.06 mmol), 2-amino-5-bromo-3-pyridinesulfonamide (280 mg, 1 mmol) and 2 M potassium carbonate (1.5 mL). The reaction mixture was heated a second time to 115 °C for 18 h. The dioxane and water were separated and the dioxane evaporated. The crude product was trituated with methylene chloride (insoluble), then dissolved in DMF and filtered through a glass fiber filter. The DMF was evaporated and the product triturated with methanol, filtered and dried. A yield of the title compound (108 mg, 22 %, two steps) was obtained. MS(ES)+ m/e 395 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 153
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0003
Scheme 5:
Figure imgf000110_0001
Conditions: a) bis(pinacolato)diboron, p palladium catalyst, potassium acetate, dioxane, heat; then heteroaryl (R2) bromide, palladium catalyst, 2 M potassium carbonate, heat; then aryl (Rl) boronic acid or aryl (Rl) boronate, palladium catalyst, 2 M potassium carbonate, heat.
Example 189
2-amino-5-{4-[3-(aminosulfonyl)phenyl]-6-quinolinyl}-3-pyridinesulfonamide
Figure imgf000110_0002
This compound was prepared in one pot (three steps) with no workups between steps. A mixture of 6-bromo-4-chloroquinoline, (484 mg, 2 mmol), bis(pinacolato)diboron, (506 mg, 2 mmol), dichloro- [l,l'bis(diphenylphosphino) ferrocene] palladium (II) dichloromethane adduct (81.5 mg, 0.1 mmol), and potassium acetate (588 mg, 6 mmol) in dioxane (6 mL) was heated at 100 °C for 4 h. To this reaction was added 2-amino-5-bromo-3-pyridinesulfonamide, (560 mg 2 mmol) an equal amount of the palladium catalyst used above (0.1 mmol) and 2 M potassium carbonate (3 mL). The reaction was heated at 95 deg centigrade for one hour. To this reaction was added 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzenesulfonamide, (566 mg 2 mmol), dichloro- [l,l'bis(diphenylphosphino) ferrocene] palladium (II) dichloromethane adduct (81.5 mg, 0.1 mmol) and 2 M potassium carbonate (3 mL). The reaction was heated at 95 °C for three hours. The solvent was evaporated and the crude material purified by silica gel chromatography, eluting with ethyl acetate. The product was purified further by crystallizing from hot ethyl acetate. Obtained 181 mg (18.7%) for three steps. MS(ES)+ m/e 484 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 189:
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0003
Scheme 6:
Figure imgf000116_0001
Conditions: a) hexamethylditin, tetrakis(thπphenylphosphine)palladmm (0), lithium chloride, tetrahydrofuran, heat; b) heteroaryl (R2) bromide, palladium catalyst, dioxane, heat.
Example 197
4-(4-pyridmyl)-6-(1H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)quinoline
Figure imgf000116_0002
a) 4-(4-pyridinyl)-6-(trimethylstannanyl)quinoline
A mixture of 4-(4-pyridinyl)-6-bromoquinoline (15 g, 53 mmol), hexamethylditin (19 g, 59 mmol), lithium chloride (16 g, 370 mmol), tetrakis(triphenyphosphine)-palladium (0) (3 g, 2.7 mmol), in tetrahydrofuran (400 mL) was heated at reflux for 16 hours, at which time the reaction was allowed to cool to room temperature and concentrated under reduced pressure. Methylene chloride (500 mL) was added to the residue and the mixture was stirred for 2 hours to help break up the solids. The mixture was then filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (gradient: CH2Cl2 to 2% MeOH/CH2Cl2) to give the title compound (11 g, 56 %) as a beige solid. MS(ES)+ m/e 370 [M+H]+.
b) 4-(4-pyridinyl)-6-(1H-[l,2,3]triazolo[4,5-b ]pyridin-6-yl)quinoline
A mixture of 6-bromo-1H-[l,2,3]triazolo[4,5-£>]pyridine (100 mg, 0.5 mmol), 4-(4-pyridinyl)-6-(trimethylstannanyl)quinoline (204 mg, 0.55 mmol), and tetrakistriphenylphosphine palladium(O) (29 mg, 0.025 mmol) in 1,4-dioxane (3.0 mL) was heated at 100 °C for 18 h. The reaction was filtered to collect the precipitate. The solid was triturated in hot ethanol to give an off-white solid, which still contained some minor impurities. The off-white solid was triturated in hot ethanol to give the title product as a beige solid (22 mg, 14%). MS(ES)+ m/e 325.1 [M+Η]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 197:
Figure imgf000117_0001
Figure imgf000118_0002
Scheme 7:
Figure imgf000118_0001
Conditions: a) diethylethoxymethylene malonate, 140 0C, then Dowtherm A, 260 0C; b) 6 N sodium hydroxide, ethanol, reflux; c) Dowtherm A, 260 °C; d) phosphorous oxychloride, reflux; e) bis(pinacolato)diboron, palladium catalyst, potassium acetate, dioxane, heat, then heteroaryl (R2) bromide, palladium catalyst, 2 M aqueous potassium carbonate, heat; then aryl (Rl) boronic acid/ester, palladium catalyst, 2 M aqueous potassium carbonate, dioxane, heat
Example 204
2-amino-N,N-dimethyl-5-[8-methyl-4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide
Figure imgf000119_0001
a) ethyl 6-bromo-4-hydroxy-8-methyl-3-quinolinecarboxylate
A mixture of 4-bromo-2-methylaniline (1.50 g, 8.04 mmol) and diethylethoxymethylene malonate (1.74 g, 8.04 mmol) was heated at 140 °C with stirring in an oil bath for 5.0 h. The reaction was transferred to a heating mantle, diluted with Dowtherm A (4 mL), and heated at 260 °C for 1 h. The reaction was cooled, diluted with hexanes, and the suspension was stirred overnight at room temperature. The suspension was filtered and the filtered solid was washed with hexanes and dried in a Buchner funnel to give the title compound (1.90 g, 76%) as a tan solid. MS(ES)+ m/e 310 [M+H].
b) 6-bromo-4-hydroxy-8-methyl-3-quinolinecarboxylic acid A mixture of ethyl 6-bromo-4-hydroxy-8-methyl-3-quinolinecarboxylate
(1.89 g, 6.09 mmol) and 6 N NaOH (1.22 g, 30.45 mmol, 5.1 mL) in ethanol (30 mL) was heated at reflux for 2.0 h and concentrated in vacuo. The residue was diluted with water and acidified with 6 N HCl to pH 4. The resulting solid was filtered, washed with water and diethyl ether, and dried overnight in a Buchner funnel to give the title compound (1.72 g, 99%) as a tan solid. MS(ES)+ m/e 282 [M+H].
c) 6-bromo-8-methyl-4-quinolinol
A mixture of 6-bromo-4-hydroxy-8-methyl-3-quinolinecarboxylic acid (1.80 g, 6.36 mmol) and Dowtherm A (10 mL) was heated at 260 °C for 1.0 h. The reaction was cooled, triturated with hexanes, filtered and dried in a Buchner funnel to give the title compound (1.43 g, 95%) as a tan solid. MS(ES)+ m/e 238 [M+H]. d) 6-bromo-4-chloro-8-methylquinoline
A mixture of 6-bromo-8-methyl-4-quinolinol (1.42 g, 5.95 mmol) and phosphorous oxychloride (10.95 g, 71.40 mmol) was heated at reflux for 1 h, cooled, poured onto ice, and neutralized by addition of 30% ammonium hydroxide. The resulting solid was filtered and dried in a vacuum oven to give the title compound
(1.45 g, 95%) as a tan solid. MS(ES)+ m/e 256 [M+H].
e) 2-amino-N,N-dimethyl-5-[8-methyl-4-(4-pyridinyl)-6-quinolinyl]-3- pyridinesulfonamide A mixture of 6-bromo-4-chloro-8-methylquinoline (0.300 g, 1.170 mmol), bis(pinacolato)diboron (0.297 g, 1.170 mmol), dichloro[l,l'- bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.029 g, 0.035 mmol), and solid anhydrous potassium acetate (0.459 g, 4.676 mmol) in dry 1,4-dioxane (8 mL) was heated at reflux for 70 minutes. The oil bath was temporarily removed and to the reaction was added 2-amino-5-bromo-N,N- dimethyl-3-pyridinesulfonamide (0.327 g, 1.17 mmol), dichloro[l,l'- bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.047 g, 0.058 mmol), and 2 M aqueous potassium carbonate (0.646 g, 4.676 mmol, 2.34 mL). The reaction was heated at reflux for 80 minutes. The oil bath was temporarily removed and to the reaction was added 4-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)pyridine (0.240 g, 1.17 mmol), dichloro[l,l'- bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.047 g, 0.058 mmol), 2 M aqueous potassium carbonate (0.485 g, 3.51 mmol, 1.76 mL), and 1,4-dioxane (6 mL). The reaction was heated at reflux for 17 h and concentrated in vacuo. The residue was triturated with 10% MeOH:EtOAc (45 mL), filtered through filter paper, and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (7% MeOH:EtOAc) to give the title compound (0.135 g, 28%) as a yellow powder. MS(ES)+ m/e 420 [M+H].
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 204:
Figure imgf000121_0001
Scheme 8:
Figure imgf000122_0001
Conditions: a) bis(pinacolato)diboron, potassium acetate, palladium catalyst, dioxane, heat; then 5- bromo-2-pyπdinamiπe, palladium catalyst, 2 M potassium carbonate, dioxane, heat, b) chlorosulfonic acid, 0 °C - reflux; c) R6R7NH, pyridine, dioxane, rt - 50 0C.
Example 211
3-(l-piperidinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine
Figure imgf000122_0002
a) 5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine
To a 1 L pressure vessel was added 6-bromo-4-(4-pyridinyl)quinoline (12 g, 42.08 mmol), bis(pinacolato)diboron (12.8 g, 50.5 mmol), anhydrous potassium acetate (8.24 g, 84.16 mmol), [l,r-bis(diphenylphosphino)-ferrocene] dichloropalladium(II)-complex with dichloromethane(l: l) (1.372 g, 1.68 mmol) and anhydrous dioxane (420 mL). The reaction vessel was purged with nitrogen, capped and heated at 100 °C for 15 hours. LCMS indicated 96% conversion to a mixture of the desired boronate ester MS(ES)+ m/e 333.2 [M+H]+ and boronic acid MS(ES)+ m/e 250.9 [M+H]+. To the reaction mixture above was added 5-bromo-2-pyridinamine (7.28 g, 42.08 mmol), [l,r-bis(diphenylphosphino)-ferrocene]dichloropalladium(II)- complex with dichloromethane(l:l) (1.718 g, 2.1 mmol), 2 M aqueous K2CO3 (300 mL). The reaction was heated at 100 °C for 21 hours. After cooling to room temperature, the organic layer was separated and concentrated in vacuo. The residue was triturated with water, and dissolved in dichloromethane. This solution was filtered through a plug of silica, washing continuously with dicholormethane and ethanol. Concentration in vacuo provided the title compound as a yellow powder (8.767 g, 70% yield). MS(ES)+ m/e 299.0 [M+H]+.
b) 2-amino-5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinesulfonyl chloride
To cold (0 °C) chlorosulfonic acid (15 mL) under vigorous stirring was added 5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine (4.348 g, 14.57 mmol) portionwise. The reaction mixture was then heated at reflux for 16 hrs. Upon cooling to room temperature, LCMS indicated 47% of the title compound MS(ES)+ m/e 396.9 [M+]+ and 37% of sulfonic acid by-product MS(ES)+ m/e 379.1 [M+]+. A 2 mL aliquot of this 0.456M solution of the title compound was used in the next reaction without further workup.
c) 3-(l-piperidinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine
To a cold (5 °C) solution of the 0.456 M solution of 2-amino-5-[4-(4- pyridinyl)-6-quinolinyl]-3-pyridinesulfonyl chloride (2 mL, 0.912 mmol) in chlorosulfonic acid from above was added anhydrous dioxane (1 mL) and piperidine (1.8 mL, 18.24 mmol). After 30 minutes of stirring, pyridine (1 mL, 12.3 mmol) was added and the reaction mixture stirred for an additional hour at room temperature. The reaction mixture was concentrated in vacuo, the residue dissolved in CH2Cl2 and the pH adjusted to 14 using 6 N NaOH (aq). The solution was extracted with CH2Cl2 (x4) and the combined organic layers dried (Na2SO4), filtered and conentrated in vacuo. The resulting residue was purified twice by silica gel chromatography (0-5% MeOH in EtOAC) to give the title compound as a pale yellow solid (269 mg, 66% yield). MS(ES)+ m/e 446.3 [M+H]+. The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 211:
Figure imgf000124_0001
Figure imgf000125_0003
Scheme 9:
Figure imgf000125_0001
Conditions: a) aryl (Rl) boronic acid or aryl (Rl) boronate, palladium catalyst, 2 M potassium carbonate, dioxane, heat; b) bis(pinacolato)diboron, potassium acetate, palladium catalyst, dioxane, heat; then heteroaryl (R2) bromide, palladium catalyst, 2 M potassium carbonate, heat.
Example 220 Preparation of 6-(lH-benzimidazol-2-yl)-4-(4-pyridinyl)quinoline
Figure imgf000125_0002
a) 4-(4-pyridinyl)-6-quinolinecarbonitrile
A mixture of 4-chloro-6-quinolinecarbonitrile (8.7 g, 46.2 mmol), 4- pyridineboronic acid (8.52 g, 69.3 mmol), tetrakis(triphenylphosphine)palladium(0) (2.67 g, 2.31 mmol) and 2 M potassium carbonate (69.3 mL, 3 eq) in 1,4-dioxane (380 mL) is heated at reflux for 3.5 hours. The dioxane is evaporated and the crude product purified by silica gel chromatography eluting with methylene chloride/methanol 0-4 %. A yield of 10.23 g (95%) of the title compounds was obtained.
b) lH-benzimidazol-2-yl)-4-(4-pyridinyl)quinoline
A mixture of 4-(4-pyridinyl)-6-quinolinecarbonitrile, (231 mg, 1 mmol) 1,2- diaminobenzene (108 mg, 1 mmol) and polyphosphoric acid (1.4 g) was heated in the microwave at 250 °C for 1.5 hours. The reaction was poured onto water which was neutralized with bicarbonate. The product was filtered, washed with water, and dried. The product was further purified by dissolving in hot methanol, filtering and cooling to obtain crystals. The yield was 47.7 mg, 30%. MS(ES)+ m/e 323 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 220:
Figure imgf000126_0001
Figure imgf000127_0003
Scheme 10:
Figure imgf000127_0001
Conditions: a) cyclic secondary amine, dimethylformamide, heat; b) bis(pinacolato)diboron, potassium acetate, palladium catalyst, dioxane, heat; then heteroaryl (R2) bromide, palladium catalyst, 2 M potassium carbonate, heat.
Example 225
4-(l-piperidinyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinolme
Figure imgf000127_0002
a) 6-bromo-4-(l-piperidinyl)quinoline
To a solution of 4-choro-6-bromoquinoline (726 mg, 3 mmol) in 3 mL of 1- methyl-2-pyrrolidinone was added piped dine (510 mg, 6 mmol). The reaction was heated to 150 °C for 5 h.The solvents were removed in vacuo at 100 °C and the residue dissolved in methylene chloride and washed with water. The methylene chloride was dried with sodium sulfate and concentrated. The residue was triturated with hexane and the solid filtered off to give 6-bromo-4-(l-piperidinyl) quinoline (877 mg, 73%).
b) 6-(7,7a-dihydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-4-(l-piperidinyl)quinoline
To a solution of 6-bromo-4-(l-piperidinyl)quinoline (429 mg, 1.47 mmol) in dioxane (4 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2-dioxaborolane
(373 mg, 1.76 mmol), potassium acetate (441 mg, 4.5 mmol), and PdC12(dppf)2 (36 mg, 0.045 mmol). The reaction was heated to 150 °C for 30 minutes to give crude
4-(l-piperidinyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinoline. The reaction was then cooled and 5-bromo-7,7a-dihydro-lH-pyrazolo[3,4-b]pyridine (348 mg, 1.76 mmol) was added, followed by PdC12(dppf)2 (36 mg, 0.045 mmol) and 2 M potassium carbonate (2.25 mL). The reaction was heated at 150 °C for 30 min, at which time the dioxane was evaporated and the crude product triturated water and collected by filtration. The crude product was partially purified by HPLC chromatography acetonitrile/water/0.1 % TFA. At this point the product was 85% pure. It was free based with sodium carbonate and further purified by silica gel chromatography eluting with methylene chloride/0-2% (methanol/concentrated ammonium hydroxide solution 9/1) to obtain the title compound (29 mg, 0 6%).
MS(ES)+ m/e 330 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 225:
Figure imgf000129_0002
Scheme 11:
Figure imgf000129_0001
Conditions: a) R-sulfonyl chloride, pyridine, methylene chloride. Example 230
2,4-difluoro-N- { 5- [4-(4-pyridinyl)-6-quinolinyl] -3-pyridinyl }benzenesulfonamide
Figure imgf000130_0001
a) 2,4-difluoro-N-{5-[4-(4-pyridinyl)-6-quinolinyl]-3- pyridinyl } benzenesulf onamide
A solution of 5-[4-(4-pyridinyl)-6-quinolinyl]-3-pyridinamine (82 mg, 0.27 mmol) in anhydrous pyridine (2.0 ml) was treated with neat 2,4- difluorobenzenesulfonyl chloride in one portion. The reaction was stirred at room temperature for 30 minutes then was purified directly by prep-HPLC. The combined, desired fractions were evaporated under reduced pressure to remove organic solvents then diluted with small portions of brine and saturated aqueous sodium bicarbonate. The basic solution was extracted with ethyl acetate then the extracts were dried over anhydrous sodium sulfate and evaporated under reduced pressure. The resulting colorless film was crystallized from methylene chloride and diethyl ether. The solids were collected by filtration, rinsed with diethyl ether then vacuum dried to afford the title compound (219 mg, 48%) as a white solid. MS(ES)+ m/e 475 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 230:
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Some non-commercially available heteroaryl (Rl) bromides were prepared and coupled to the corresponding boronic ester or boronic acid as noted above. Scheme 12:
Figure imgf000137_0001
Conditions: a) Chlorosulfonic acid, 0 °C-reflux; b) Morphohne, pyridine, dioxane, 5 °C- rt - 500C.
Example 239
3 - (4-morpholinylsulf onyl) - 5 - [4- (4-pyridinyl) -6-quinolinyl] -2-pyridinamine
Figure imgf000137_0002
a) 2-amino-5-bromo-3-pyridinesulfonyl chloride
To a cooled (0 °C) solution of chlorosulfonic acid (58 mL) under vigorous stirring was added 5-bromo-2-pyridinamine (15 g, 86.7 mmol) portionwise. The reaction mixture was then heated at reflux for 3 hrs. Upon cooling to room temperature, the reaction mixture was poured over ice (-100 g) with vigorous stirring. The resulting yellow precipitate was collected by suction filtration, washing with cold water and petroleum ether to provide the title compound as an orange- yellow solid (18.1 g, 77% yield). MS(ES)+ m/e 272.8 [M+H]+.
b) 5-bromo-3-(4-morpholinylsulfonyl)-2-pyridinamine
To a solution of 2-amino-5-bromo-3-pyridinesulfonyl chloride (0.50 g, 1.84 mmol) in anhydrous dioxane (2 mL) cooled to 5 °C was added (0.16 mL, 1.84 mmol) of morpholine followed by (0.174 mL, 2.15 mmol) of pyridine. The reaction mixture was stirred at room temperature for 2 hrs and then heated at 50 °C for 1 hour. After cooling to room temperature, a white precipitate formed which was collected by suction filtration, washing with water and petroleum ether to give the title compound as an off-white solid. (0.539 g, 91% yield). MS(ES)+ m/e 323.9 [M+H]+.
c) 3-(4-morpholinylsulfonyl)-5-[4-(4-pyridinyl)-6-quinolinyl]-2-pyridinamine A mixture of 5-bromo-3-(4-morpholinylsulfonyl)-2-pyridinamine (0.296 g,
0.92 mmol), 4-(4-pyridmyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)quinoline (0.306 mg, 0.92 mmol), [l,l'-bis(diphenylphosphino)- ferrocene]dichloropalladium(II)-complex with dichloromethane(l:l) (37.6 mg, 0.046 mmol), 2 M aqueous K2CO3 (5 niL) and dioxane (5 mL) was heated at 100 °C for 18 h. After cooling to room temperature, the organic layer was separated and the aqueous portion extracted three times with EtOAc. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified twice by silica gel chromatography (eluent: i)l-5% MeOH in CH2Cl2 and ii) 0-20% MeOH in CH2Cl2) to provide the title compound as a white solid (150 mg, 37% yield). MS(ES)+ m/e 448.0 [M+H]+.
Scheme 13:
Figure imgf000138_0001
Conditions: a) i) LDA, THF, -78 0C; ii) N-formylpiperidine, -780C; b) i) pinacol, /?-TsOH, benzene, reflux; ii) anhydrous hydrazine, DIPEA, EtOH, reflux; c) cone aq HCl (36.5%-38%), EtOH, H2O, 60 0C to rt.
Example 240
5-bromo-1H-pyrazolo[3,4-b ]pyridine
Figure imgf000139_0001
a) S-bromo^-fluoro-S-pyridinecarbaldehyde
Following the procedure described m WO2006015124 and trituration of the crude product in hexanes instead of crystallization from cyclohexane afforded the title compound as an off-white solid (68%). MS(ES)+ m/e 203.8, 205.7 [M+Η]+.
b) 5-bromo-3-(4,4,5,5-tetramethyl-l,3-dioxolan-2-yl)-2(1H)-pyridinone hydrazone
Following the procedure described in WO2006015124 without the addition of hydrogen chloride provided the title compound as a yellow solid. MS(ES)+ m/e 317.9 [M+Η]+. This crude material was used directly in the next step.
c) 5-bromo-1H-pyrazolo[3,4-b ]pyridine
Following the procedure described in WO2006015124 provided the title compound as a yellow solid (94%, 2 steps). MS(ES)+ m/e 197.7, 199.7 [M+Η]+.
Scheme 14:
Figure imgf000139_0002
Conditions: a) tin(II)chlonde, concentrated HCl, room temperature; b) R-sulfonyl chloride, pyridine, methylene chloride.
Example 241
N-(5-bromo-2-chloro-3-pyridinyl)benzenesurfonamide
Figure imgf000140_0001
a) 3-amino-5-bromo-2-chloropyridine
To a stirred suspension of 5-bromo-2-chloro-3-nitropyridine (20.0 g, 84.2 mMol) in cone. HCl (90 mL) was added SnCl22H2O (60.0 g, 266 mMol) portionwise over 2 h. (The reaction got very warm to the touch.) The reaction was stirred at RT for 18 h, poured onto ice, and basified with aq. 6 Ν NaOH (300 mL). The resultant slurry was filtered, washed with H2O, and dried under vacuum to give the title compound (15.53 g, 89%) as an off-white solid: 1H ΝMR (400 MHz, DMSO-d6) δ ppm 7.66 (d, / = 2.3 Hz, 1 H), 7.30 (d, / = 2.3 Hz, 1 H), 5.90 (br. s., 2 H); MS (ES) m/e 206.7 (M + H)+.
b) N-(5-bromo-2-chloro-3-pyridinyl)benzenesulfonamide
To a stirred solution of 3-amino-5-bromo-2-chloropyridine (5.0 g, 24 mMol) in CH2Cl2 (50 mL) was added pyridine (3.0 mL, 37 mMol) followed by benzenesulfonyl chloride (4.5 mL, 35 mMol) drop wise over 5 minutes. The reaction was stirred at RT for 18 h and evaporated to dryness under vacuum. Purified by flash chromatography on silica gel (15% hexanes in CH2Cl2 then 0 to 5% EtOAc in 15% hexanes in CH2Cl2). During evaporation of the solvents the product crashed out. The resultant slurry was diluted with hexane, filtered and dried under vacuum to give the title compound (2.89 g, 34%) as a white solid. [An overlap fraction which contained 30% starting amine (2.60 g) was also obtained.]: 1H ΝMR (400 MHz, DMSO-d6) δ ppm 10.61 (br. s., 1 H), 8.41 (d, / = 2.27 Hz, 1 H), 7.91 (d, / = 2.27 Hz, 1 H), 7.73 - 7.77 (m, 2 H), 7.67 - 7.72 (m, 1 H), 7.56 - 7.64 (m, 2 H); MS (ES) m/e 346.7 (M + H)+. Other non-commercially available heteroaryl (Rl) bromides were prepared according to the following literature procedures and coupled to the corresponding boronic ester as noted above:
WO2005110410 was used to prepare intermediates A-C.
Figure imgf000141_0001
Scheme 15:
Figure imgf000141_0002
Conditions: a) methyl (triphenylphosphoranyhdene)acetate, methanol, rt; b) bromine, methylene chloride, rt; c) i] potassium hydroxide, ethanol, 95 0C, π] sulfuric acid, ethanol , 95 0C, d) potassium ferf-butoxide, (R8) -hydrazine, tetrahydrofuran, rt - 65 0C.
Example 242
l-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one
Figure imgf000141_0003
a) methyl 3-[4-(4-pyridinyl)-6-quinolinyl]-2-propenoate
A mixture of 4-(4-pyridinyl)-6-quinolinecarbaldehyde (2.29 g, 9.78 mmol), methyl (triphenylphosphoranylidene)acetate (3.30 g, 9.78 mmol) in MeOH (75 mL) was stirred at room temperature for 1 hour. The reaction was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (1% MeOH in EtOAc) to give the title compound (2.71 g, 95 %) as a white solid. MS(ES)+ m/e 291 [M+H]+.
b) methyl 2,3-dibromo-3-[4-(4-pyridinyl)-6-quinolinyl]propanoate
A solution of methyl 3-[4-(4-pyridinyl)-6-quinolinyl]-2-propenoate (2.71 g,
9.33 mmol) in dichloromethane (90 ml) was treated with neat bromine (4.80 ml, 9.33 mmol) then stirred at room temperature for 4 hours. Evaporation under reduced pressure gave the title compound (4.20 g, 100 %) as a yellow solid. MS(ES)+ m/e
451 [M+H]+.
c) ethyl 3-[4-(4-pyridinyl)-6-quinolinyl]-2-propynoate
A slurry of methyl 2,3-dibromo-3-[4-(4-pyridinyl)-6-quinolinyl]propanoate (4.20 g, 9.33 mmol) in ethanol (120 ml) was treated with solid potassium hydroxide pellets in one portion then heated at 95 °C for 2 hours. The reaction was cooled to room temperature then evaporated under reduced pressure. The resulting residue was diluted with ethanol (90 ml) and concentrated H2SO4 (3 ml) then heated at 95 °C for 3.5 hours. Cooled to room temperature then concentrated under reduced pressure. The resulting wet residue was taken into a minimum of water then made neutral with the addition of saturated aqueous NaHCO3 solution. This solution was extracted with EtOAc and the extracts were dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (EtOAc) to give the title compound (1.68 g, 60 %) as a pale yellow solid. MS(ES)+ m/e 303 [M+H]+. d) l-phenyl-5-[4-(4-pyridinyl)-6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one
A solution of phenylhydrazine (0.093 ml, 0.95 mmol) in anhydrous TΗF (4.0 ml) was treated with a IM solution of potassium te/t-butoxide in TΗF (1.89 ml, 1.89 mmol). The resulting solution was added to a solution of ethyl 3-[4-(4-pyridinyl)-6- quinolinyl]-2-propynoate (0.268 g, 0.95 mmol) in TΗF (10 ml). The resulting brown solution was stirred at room temperature for 1 hour then at 65 °C for 1 hour. The resulting orange slurry was cooled to room temperature then concentrated under reduced pressure. The resulting residue was taken into saturated aqueous NaΗCθ3 then extracted into methylene chloride and the extracts were dried over sodium sulfate then evaporated under reduced pressure. The resulting oil was purified by HPLC (acetonitrile/water, 5 - 80% gradient). The product was concentrated to a residue then recrystallized from ethanol to give the title compound (0.020 g, 6 %) as a white solid. MS(ES)+ m/e 365 [M+H]+.
The following compounds were or can be prepared following the general procedures used to prepare the compound of Example 242:
Figure imgf000143_0001
Figure imgf000144_0001
Following the procedure used to prepare Example 242, 2-ethyl-6-[4-(4-pyridinyl)-6- quinolinyl]-4(1H)-pyrimidinone was or can be prepared by substituting ethylamidine hydrochloride for hydrazine. MS(ES)+ m/e 329 [M+Η]+.
Figure imgf000144_0002
Following the procedure used to prepare Example 242, 2-phenyl-5-[4-(4-pyridinyl)- 6-quinolinyl]-l,2-dihydro-3H-pyrazol-3-one was or can be prepared by substituting an alkynyl methyl ester for the alkynyl ethyl ester. MS(ES)+ m/e 365 [M+Η]+.
Figure imgf000144_0003
Scheme 16:
Figure imgf000145_0001
Conditions: a) aryl (Rl) stannane, palladium catalyst, dioxane, heat; b) bis(pinacolato)diboron, potassium acetate, palladium catalyst, dioxane, heat; then heteroaryl (R2) bromide, palladium catalyst, saturated aqueous Na2CO3, dioxane, heat.
Example 345
2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl } benzenesulf onamide
Figure imgf000145_0002
a) 6-bromo-4-(4-pyridazinyl)quinoline
Dissolved 6-bromo-4-iodoquinoline (17.43 g, 52.2 mmol), 4- (tributylstannanyl)pyridazine (19.27 g, 52.2 mmol), and PdC12(dppf)-CH2C12 (2.132 g, 2.61 mmol) in 1,4-dioxane (200 mL) and heated to 105 °C. After 3 h, added more palladium catalyst and heated for 6 h. Concentrated and dissolved in methylene chloride/methanol. Purified by column chromatography (combiflash) with 2% MeOH/EtOAc to 5% MeOH/EtOAc to give the crude title compound. Trituration with EtOAc furnished 6-bromo-4-(4-pyridazinyl)quinoline (5.8 g, 20.27 mmol, 38.8 % yield). MS(ES)+ m/e 285.9, 287.9 [M+H]+.
b) 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl } benzenesulf onamide A slurry of 6-bromo-4-(4-pyridazinyl)quinoline (4.8 g, 16.78 mmol), bis(pinacolato)diboron (4.69 g, 18.45 mmol) , PdC12(dppf)-CH2C12 (530 mg, 0.649 mmol) and potassium acetate (3.29 g, 33.6 mmol) in anhydrous 1,4-dioxane (120 ml) was heated at 100 °C for 3 h. The complete disappearance of the starting bromide was observed by LCMS. The reaction was then treated with N-[5-bromo-2- (methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide (6.68 g, 17.61 mmol) and another portion of PdC12(dppf)-CH2C12 (550 mg, 0.673 mmol), then heated at 110 °C for 16 h. The reaction was allowed to cool to room temperature, filtered, and concentrated. Purification of the residue by chromatography (Analogix; 5% MeOH / 5% CH2C12 / 90% EtOAC) gave 6.5 g (76%) desired product. MS(ES)+ m/e 505.9 [M+H]+.
The following examples were or can be prepared following the general procedure used in Example 345
Figure imgf000146_0001
INTERMEDIATES:
Intermediate 1
Scheme A:
Figure imgf000147_0001
Conditions: a) Tributyl(vinyl)tin, Pd(PPh3)4, dioxane, reflux; b) OsO4, NaIO4, 2,6- lutidine, r-BuOH, dioxane, H2O, rt; c) (4-pyridyl)boronic acid, Pd(PPh3)4, 2 M K2CO35 DMF, 100 DC.
4-(4-pyridinyl)-6-quinolinecarbaldehyde
Figure imgf000147_0002
a) 4-chloro-6-ethenylquinoline
A mixture of 6-bromo-4-chloroquinoline (6.52 g, 26.88 mmol; see J. Med. Chem., H 268 (1978) ), tributyl(vinyl)tin (8.95 g, 28.22 mmol), and tetrakistriphenylphospbine palladium (0) (0.62 g, 0.54 mmol) in 1,4-dioxane (150 mL) was refluxed for 2.0 h, cooled to room temperature, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (0-4% MeOH:CH2Cl2) to give the title compound (5.1 g) as a pale yellow solid. MS (ES)+ m/e 190 [M+H]+. This material was used directly in the next step.
b) 4-chloro-6-quinolinecarbaldehyde
A mixture of 4-chloro-6-ethenylquinoline (5.1 g, 26.88 mmol), 2,6-lutidine
(5.76 g, 53.75 mmol), sodium (meta) periodate (22.99 g, 107.51 mmol), and osmium tetroxide (5.48 g of a 2.5% solution in tert-butanol, 0.538 mmol) in l,4-dioxane:H2θ (350 mL of 3: 1 mixture) was stirred for 3.5 h at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (CH2Cb) to give the title compound (4.26 g, 83% for 2 steps) as a pale yellow solid. MS (ES)+ m/e 192 [M+H]+.
c) 4-(4-pyridmyl)-6-qumolinecarbaldehyde
A mixture of 4-chloro-6-quinolinecarbaldehyde (3.24 g, 16.92 mmol), A- pyridylboronic acid (3.12 g, 25.38 mmol), tetrakistriphenylphosphine palladium (0) (0.978 g, 0.846 mmol), and 2M aqueous K2CO3 (7.02 g, 50.76 mmol, 25.4 mis of 2M solution) in DMF (100 mL) was heated at 100 °C for 3.0 h and cooled to room temperature. The mixture was filtered through Celite and the Celite was washed with EtOAc. The filtrate was transferred to a separatory funnel, washed with water and saturated NaCl, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (5% MeOH:CH2Cl2) to give the title compound (2.03 g, 51%) as a tan solid. MS (ES)+ m/e 235 [M+H]+.
Intermediate 2
Preparation of 2-amino-5 -bromo-N,N-dimethyl-3 -pyridinesulfonamide
Figure imgf000148_0001
a) 2-ammo-5-bromo-3-pyridinesulfonyl chloride
To a cooled (0 °C) solution of chlorosulfonic acid (58 mL) under vigorous stirring was added 5-bromo-2-pyridinamine (86.7 mmol) portionwise. The reaction mixture was then heated at reflux for 3 hrs. Upon cooling to room temperature, the reaction mixture was poured over ice (-100 g) with vigorous stirring. The resulting yellow precipitate was collected by suction filtration, washing with cold water and petroleum ether to provide the title compound as an orange-yellow solid (18.1 g, 77% yield). MS(ES)+ m/e 272.8 [M+H]+.
* Other sulfonyl chlorides can be prepared using this procedure by varying the choice of substituted aryl or heteroaryl.
b) 2-amino-5-bromo-N,N-dimethyl-3-pyridinesulfonamide
To a cold (0 DC) suspension of 2-amino-5-bromo-3-pyridinesulfonyl chloride (92.1 mmol) in dry 1,4-dioxane (92 mL) was added pyridine (101.3 mmol) followed by a 2M solution of dimethylamine in THF (101.3 mmol). The reaction was allowed to warm to rt for 2 h, heated to 50 DC for 1 h, then cooled to rt. After standing for 2 h, the precipitate was collected by filtration and rinsed with a minimal amount of cold water. Drying the precipitate to constant weight under high vacuum provided 14.1 g (55%) of the title compound as a white solid. MS(ES)+ m/e 279.8, 282.0 [M+H]+.
* Other sulfonamides were or can be prepared using this procedure by varying the choice of sulfonyl chloride and amine.
Figure imgf000149_0001
Figure imgf000150_0002
Intermediate 3
Preparation of 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-l,3.2-dioxaborolan-2- yl)-3 -pyridinesulfonamide
Figure imgf000150_0001
c) To a solution of 2-amino-5-bromo-N,N-dimethyl-3 -pyridinesulfonamide (7.14 mmol) in 1,4-dioxane (35 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2- dioxaborolane (7.86 mmol), potassium acetate (28.56 mmol) and [1,1 '- bis(diphenylphosphmo)-ferrocene] dichloropalladium(II) dichloromethane complex (1 :1) (0.571 mmol). The reaction mixture was stirred at 100 °C for 18 h. The reaction was concentrated in vacuo, re-dissolved in ethyl acetate (50 mL) and purified on silica using 60% ethyl acetate/hexanes to yield the title compound as a tan solid (86 %). IH ΝMR (400 MHz, DMSOd6) δ ppm 8.41 (d, 1 H, J =1.52), 7.92 (d, 1 H, J = 1.77), 2.68 (s, 6 H), 1.28 (s, 12 H).
* Other boronate or boronic acids can be prepared using this procedure by varying the choice of aryl or heteroaryl bromide. Scheme 17:
Figure imgf000151_0001
Conditions: a) NaO(Rl), (Rl)OH, O 0C to room temperature; b) SnCl2-2H2O, ethyl acetate, reflux; c) (R2)SO2C1, pyridine, O 0C to room temperature.
Intermediate 4
Preparation of N-r5-bromo-2-(methyloxy)-3-pyridinyll-2,4- difluorobenzenesulfonamide
Figure imgf000151_0002
a) 5-bromo-2-(methyloxy)-3-nitropyridine
To a cooled (0 °C) solution of 5-bromo-2-chloro-3-nitropyridine (50 g, 211 mmol) in methanol (200 mL) was added dropwise over 10 minutes 20% sodium methoxide (50 mL, 211 mmol) solution. The reaction, which quickly became heterogeneous, was allowed to warm to ambient temperature and stirred for 16 h. The reaction was filtered and the precipitate diluted with water (200 mL) and stirred for 1 h. The solids were filtered, washed with water (3 x 100 mL) and dried in a vac oven (40 °C) to give 5-bromo-2-(methyloxy)-3-nitropyridine (36 g, 154 mmol, 73.4 % yield) as a pale yellow powder. The original filtrate was concentrated in vacuo and diluted with water (150 mL). Saturated ammonium chloride (25 mL) was added and the mixture stirred for 1 h. The solids were filtered, washed with water, and dried in a vac oven (40 °C) to give a second crop of 5-bromo-2-(methyloxy)-3- nitropyridine (9 g, 38.6 mmol, 18.34 % yield). Total yield = 90%. MS(ES)+ m/e 232.8, 234.7 [M+H]+.
b) 5-bromo-2-(methyloxy)-3-pyridinamine
To a solution of 5-bromo-2-(methyloxy)-3-nitropyridine (45 g, 193 mmol) in ethyl acetate (1 L) was added tin(II) chloride dihydrate (174 g, 772 mmol). The reaction mixture was heated at reflux for 4 h. LC/MS indicated some starting material remained, so added 20 mol% tin (II) chloride dihydrate and continued to heat at reflux. After 2 h, the reaction was allowed to cool to ambient temperature and concentrated in vacuo. The residue was treated with 2 N sodium hydroxide and the mixture stirred for 1 h. The mixture was then with methylene chloride (1 L), filtered through Celite, and washed with methylene chloride (500 mL). The layers were separated and the organics dried over magnesium sulfate and concentrated to give 5-bromo-2-(methyloxy)-3-pyridinamine (23 g, 113 mmol, 58.7 % yield). The product was used crude in subsequent reactions. MS(ES)+ m/e 201.9, 203.9 [M+H]+.
c) N-[5-bromo-2-(methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide
To a cooled (0 °C) solution of 5-bromo-2-(methyloxy)-3-pyridinamine (20.3 g, 100 mmol) in pyridine (200 mL) was added slowly 2,4-difluorobenzenesulfonyl chloride (21.3 g, 100 mmol) over 15 min (reaction became heterogeneous). The ice bath was removed and the reaction was stirred at ambient temperature for 16 h, at which time the reaction was diluted with water (500 mL) and the solids filtered off and washed with copious amounts of water. The precipitate was dried in a vacuum oven at 50 °C to give N-[5-bromo-2-(methyloxy)-3-pyridinyl]-2,4- difluorobenzenesulfonamide (12 g, 31.6 mmol, 31.7 % yield) MS(ES)+ m/e 379.0, 380.9 [M+H]+.
*Other N- [5-bromo-2-(alkoxy)-3-pyridinyl] sulfonamides were or can be prepared using this procedure by varying the choice of sulfonyl chloride and alkoxide.
Figure imgf000153_0001
Exemplary capsule composition
An oral dosage form for administering the present invention is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.
Table I
Figure imgf000153_0002
Exemplary Injectable Parenteral Composition
An injectable form for administering the present invention is produced by stirring 1.5% by weight of compound of example 1 in 10% by volume propylene glycol in water.
Exemlary Tablet Composition
The sucrose, calcium sulfate dihydrate and an PI3K inhibitor as shown in
Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid;, screened and compressed into a tablet.
Table II
INGREDIENTS AMOUNTS compound of example 1 20 mg calcium sulfate dehydrate 30 mg
Sucrose 4 mg
Starch 2 mg
Talc 1 mg stearic acid 0.5 mg
While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

What is claimed is:
1. A compound of Formula (I):
Figure imgf000155_0001
in which R2 is a pyridinyl or substituted pyridinyl group,
Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein the compound is a compound of formula (I)(G):
Figure imgf000155_0002
(I)(G)
in which each Rl, R3, R4 and R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino,
Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, acyloxy, and aryloxy; n is 1-2, m is 0-3; or R5 is R6, wherein R6 is -SO2NR80 or -NSO2R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, Cl- Cβheterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, C1-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or - (CH2)nCOOH, wherein n is 0-2; or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1, wherein the compound is a compound of formula (I)(K) :
(
Figure imgf000156_0001
in which
Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted
Cl-6alkyl; each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy; m is 0-1;
R6 is -SO2NR80 or -NSO2R80, in which R80 is selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, C1-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted C1-C6cycloalkyl, substituted Cl-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or -(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH, wherein n is 0-2; or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1, wherein the compound is a compound of formula (I)(M):
Figure imgf000157_0001
in which
Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted
Cl-6alkyl;
each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy;
m is 0-1;
R6 is -NSO2RSO, wherein R80 is selected from a group consisting of: Cl- C6alkyl, Cl-C6cycloalkyl, Cl-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1-Cβheterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or - (CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH, wherein n is 0-2; or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1, wherein the compound is a compound of formula (I)(N) :
Figure imgf000158_0001
in which
Rl is selected from a group consisting of: heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, amino, substituted amino, arylamino, acylamino, hetercycloalkylamino, alkoxy, Cl-6alkyl and substituted Cl-6alkyl;
each R5 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, cyano, hydroxyl, alkoxy;
m is 0-1;
R6 is -SO2NR80, wherein R80 is selected from a group consisting of: Cl- C6alkyl, Cl-C6cycloalkyl, Cl-C6heterocycloalkyl, substituted Cl-C6alkyl, substituted Cl-C6cycloalkyl, substituted C1-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl-C6alkyl, Cl-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or - (CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of: Cl- C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or -(CH2)nCOOH, wherein n is 0-2; or a pharmaceutically acceptable salt thereof.
6. The compound of Formula (I)(M).
7. The compound of Formuma (I)(N).
8. A method of inhibiting one or more phosphatoinositides 3-kinases
(PBKs) in a human; comprising administering to the human in need thereof a therapeutically effective amount of a compound of Formula (I)
Figure imgf000160_0001
or a pharmaceutically acceptable salt thereof; in which
R2 is pyridinyl or substituted pyridinyl;
Rl is selected from a group consisting of: heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; each R3 and R4 is independently selected from: hydrogen, halogen, acyl, amino, substituted amino, Cl-6alkyl, substituted Cl-6alkyl, C3-7cycloalkyl, substituted
C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, nitro, acyloxy, and aryloxy; n is 1-2;
X is C or N; Y is C, O, N, or S; or a pharmaceutically acceptable salt thereof.
9. A method of treating one or more disease states selected from a group consisting of: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries, in a human in need thereof, which method comprises administering to such human , a therapeutically effective amount of a compound according to claim 1.
10. A method of treating cancer comprises co-administration a compound according to claim 1; and/or a pharmaceutically acceptable salt thereof; and at least one anti-neoplastic agent, such as one selected from a group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors.
11. A method of claim 9, wherein the disease state is selected from a group consisting of: multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis, brain infection/inflammation, meningitis and encephalitis.
12. A method of claim 9, wherein the disease state is selected from a group consisting of: Alzheimer's disease, Huntington's disease, CNS trauma, stroke and ischemic conditions.
13. A method of claim 9, wherein the disease state is selected from a group consisting of: atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and vasoconstriction.
14. A method of claim 9, wherein the disease state is selected from a group consisting of: chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, antiogenesis, invasion metastasis, melanoma, Karposi's sarcoma, acute and chronic bacterial and virual infections, sepsis, transplantation rejection, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airways inflammation.
15. A method of claim 9, wherein the disease is cancer.
16. A method of claim 15 wherein the cancer is selected from a group consisting of: brain (gliomas), glioblastomas, leukemias, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid.
17. A method of claim 15 wherein the cancer is selected from a group consisting of: ovarian cancer, pancreatic cancer, breast cancer, prostate cancer and leukemia.
18. A method of claim 8, wherein said PI3 kinase is a PI3α.
19. A method of claim 8, wherein said PI3 kinase is a PI3γ.
20. A method of claim 8, wherein said PI3 kinase is a PI3δ.
21. A method of claim 9, wherein the compound or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical composition.
22. A pharmaceutical composition comprising a compound according to any one of claims 1 -7 and a pharmaceutically acceptable carrier.
PCT/US2008/063819 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors WO2008144463A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ES08755632T ES2404557T3 (en) 2007-05-18 2008-05-16 Quinoline derivatives as inhibitors of Pl3 kinase
US12/600,745 US8404837B2 (en) 2007-05-18 2008-05-16 Quinoline derivatives as P13 kinase inhibitors
JP2010509462A JP4814396B2 (en) 2007-05-18 2008-05-16 Quinoline derivatives as PI3 kinase inhibitors
PL08755632T PL2162131T3 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
CA2686016A CA2686016C (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
KR1020097026354A KR101458660B1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
EA200971072A EA019540B1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
DK08755632.0T DK2162131T3 (en) 2007-05-18 2008-05-16 QUINOLINE DERIVATIVES AS PI3-KINASE INHIBITORS
MX2009012479A MX2009012479A (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors.
SI200830965T SI2162131T1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
EP08755632A EP2162131B1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
AU2008254915A AU2008254915B2 (en) 2007-05-18 2008-05-16 Quinoline derivatives as PI3 kinase inhibitors
BRPI0811761-6A2A BRPI0811761A2 (en) 2007-05-18 2008-05-16 Quinoline derivatives as P13 kinase inhibitors
NZ580979A NZ580979A (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
UAA200913251A UA104408C2 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors
MX2012009210A MX342959B (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors.
CN2008800249784A CN101754759B (en) 2007-05-18 2008-05-16 Quinoline derivatives as PI3 kinase inhibitors
IL202018A IL202018A (en) 2007-05-18 2009-11-09 2,4-difluoro-n-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, pharmaceutical compositions comprising the same and its use for the treatment of pi3 kinases related diseases
HK10104231.9A HK1137938A1 (en) 2007-05-18 2010-04-29 Quinoline derivatives as pi3 kinase inhibitors
HRP20130252AT HRP20130252T1 (en) 2007-05-18 2013-03-21 Quinoline derivatives as pi3 kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93876107P 2007-05-18 2007-05-18
US60/938,761 2007-05-18

Publications (1)

Publication Number Publication Date
WO2008144463A1 true WO2008144463A1 (en) 2008-11-27

Family

ID=40088996

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/063821 WO2008144464A1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as p13 kinase inhibitors
PCT/US2008/063819 WO2008144463A1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as pi3 kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063821 WO2008144464A1 (en) 2007-05-18 2008-05-16 Quinoline derivatives as p13 kinase inhibitors

Country Status (32)

Country Link
US (6) US20100168100A1 (en)
EP (3) EP2596793B1 (en)
JP (3) JP2010528027A (en)
KR (1) KR101458660B1 (en)
CN (1) CN101754759B (en)
AR (1) AR066614A1 (en)
AU (1) AU2008254915B2 (en)
BR (1) BRPI0811761A2 (en)
CA (1) CA2686016C (en)
CL (1) CL2008001457A1 (en)
CO (1) CO6241101A2 (en)
CR (1) CR11165A (en)
CY (1) CY1114070T1 (en)
DK (1) DK2162131T3 (en)
EA (1) EA019540B1 (en)
ES (2) ES2404557T3 (en)
HK (1) HK1137938A1 (en)
HR (1) HRP20130252T1 (en)
IL (1) IL202018A (en)
JO (1) JO2891B1 (en)
MA (1) MA31443B1 (en)
MX (2) MX2009012479A (en)
MY (1) MY158843A (en)
NZ (1) NZ580979A (en)
PE (1) PE20090717A1 (en)
PL (1) PL2162131T3 (en)
PT (1) PT2162131E (en)
SI (1) SI2162131T1 (en)
TW (1) TWI410417B (en)
UA (1) UA104408C2 (en)
WO (2) WO2008144464A1 (en)
ZA (1) ZA200907777B (en)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009157196A1 (en) * 2008-06-25 2009-12-30 武田薬品工業株式会社 Amide compound
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2010135568A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
JP2011500823A (en) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyridosulfonamide derivatives as PI3 kinase inhibitors
WO2011028741A1 (en) 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
WO2011038380A2 (en) 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
WO2011046894A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068106A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
JP2012513410A (en) * 2008-12-23 2012-06-14 アボット・ラボラトリーズ Antiviral compounds
JP2012531436A (en) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド Heterocyclic compounds and their use as PI3K activity inhibitors
US8383827B2 (en) 2009-05-15 2013-02-26 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8410112B2 (en) 2008-11-10 2013-04-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US20130137701A1 (en) * 2010-08-09 2013-05-30 Tona M. Gilmer Combination
WO2013117504A1 (en) 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No.2) Limited Pi3k inhibitors for treating cough
WO2013117503A2 (en) 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No. 2) Limited Novel use
JP2013532727A (en) * 2010-07-30 2013-08-19 オンコセラピー・サイエンス株式会社 MELK inhibitors containing quinoline derivatives and the same
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841308B2 (en) 2008-12-19 2014-09-23 Vertex Pharmaceuticals Incorporated Pyrazin-2-amines useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846686B2 (en) 2011-09-30 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8877759B2 (en) 2011-04-05 2014-11-04 Vertex Pharnaceuticals Incorporated Aminopyrazines as ATR kinase inhibitors
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2015027667A1 (en) 2013-08-30 2015-03-05 浙江医药股份有限公司新昌制药厂 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof
US9035053B2 (en) 2011-09-30 2015-05-19 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2915810A4 (en) * 2012-11-01 2016-04-13 Univ Pla 2Nd Military Medical N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives, preparation method and therapeutic use thereof
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2016142508A1 (en) 2015-03-11 2016-09-15 Centre Léon-Bérard Composition for treating pancreatic neuroendocrine tumours
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9791456B2 (en) 2012-10-04 2017-10-17 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US9868737B2 (en) 2014-06-17 2018-01-16 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor
CN107793404A (en) * 2017-11-07 2018-03-13 全椒先奇医药科技有限公司 One kind treats ischemic brain damage pharmaceutical composition and its application
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10478430B2 (en) 2012-04-05 2019-11-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2022177267A1 (en) 2021-02-16 2022-08-25 라이보텍(주) Compound for suppressing nonsense-mediated mrna decay
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11542492B2 (en) 2009-12-30 2023-01-03 Celgene Car Llc Ligand-directed covalent modification of protein
US11547697B2 (en) 2009-08-17 2023-01-10 Millennium Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2023046182A1 (en) * 2021-09-27 2023-03-30 广州嘉越医药科技有限公司 Application of pyrido[1,2-a]pyrimidone compound
CN116239594A (en) * 2023-03-05 2023-06-09 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 6- (imidazo [1,2-a ] pyridin-6-yl) quinazoline derivatives and uses thereof

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090717A1 (en) * 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
MX2011002367A (en) 2008-09-02 2011-04-04 Novartis Ag Bicyclic kinase inhibitors.
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
WO2010127307A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2011021678A1 (en) * 2009-08-21 2011-02-24 武田薬品工業株式会社 Fused heterocyclic compound
CN102625708A (en) * 2009-09-09 2012-08-01 阿维拉制药公司 Pi3 kinase inhibitors and uses thereof
CA2810162A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
US20130317037A1 (en) * 2010-11-16 2013-11-28 Glaxosmithkline Intellectual Property Development Limited Method of administration and treatment
EA201390740A1 (en) * 2010-11-19 2013-12-30 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед METHOD OF TREATMENT USING A BRAF INHIBITOR
EP2680844B1 (en) 2011-03-04 2016-10-19 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN102718745A (en) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 Novel amino pyridine compound, its preparation method, pharmaceutical composition containing compound and application thereof
UY34044A (en) * 2011-04-29 2012-11-30 Sanofi Sa TREATMENT METHOD AGAINST LYMPHOMA WITH P13K / MTOR PYRIDOPIRIMIDINONE INHIBITORS
TWI547494B (en) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
JP6170060B2 (en) 2011-11-04 2017-07-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel aryl-quinoline derivatives
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2868002C (en) 2012-03-21 2021-07-13 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
TW201425307A (en) 2012-09-13 2014-07-01 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
TWI592417B (en) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 Prodrugs of amino quinazoline kinase inhibitor
CN103497177B (en) * 2012-09-29 2017-03-22 天津滨江药物研发有限公司 Amino heterocyclic aromatic compound serving as c-Met inhibitor, and preparation method thereof
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
RU2662810C2 (en) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Quinazolines as kinase inhibitors
CN104098542A (en) * 2013-04-11 2014-10-15 苏州朗信医药科技有限公司 6-bromo-4-( 4-pyrazinyl) quinoline preparation method
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
SG11201600707QA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
CN104557955B (en) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 Tricyclic compound as PI3K/mTOR inhibitor as well as preparation method and application of tricyclic compound
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
MX2016006815A (en) * 2013-11-27 2016-12-02 Signalchem Lifesciences Corp Aminopyridine derivatives as tam family kinase inhibitors.
ES2921874T3 (en) 2014-02-28 2022-09-01 Nimbus Lakshmi Inc TYK2 inhibitors and uses thereof
CN104922116B (en) * 2014-03-23 2020-08-11 上海诗丹德生物技术有限公司 Use of methacryloyl benzimidazolone derivatives
NO2714752T3 (en) * 2014-05-08 2018-04-21
JP6749890B2 (en) 2014-08-12 2020-09-02 モナッシュ ユニバーシティ Lymphoid prodrug
CN105330699B (en) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 A kind of phosphorous pyrido [2,3-d] pyrimidin-7-ones class compound or its pharmaceutically acceptable salt, pharmaceutical composition and its application
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN104961725B (en) * 2015-06-18 2017-04-19 浙江大学 4-alpha, beta-unsaturated carboxamidoquinoline compounds and preparation and application
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20180026760A (en) * 2015-07-09 2018-03-13 얀센 파마슈티카 엔.브이. Substituted 4-azaindoles and their use as GLUN2B receptor modulators
WO2017019828A1 (en) * 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
WO2017027768A1 (en) 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
CN118063537A (en) 2015-09-08 2024-05-24 莫纳什大学 Prodrugs of directed lymphatics
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
MX2018004674A (en) 2015-10-23 2018-09-11 Navitor Pharm Inc Modulators of sestrin-gator2 interaction and uses thereof.
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Caffeine inhibitors of mthfd2 and uses thereof
TWI713655B (en) * 2015-12-16 2020-12-21 大陸商上海嘉坦醫藥科技有限公司 CRYSTALLINE FORMS OF PYRIDO[1,2-a]PYRIMIDINONES AND MANUFACTURE PROCESSES THEREFOR AND INTERMEDIATES
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
CA3015768A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
US11014882B2 (en) 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3426243B1 (en) 2016-03-09 2021-05-19 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
US10154992B2 (en) * 2016-07-12 2018-12-18 The Regents Of The University Of California Compounds and methods for treating HIV infection
CA3034239A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
TW201819376A (en) 2016-10-06 2018-06-01 比利時商健生藥品公司 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
CN106580986B (en) * 2016-11-28 2017-09-15 王保亮 A kind of pharmaceutical composition for treating teen bra
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
US20180153922A1 (en) 2016-12-06 2018-06-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
CN110603261A (en) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 Peptide derivatives having novel bond structure
CA3048546A1 (en) * 2016-12-26 2018-07-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
EP4338802A3 (en) 2017-03-08 2024-09-04 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
WO2018183917A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
AU2018258355B2 (en) 2017-04-26 2024-05-30 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US11168082B2 (en) * 2017-05-15 2021-11-09 The Regents Of The University Of Michigan Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
CN111032678A (en) 2017-06-26 2020-04-17 拜西克尔德有限公司 Bicyclic peptide ligands with detectable moieties and uses thereof
JP7216705B2 (en) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitors and methods of use thereof
CN118772242A (en) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 CD137 specific bicyclic peptide ligands
EP3668550A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2019046491A1 (en) 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein degraders and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
TWI825046B (en) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Bicyclic peptide ligands specific for epha2
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CA3089769A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
AU2019211485A1 (en) 2018-01-29 2020-08-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2019169001A1 (en) 2018-02-27 2019-09-06 Artax Biopharma Inc. Chromene derivatives as inhibitors of tcr-nck interaction
HRP20220331T1 (en) * 2018-03-08 2022-05-13 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
TW202010744A (en) 2018-04-24 2020-03-16 美商維泰克斯製藥公司 Pteridinone compounds and uses thereof
IL278142B2 (en) 2018-04-24 2023-11-01 Merck Patent Gmbh Antiproliferation compounds and uses thereof
EP3575305A1 (en) * 2018-05-31 2019-12-04 Biocidal Alternative Solutions Method for producing compounds comprising an oxazolopyridinone functional group
DK3813946T3 (en) 2018-06-15 2024-08-19 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
KR102595520B1 (en) * 2018-07-05 2023-10-30 엘지디스플레이 주식회사 Benzazole derivative having heteroaryl group and organic light emitting diode device including the same
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022500499A (en) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド EIF4E Inhibitors and Their Use
JP2022502515A (en) 2018-10-15 2022-01-11 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitors and their use
JP2022512779A (en) 2018-10-23 2022-02-07 バイスクルテクス・リミテッド Bicyclic peptide ligands and their use
EP3870158A4 (en) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
EP3886904A4 (en) 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN113271938A (en) 2018-11-30 2021-08-17 林伯士拉克许米公司 TYK2 inhibitors and uses thereof
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
AU2020253633A1 (en) 2019-04-05 2021-11-04 Kymera Therapeutics, Inc. STAT degraders and uses thereof
EP3976027A4 (en) * 2019-05-30 2023-01-11 Merck Sharp & Dohme LLC Factor xi activation inhibitors
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
JOP20210328A1 (en) 2019-06-14 2023-01-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020293584A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GluN2B receptor modulators
WO2020249796A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
JP2022536773A (en) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． Substituted pyrazolopyrazines and their use as GLUN2B receptor modulators
TW202110485A (en) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 Heterotandem bicyclic peptide complex
WO2021050992A1 (en) 2019-09-11 2021-03-18 Vincere Biosciences, Inc. Usp30 inhibitors and uses thereof
BR112022004451A2 (en) 2019-09-13 2022-06-21 Nimbus Saturn Inc hpk1 antagonists and uses thereof
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
JP2023506410A (en) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド Rapamycin analogues and uses thereof
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022012410A2 (en) 2019-12-23 2022-08-30 Kymera Therapeutics Inc SMARCA DEGRADATORS AND USE THEREOF
AU2021217172A1 (en) 2020-02-05 2022-09-22 Monash University Lipid prodrugs of neurosteroids
MX2022010944A (en) 2020-03-03 2022-11-09 Pic Therapeutics Inc Eif4e inhibitors and uses thereof.
BR112022018678A2 (en) 2020-03-19 2022-11-01 Kymera Therapeutics Inc MDM2 DEGRADATORS AND THEIR USES
TW202203916A (en) 2020-03-31 2022-02-01 美商卡默森屈有限公司 Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
KR20230074721A (en) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 NECTIN-4 Specific Bicyclic Conjugates and Uses Thereof
CN117015531A (en) 2020-12-02 2023-11-07 医肯纳肿瘤学公司 TEAD inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230153387A (en) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 GPR84 antagonists and their uses
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CN117295737A (en) 2021-03-05 2023-12-26 林伯士萨顿公司 HPK1 antagonists and uses thereof
EP4313989A1 (en) 2021-03-29 2024-02-07 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
IL307673A (en) 2021-04-16 2023-12-01 Ikena Oncology Inc Mek inhibitors and uses thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
CN115353512A (en) * 2021-07-30 2022-11-18 上海翊石医药科技有限公司 Heterocyclic urea compound and preparation method and application thereof
CN113416181B (en) * 2021-08-02 2022-05-03 四川大学 Quinazoline derivative and application thereof
US20230134932A1 (en) 2021-08-25 2023-05-04 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202315621A (en) 2021-08-25 2023-04-16 美商皮克醫療公司 Eif4e inhibitors and uses thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
TW202404581A (en) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek inhibitors and uses thereof
CN117402146A (en) * 2022-07-13 2024-01-16 武汉人福创新药物研发中心有限公司 Heterocyclic benzene ring compound and preparation method and application thereof
TW202416950A (en) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
TW202416972A (en) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 Substituted pyridone gpr84 antagonists and uses thereof
WO2024086296A1 (en) * 2022-10-20 2024-04-25 Mekanistic Therapeutics Llc Compounds useful in modulating egfr and pi3k
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN118126038B (en) * 2024-05-08 2024-07-12 烟台大学 Pyrazolopyridine derivative, and preparation method and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6268391B1 (en) 1997-08-06 2001-07-31 Glaxo Wellcome Inc. Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases
WO2005011686A1 (en) 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
US6949537B2 (en) * 2003-04-03 2005-09-27 Semafore Pharmaceuticals, Inc. PI-3 kinase inhibitor prodrugs
US20070054903A1 (en) * 2005-06-30 2007-03-08 Amgen Inc. Bis-aryl kinase inhibitors and method

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE533691C (en) * 1929-06-10 1931-09-23 I G Farbenindustrie Akt Ges Process for the preparation of quinoline and acridine compounds which contain in the core a benzthiazolyl, benzoxazolyl or benzimidazolyl group and a primary, secondary or tertiary amino group
EP0783496B9 (en) 1994-08-10 2003-09-03 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
US5925656A (en) 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
EP0801063B1 (en) 1996-04-09 2003-01-15 Dr. Reddy's Laboratories Ltd. Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
EP1045846B1 (en) 1997-11-28 2003-05-02 Lg Chemical Limited Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
DE60144322D1 (en) 2000-04-27 2011-05-12 Astellas Pharma Inc CONDENSED HETEROARYL DERIVATIVES
US7343348B2 (en) * 2000-05-19 2008-03-11 First American Residential Group, Inc. System for performing real-estate transactions over a computer network using participant templates
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AU2002252227A1 (en) * 2001-03-07 2002-09-24 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002080161A2 (en) * 2001-03-28 2002-10-10 Bayer Aktiengesellschaft Optical data carrier that contains a merocyanine dye as the light-absorbing compound in the information layer
WO2002092076A1 (en) 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
HU228844B1 (en) * 2001-05-24 2013-06-28 Lilly Co Eli Pyrrole derivatives and pharmaceutical compositions containing them
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
US20050019825A9 (en) * 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
WO2004024061A2 (en) * 2002-04-30 2004-03-25 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
EP1531813A1 (en) * 2002-07-10 2005-05-25 Applied Research Systems ARS Holding N.V. Use of compounds for increasing spermatozoa motility
RS115904A (en) 2002-07-10 2006-12-15 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused benzene derivatives
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
HUP0203985A3 (en) 2002-11-18 2005-04-28 Gene Res Lab Inc New York N Use of a pharmaceutical composition for alleviating side effect
GB0302882D0 (en) 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
MXPA05009722A (en) 2003-03-10 2006-03-09 Schering Corp Heterocyclic kinase inhibitors: methods of use and synthesis.
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd Treatment of neurological conditions
WO2005007123A2 (en) * 2003-07-18 2005-01-27 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2005016227A2 (en) 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
GT200500008A (en) 2004-01-16 2005-08-16 QUINOLINE INTERMEDIARIES AS INHIBITORS OF THIROSINE KINASE RECEPTORS AND THE SYNTHESIS OF THE SAME
WO2005085277A1 (en) * 2004-02-06 2005-09-15 Concepcion Gisela P Cyclic hexapeptides, process and use thereof
JP2007537296A (en) 2004-05-14 2007-12-20 アボット・ラボラトリーズ Kinase inhibitors as therapeutic agents
WO2006002828A1 (en) * 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Quinoline thiazolinones with cdk1 antiproliferative activity
BRPI0513899A (en) 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc fused ring heterocyclic kinase modulators
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US20060249289A1 (en) 2005-05-05 2006-11-09 Halliburton Energy Services, Inc. Set-delayed cement compositions comprising hydrated lime and silica and methods of cementing in subterranean formations
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US7449571B2 (en) * 2005-06-14 2008-11-11 Board Of Regents Of The University Of Nebraska Halogenated aminoquinolines and oligonucleotides containing the same
CN101287727A (en) * 2005-08-17 2008-10-15 先灵公司 Novel high affinity quinoline-based kinase ligands
US20090170848A1 (en) * 2006-03-02 2009-07-02 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
US7667043B2 (en) * 2006-03-20 2010-02-23 E.I. Du Pont De Nemours And Company Molecular structures with controllable electron conducting properties
PE20080038A1 (en) * 2006-04-11 2008-02-22 Smithkline Beecham Corp THIAZOLIDINADIONE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2007139496A1 (en) 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
PL2049502T3 (en) * 2006-07-28 2012-06-29 Novartis Ag 2,4-substituted quinazolines as lipid kinase inhibitors
JP2010526823A (en) * 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5877219A (en) 1994-04-25 1999-03-02 Glaxo Wellcomeinc. Non-steroidal ligands for the estrogen receptor
US6207716B1 (en) 1994-04-25 2001-03-27 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6063923A (en) 1994-05-03 2000-05-16 Glaxo Wellcome Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6268391B1 (en) 1997-08-06 2001-07-31 Glaxo Wellcome Inc. Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases
US6949537B2 (en) * 2003-04-03 2005-09-27 Semafore Pharmaceuticals, Inc. PI-3 kinase inhibitor prodrugs
WO2005011686A1 (en) 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
US20070054903A1 (en) * 2005-06-30 2007-03-08 Amgen Inc. Bis-aryl kinase inhibitors and method

Non-Patent Citations (85)

* Cited by examiner, † Cited by third party
Title
"Cancer Principles and Practice of Oncology", 15 February 2001, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS
"Tyrosine Kinase Signalling in Breast cancer:erbB Family Receptor Tyrosine Kniases", BREAST CANCER RES., vol. 2, no. 3, 2000, pages 176 - 183
ABID ET AL., ARTERIOSCLER, THROMB. VASC. BIOL., vol. 24, 2004, pages 294 - 300
ABRAHAM, R.T., CURRENT OPINION IN IMMUNOLOGY, vol. 8, no. 3, 1996, pages 412 - 418
ASHBY, M.N., CURRENT OPINION IN LIPIDOLOGY, vol. 9, no. 2, 1998, pages 99 - 102
BIOCHIM. BIOPHYS. ACTA, vol. 1423, no. 3, pages 19 - 30
BOLEN, J.B.; BRUGGE, J.S., ANNUAL REVIEW OF IMMUNOLOGY., vol. 15, 1997, pages 371 - 404
BREKKEN, R.A. ET AL.: "Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice", CANCER RES., vol. 60, 2000, pages 5117 - 5124, XP002340113
BRODT, P; SAMANI, A.; NAVAB, R., BIOCHEMICAL PHARMACOLOGY, vol. 60, 2000, pages 1101 - 1107
BRUNS CJ ET AL., CANCER RES., vol. 60, 2000, pages 2926 - 2935
CANMAN, C.E.; LIM, D.S., ONCOGENE, vol. 17, no. 25, 1998, pages 3301 - 3308
CHEN Y; HU D; ELING DJ; ROBBINS J; KIPPS TJ, CANCER RES., vol. 58, 1998, pages 1965 - 1971
D. G. I. KINGSTON ET AL.: "Studies in Organic Chemistry", vol. 26, 1986, ELSEVIER, article "New trends in Natural Products Chemistry 1986", pages: 219 - 235
DREES, B.E.; WEIPERT, A.; HUDSON, H.; FERGUSON, C.G.; CHAKRAVARTY, L.; PRESTWICH, G.D.: "Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity", COMB. CHEM. HIGH THROUGHPUT. SCREEN., vol. 6, no. 4, 2003, pages 321, XP009150069
EINZIG, PROC. AM. SOC. CLIN. ONCOL., vol. 20, pages 46
FORASTIRE, SEM. ONCOL., vol. 20, 1990, pages 56
FOSTER ET AL., J. CELL SCIENCE, vol. 116, 2003, pages 3037 - 3040
FRASER ET AL., SCIENCE, vol. 251, 1991, pages 313 - 316
FRUMAN ET AL., ANN. REV. BIOCHEM., vol. 67, 1998, pages 481 - 507
GERARD, NAT. IMMUNOL., vol. 2, no. 2, 2001, pages 108 - 115
GREEN, M.C. ET AL.: "Monoclonal Antibody Therapy for Solid Tumors", CANCER TREAT. REV., vol. 26, no. 4, 2000, pages 269 - 286, XP009019784, DOI: doi:10.1053/ctrv.2000.0176
HARARI ET AL., ONCOGENE, vol. 19, 2000, pages 6102 - 6114
HIRSCH, FASEB J., vol. 15, no. 11, 2001, pages 2019 - 2021
HIRSCH, SCIENCE, vol. 287, no. 5455, 2000, pages 1049 - 1053
HOLMES ET AL., J. NAT. CANCER INST., vol. 83, 1991, pages 1797
IGNOFF, R.J.: "Cancer Chemotherapy Pocket Guide", 1998
JACKSON, S.P., INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 29, no. 7, 1997, pages 935 - 938
JOHN M. JANUSZ ET AL., J. MED. CHEM., vol. 41, no. 18, 1998
KATH, JOHN C., EXP. OPIN. THER. PATENTS, vol. 10, no. 6, 2000, pages 803 - 818
KATSO ET AL., ANNUAL REV. CELL DEV. BIOL., vol. 17, 2001, pages 615 - 617
KATSO, ANNU. REV. CELL.DEV. BIOL., vol. 17, 2001, pages 615 - 675
KAUFFMANN-ZEH ET AL., NATURE, vol. 385, 1997, pages 544 - 548
KEARNS, C.M., SEMINARS IN ONCOLOGY, vol. 3, no. 6, 1995, pages 16 - 23
KITADA S ET AL., ANTISENSE RES. DEV., vol. 4, 1994, pages 71 - 79
KUMAR, J. BIOL, CHEM, vol. 256, 1981, pages 10435 - 10441
LACKEY, K. ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 223 - 226
LAFFARGUE ET AL., IMMUNITY, vol. 16, no. 3, 2002, pages 441 - 451
LAWLOR, J. CELL. SCI., vol. 114, 2001, pages 2903 - 2910
LESLIE ET AL., CHEM. REV., vol. 101, no. 8, 2001, pages 2365 - 2380
LOFTS, F. J. ET AL.: "New Molecular Targets for Cancer Chemotherapy", 1994, CRC PRESS, article "Growth factor receptors as targets"
LOPEZ-LLASACA ET AL., J. BIOL. CHEM., vol. 273, no. 5, 1998, pages 2505 - 2508
MA ET AL., ONCOGENE, vol. 19, 2000, pages 2739 - 2744
MARKMAN ET AL., YALE JOURNAL OF BIOLOGY AND MEDICINE, vol. 64, 1991, pages 583
MARTINEZ-IACACI, L. ET AL., INT. J. CANCER, vol. 88, no. 1, 2000, pages 44 - 52
MASSAGUE, J.; WEIS-GARCIA, F., CANCER SURVEYS., vol. 27, 1996, pages 41 - 64
MCGUIRE ET AL., ANN. LNTEM, MED., vol. 111, 1989, pages 273
MEIER, T.I.; COOK, J.A.; THOMAS, J.E.; RADDING, J.A.; HORN, C.; LINGARAJ, T.; SMITH, M.C.: "Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms", PROTEIN EXPR. PURIF., vol. 35, no. 2, 2004, pages 218, XP004506556, DOI: doi:10.1016/j.pep.2003.12.010
NICHOLSON; ANDESON, CELLULAR SIGNALING, vol. 14, 2002, pages 381 - 395
PAGES ET AL., NATURE, vol. 369, 1994, pages 327 - 329
PANAYOTOU ET AL., TRENDS CELL BIOL., vol. 2, 1992, pages 358 - 360
PARKER ET AL., CURRENT BIOLOGY, vol. 5, 1995, pages 577 - 599
PHILIP, P.A.; HARRIS, A.L., CANCER TREATMENT AND RESEARCH., vol. 78, 1995, pages 3 - 27
PHILP ET AL., CANCER RESEARCH, vol. 61, 2001, pages 7426 - 7429
POWIS, G.; KOZIKOWSKI A.: "New Molecular Targets for Cancer Chemotherapy", 1994, CRC PRESS
REILLY RT ET AL., CANCER RES., vol. 60, 2000, pages 3569 - 3576
ROSANIA ET AL., EXP. OPIN. THER. PATENTS, vol. 10, no. 2, 2000, pages 215 - 230
RUDD, IMMUNITY, vol. 4, 1996, pages 527 - 534
SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554
SAWYER, EXPERT OPINION INVESTING. DRUGS, vol. 13, 2004, pages 1 - 19
SCHAROVSKY, O.G.; ROZADOS, V.R.; GERVASONI, S.I.; MATAR, P., JOURNAL OF BIOMEDICAL SCIENCE, vol. 7, no. 4, 2000, pages 292 - 298
SCHIFF ET AL., NATURE, vol. 277, 1979, pages 665 - 667
SCHIFF ET AL., PROC. NATL, ACAD, SCI. USA, vol. 77, 1980, pages 1561 - 1565
SCHREIBER AB; WINKLER ME; DERYNCK R., SCIENCE, vol. 232, 1986, pages 1250 - 1253
See also references of EP2162131A4
SHAWVER ET AL., DDT, vol. 2, no. 2, February 1997 (1997-02-01)
SHAYESTEH ET AL., NATURE GENETICS, vol. 21, 1999, pages 99 - 102
SIMPSON; PARSONS, EXP. CELL RES., vol. 264, 2001, pages 29 - 41
SINH, S.; COREY, S.J., JOURNAL OF HEMATOTHERAPY AND STEM CELL RESEARCH, vol. 8, no. 5, 1999, pages 465 - 480
SMITHGALL, T.E., JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, vol. 34, no. 3, 1995, pages 125 - 132
STEIN, MOL. MED. TODAY, vol. 6, no. 9, 2000, pages 347 - 357
STEPHENS, CURR. OPINION CELL BIOL., vol. 14, no. 2, 2002, pages 203 - 213
THELEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 4960 - 4964
TOKER, CELL. MOL. LIFE SCI., vol. 59, no. 5, 2002, pages 761 - 779
VANHAESEBROECK, TRENDS BIOCHEM. SCI., vol. 22, no. 7, 1997, pages 267 - 272
VANHAESEBROECK; KATSO, EXP. CELL. RES., vol. 25, no. 1, 1999, pages 239 - 254
VARA ET AL., CANCER TREATMENT REVIEWS, vol. 30, 2004, pages 193 - 204
VIVANCO; SAWYERS, NATURE REVIEWS CANCER, vol. 2, 2002, pages 489 - 501
WANI ET AL., J. AM. CHEM, SOC., vol. 93, 1971, pages 2325
WATER JS ET AL., J. CLIN. ONCOL., vol. 18, 2000, pages 1812 - 1823
WOO, NATURE, vol. 368, 1994, pages 750
WYMAN, IMMUNOL. TODAY, vol. 21, no. 6, 2000, pages 260 - 264
YAMAMOTO, T.; TAYA, S.; KAIBUCHI, K., JOURNAL OF BIOCHEMISTRY, vol. 126, no. 5, 1999, pages 799 - 803
YAO ET AL., SCIENCE, vol. 267, 1995, pages 2003 - 2005
YEN L ET AL., ONCOGENE, vol. 19, 2000, pages 3460 - 3469
ZHONG, H. ET AL., CANCER RES, vol. 60, no. 6, 2000, pages 1541 - 1545

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
JP2011500823A (en) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyridosulfonamide derivatives as PI3 kinase inhibitors
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
WO2009157196A1 (en) * 2008-06-25 2009-12-30 武田薬品工業株式会社 Amide compound
US8410112B2 (en) 2008-11-10 2013-04-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9365557B2 (en) 2008-12-19 2016-06-14 Vertex Pharmaceuticals Incorporated Substituted pyrazin-2-amines as inhibitors of ATR kinase
US10961232B2 (en) 2008-12-19 2021-03-30 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US9701674B2 (en) 2008-12-19 2017-07-11 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US8841308B2 (en) 2008-12-19 2014-09-23 Vertex Pharmaceuticals Incorporated Pyrazin-2-amines useful as inhibitors of ATR kinase
US10479784B2 (en) 2008-12-19 2019-11-19 Vertex Pharmaceuticals Incorporated Substituted pyrazin-2-amines as inhibitors of ATR kinase
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
JP2012513410A (en) * 2008-12-23 2012-06-14 アボット・ラボラトリーズ Antiviral compounds
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US8519142B2 (en) 2009-05-15 2013-08-27 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8809545B2 (en) 2009-05-15 2014-08-19 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8383827B2 (en) 2009-05-15 2013-02-26 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
WO2010135568A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
JP2012531436A (en) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド Heterocyclic compounds and their use as PI3K activity inhibitors
US11547697B2 (en) 2009-08-17 2023-01-10 Millennium Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3124475A1 (en) 2009-09-03 2017-02-01 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
WO2011028741A1 (en) 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
JP2013503875A (en) * 2009-09-03 2013-02-04 ブリストル−マイヤーズ スクイブ カンパニー Quinazolines as potassium ion channel inhibitors
EP3575288A1 (en) 2009-09-03 2019-12-04 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US10662195B2 (en) 2009-09-16 2020-05-26 Celgene Car Llc Protein kinase conjugates and inhibitors
CN102665719A (en) * 2009-09-28 2012-09-12 葛兰素史密斯克莱有限责任公司 Combination
AU2010298020B2 (en) * 2009-09-28 2013-09-12 Glaxosmithkline Llc Combination
AU2010298020B8 (en) * 2009-09-28 2013-10-10 Glaxosmithkline Llc Combination
AU2010298020A8 (en) * 2009-09-28 2013-10-10 Glaxosmithkline Llc Combination
WO2011038380A3 (en) * 2009-09-28 2011-09-15 Glaxosmithkline Llc Combination
WO2011038380A2 (en) 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
JP2013505962A (en) * 2009-09-28 2013-02-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー combination
CN102665720A (en) * 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 Combination
JP2013507442A (en) * 2009-10-12 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー combination
WO2011046894A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
EA020965B1 (en) * 2009-10-12 2015-03-31 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Method and pharmaceutical combination for treating cancer
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
US11542492B2 (en) 2009-12-30 2023-01-03 Celgene Car Llc Ligand-directed covalent modification of protein
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013532727A (en) * 2010-07-30 2013-08-19 オンコセラピー・サイエンス株式会社 MELK inhibitors containing quinoline derivatives and the same
US20130137701A1 (en) * 2010-08-09 2013-05-30 Tona M. Gilmer Combination
WO2012068106A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
US8877759B2 (en) 2011-04-05 2014-11-04 Vertex Pharnaceuticals Incorporated Aminopyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US10208027B2 (en) 2011-09-30 2019-02-19 Vertex Pharmaceuticals Incorporated Processes for preparing ATR inhibitors
US9035053B2 (en) 2011-09-30 2015-05-19 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US9862709B2 (en) 2011-09-30 2018-01-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
US10822331B2 (en) 2011-09-30 2020-11-03 Vertex Pharmaceuticals Incorporated Processes for preparing ATR inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846686B2 (en) 2011-09-30 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
WO2013117503A2 (en) 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No. 2) Limited Novel use
WO2013117504A1 (en) 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No.2) Limited Pi3k inhibitors for treating cough
US11110086B2 (en) 2012-04-05 2021-09-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US10478430B2 (en) 2012-04-05 2019-11-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US9791456B2 (en) 2012-10-04 2017-10-17 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2915810A4 (en) * 2012-11-01 2016-04-13 Univ Pla 2Nd Military Medical N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives, preparation method and therapeutic use thereof
US9650381B2 (en) 2012-12-07 2017-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9718827B2 (en) 2012-12-07 2017-08-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10392391B2 (en) 2012-12-07 2019-08-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11370798B2 (en) 2012-12-07 2022-06-28 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11117900B2 (en) 2012-12-07 2021-09-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10787452B2 (en) 2012-12-07 2020-09-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2015027667A1 (en) 2013-08-30 2015-03-05 浙江医药股份有限公司新昌制药厂 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof
US11485739B2 (en) 2013-12-06 2022-11-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10815239B2 (en) 2013-12-06 2020-10-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10800781B2 (en) 2014-06-05 2020-10-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10093676B2 (en) 2014-06-05 2018-10-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US9868737B2 (en) 2014-06-17 2018-01-16 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor
WO2016142508A1 (en) 2015-03-11 2016-09-15 Centre Léon-Bérard Composition for treating pancreatic neuroendocrine tumours
US10882858B2 (en) 2015-09-17 2021-01-05 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US11613539B2 (en) 2015-09-17 2023-03-28 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN107793404A (en) * 2017-11-07 2018-03-13 全椒先奇医药科技有限公司 One kind treats ischemic brain damage pharmaceutical composition and its application
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
WO2022177267A1 (en) 2021-02-16 2022-08-25 라이보텍(주) Compound for suppressing nonsense-mediated mrna decay
WO2022177269A1 (en) 2021-02-16 2022-08-25 라이보텍(주) Compound for inhibiting nonsense-mediated mrna decay
WO2023046182A1 (en) * 2021-09-27 2023-03-30 广州嘉越医药科技有限公司 Application of pyrido[1,2-a]pyrimidone compound
CN116239594A (en) * 2023-03-05 2023-06-09 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 6- (imidazo [1,2-a ] pyridin-6-yl) quinazoline derivatives and uses thereof
CN116239594B (en) * 2023-03-05 2023-09-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 6- (imidazo [1,2-a ] pyridin-6-yl) quinazoline derivatives and uses thereof

Also Published As

Publication number Publication date
MX2009012479A (en) 2009-12-02
IL202018A (en) 2016-03-31
JO2891B1 (en) 2015-09-15
PE20090717A1 (en) 2009-07-18
US20100152112A1 (en) 2010-06-17
DK2162131T3 (en) 2013-05-27
CO6241101A2 (en) 2011-01-20
HRP20130252T1 (en) 2013-04-30
US20120165321A1 (en) 2012-06-28
AU2008254915A1 (en) 2008-11-27
AR066614A1 (en) 2009-09-02
MY158843A (en) 2016-11-15
PT2162131E (en) 2013-04-23
JP2011126913A (en) 2011-06-30
EA200971072A1 (en) 2010-06-30
EP2596793A1 (en) 2013-05-29
CA2686016C (en) 2015-04-21
EP2192902A4 (en) 2010-11-03
EP2162131A4 (en) 2010-11-03
US20100168100A1 (en) 2010-07-01
SI2162131T1 (en) 2013-07-31
CR11165A (en) 2010-03-01
US20080300239A1 (en) 2008-12-04
ES2547256T3 (en) 2015-10-02
CN101754759A (en) 2010-06-23
EP2192902A1 (en) 2010-06-09
AU2008254915B2 (en) 2012-02-09
CA2686016A1 (en) 2008-11-27
KR101458660B1 (en) 2014-11-06
JP4814396B2 (en) 2011-11-16
US8138347B2 (en) 2012-03-20
BRPI0811761A2 (en) 2014-11-11
UA104408C2 (en) 2014-02-10
US8785433B2 (en) 2014-07-22
US8404837B2 (en) 2013-03-26
WO2008144464A1 (en) 2008-11-27
MX342959B (en) 2016-10-18
TWI410417B (en) 2013-10-01
EP2162131A1 (en) 2010-03-17
PL2162131T3 (en) 2013-07-31
MA31443B1 (en) 2010-06-01
EP2162131B1 (en) 2013-03-06
US8633187B2 (en) 2014-01-21
NZ580979A (en) 2012-01-12
IL202018A0 (en) 2010-06-16
EA019540B1 (en) 2014-04-30
HK1137938A1 (en) 2010-08-13
CL2008001457A1 (en) 2008-11-21
JP2010528027A (en) 2010-08-19
JP2010528026A (en) 2010-08-19
CN101754759B (en) 2013-10-09
CY1114070T1 (en) 2016-07-27
TW200911784A (en) 2009-03-16
EP2596793B1 (en) 2015-07-08
US20140296224A1 (en) 2014-10-02
US20140100234A1 (en) 2014-04-10
ES2404557T3 (en) 2013-05-28
ZA200907777B (en) 2010-07-28
KR20100017852A (en) 2010-02-16

Similar Documents

Publication Publication Date Title
US8785433B2 (en) Quinoline derivatives as PI3 kinase inhibitors
WO2008150827A1 (en) Naphthyridine, derivatives as p13 kinase inhibitors
WO2008157191A2 (en) Quinazoline derivatives as pi3 kinase inhibitors
US20100311736A1 (en) Pyridosulfonamide derivatives as p13 kinase inhibitors
US20100234386A1 (en) Quinoxaline derivatives as pi3 kinase inhibitors
US20100204222A1 (en) Pyridopyrimidine derivatives as p13 kinase inhibitors
US20090215818A1 (en) Thiozolidinedione derivatives as pi3 kinase inhibitors
EP2173354A1 (en) Quinoxaline derivatives as pi3 kinase inhibitors
AU2012202710A1 (en) Quinoline derivatives as P13 kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880024978.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755632

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 580979

Country of ref document: NZ

Ref document number: 12009502106

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008254915

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09130508

Country of ref document: CO

Ref document number: 2009111680

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2686016

Country of ref document: CA

Ref document number: 2010509462

Country of ref document: JP

Ref document number: 12600745

Country of ref document: US

Ref document number: MX/A/2009/012479

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7513/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008254915

Country of ref document: AU

Date of ref document: 20080516

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2009000724

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: CR2009-011165

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2008755632

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097026354

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200971072

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PI 20094867

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0811761

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091117